<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22101737</PMID><DateCompleted><Year>2013</Year><Month>01</Month><Day>08</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1573-6709</ISSN><JournalIssue CitedMedium="Internet"><Volume>83</Volume><Issue>3</Issue><PubDate><Year>2012</Year><Month>Sep</Month></PubDate></JournalIssue><Title>The Psychiatric quarterly</Title><ISOAbbreviation>Psychiatr Q</ISOAbbreviation></Journal><ArticleTitle>Insight in bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>293-310</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s11126-011-9200-4</ELocationID><Abstract><AbstractText>Although there has been interest in insight in bipolar disorder, research has not been as developed as in schizophrenia. The Medline, Embase, and PsychInfo data bases were searched. The key words used in the search were "bipolar", "mania", "manic", "awareness", and "insight". Books, editorials, letters, and reports on pediatric subjects were excluded. Abstracts or full texts were screened for relevance. Better insight is associated with better adherence to treatment and better outcomes. Impairments of executive functions and memory, as well as higher severity of psychotic symptoms, are associated with impairments of insight. Insight is more impaired during an illness episode than during remission, in mixed than in pure manic episodes, in bipolar II than in bipolar I patients, in pure mania than in bipolar or unipolar depression. Psychosocial treatments improve insight and outcomes. There is a need for integration of quantitative assessment methods and their introduction into research and clinical practice.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Látalová</LastName><ForeName>Klára</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Faculty of Medicine and Dentistry, Palacký University Olomouc, I.P.Pavlova 6, 77520, Olomouc, Czech Republic. klaralat@centrum.cz</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Psychiatr Q</MedlineTA><NlmUniqueID>0376465</NlmUniqueID><ISSNLinking>0033-2720</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001294" MajorTopicYN="Y">Attitude to Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001364" MajorTopicYN="Y">Awareness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016206" MajorTopicYN="N">Databases, Bibliographic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003717" MajorTopicYN="Y">Denial, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055118" MajorTopicYN="N">Medication Adherence</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011859" MajorTopicYN="N">Radiography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="Y">Schizophrenia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="Y">Schizophrenic Psychology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>11</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>11</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>1</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22101737</ArticleId><ArticleId IdType="doi">10.1007/s11126-011-9200-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bipolar Disord. 2004 Aug;6(4):294-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15225146</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2004 Mar-Apr;38(2):185-91</Citation><ArticleIdList><ArticleId IdType="pubmed">14757333</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1990 Jun;156:798-808</Citation><ArticleIdList><ArticleId IdType="pubmed">2207510</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2010 Apr 27;340:c1900</Citation><ArticleIdList><ArticleId IdType="pubmed">20423957</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1973 Dec 21;182(4118):1275-8</Citation><ArticleIdList><ArticleId IdType="pubmed">4752222</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nerv Ment Dis. 2002 Oct;190(10):713-5</Citation><ArticleIdList><ArticleId IdType="pubmed">12409868</ArticleId></ArticleIdList></Reference><Reference><Citation>Compr Psychiatry. 2000 May-Jun;41(3):167-71</Citation><ArticleIdList><ArticleId IdType="pubmed">10834624</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 1994 Jul;90(1):46-9</Citation><ArticleIdList><ArticleId IdType="pubmed">7976449</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2000 Nov 20;100(1):49-58</Citation><ArticleIdList><ArticleId IdType="pubmed">11090725</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1998 Apr;49(1):55-8</Citation><ArticleIdList><ArticleId IdType="pubmed">9574860</ArticleId></ArticleIdList></Reference><Reference><Citation>Compr Psychiatry. 2007 Nov-Dec;48(6):583-91</Citation><ArticleIdList><ArticleId IdType="pubmed">17954145</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nerv Ment Dis. 1995 Dec;183(12):743-51</Citation><ArticleIdList><ArticleId IdType="pubmed">8522935</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 1998 May;28(3):551-8</Citation><ArticleIdList><ArticleId IdType="pubmed">9626712</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2009 Jul;116(1-2):56-63</Citation><ArticleIdList><ArticleId IdType="pubmed">19062101</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nerv Ment Dis. 1989 Jan;177(1):48-51</Citation><ArticleIdList><ArticleId IdType="pubmed">2535871</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 1998 Apr;97(4):297-301</Citation><ArticleIdList><ArticleId IdType="pubmed">9570491</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Serv. 2002 Jan;53(1):96-8</Citation><ArticleIdList><ArticleId IdType="pubmed">11773658</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2002 Dec;4(6):386-92</Citation><ArticleIdList><ArticleId IdType="pubmed">12519098</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2000 Oct 27;45(3):203-11</Citation><ArticleIdList><ArticleId IdType="pubmed">11042438</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 1998 Mar;28(2):437-46</Citation><ArticleIdList><ArticleId IdType="pubmed">9572100</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 1992 Aug;86(2):159-64</Citation><ArticleIdList><ArticleId IdType="pubmed">1529740</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2009 Jul;116(1-2):51-5</Citation><ArticleIdList><ArticleId IdType="pubmed">19101038</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2002 Oct;4(5):315-22</Citation><ArticleIdList><ArticleId IdType="pubmed">12479664</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2009;70 Suppl 4:1-46; quiz 47-8</Citation><ArticleIdList><ArticleId IdType="pubmed">19686636</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nerv Ment Dis. 1995 Feb;183(2):103-6</Citation><ArticleIdList><ArticleId IdType="pubmed">7844571</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2009 Mar;35(2):336-46</Citation><ArticleIdList><ArticleId IdType="pubmed">18586692</ArticleId></ArticleIdList></Reference><Reference><Citation>Compr Psychiatry. 2008 Jul-Aug;49(4):335-9</Citation><ArticleIdList><ArticleId IdType="pubmed">18555052</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Psychopharmacol. 2010 Jan;25(1):1-16</Citation><ArticleIdList><ArticleId IdType="pubmed">20041478</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 1996 Dec 15;22(3):257-63</Citation><ArticleIdList><ArticleId IdType="pubmed">9000323</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2008 May;108(1-2):121-7</Citation><ArticleIdList><ArticleId IdType="pubmed">17997489</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nerv Ment Dis. 1998 Jan;186(1):44-50</Citation><ArticleIdList><ArticleId IdType="pubmed">9457146</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2008 Mar 29;371(9618):1085-97</Citation><ArticleIdList><ArticleId IdType="pubmed">18374841</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2003 Apr;60(4):402-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12695318</ArticleId></ArticleIdList></Reference><Reference><Citation>Harv Rev Psychiatry. 1994 May-Jun;2(1):22-33</Citation><ArticleIdList><ArticleId IdType="pubmed">9384876</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nerv Ment Dis. 2001 Jun;189(6):398-9</Citation><ArticleIdList><ArticleId IdType="pubmed">11434641</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Psychiatry. 2004 Feb;19(1):8-14</Citation><ArticleIdList><ArticleId IdType="pubmed">14969775</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2009 Mar;11(2):190-7</Citation><ArticleIdList><ArticleId IdType="pubmed">19267701</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2008 Sep;110(1-2):75-83</Citation><ArticleIdList><ArticleId IdType="pubmed">18272231</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2011 Jan;37(1):38-51</Citation><ArticleIdList><ArticleId IdType="pubmed">20884756</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1978 Nov;133:429-35</Citation><ArticleIdList><ArticleId IdType="pubmed">728692</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry Suppl. 1989 Nov;(7):59-67</Citation><ArticleIdList><ArticleId IdType="pubmed">2619982</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nerv Ment Dis. 1996 Nov;184(11):653-9</Citation><ArticleIdList><ArticleId IdType="pubmed">8955677</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Clin Neurosci. 2005 Aug;59(4):403-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16048445</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 1999 Jun 30;86(3):239-49</Citation><ArticleIdList><ArticleId IdType="pubmed">10482343</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 1989;15(2):245-52</Citation><ArticleIdList><ArticleId IdType="pubmed">2749187</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 1994 Jan;89(1):62-7</Citation><ArticleIdList><ArticleId IdType="pubmed">7908156</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nerv Ment Dis. 1989 Jan;177(1):43-7</Citation><ArticleIdList><ArticleId IdType="pubmed">2562850</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neurol Neurosurg Psychiatry. 1960 Feb;23:56-62</Citation><ArticleIdList><ArticleId IdType="pubmed">14399272</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2002 May;63(5):384-90</Citation><ArticleIdList><ArticleId IdType="pubmed">12019661</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1976 Jun;33(6):766-71</Citation><ArticleIdList><ArticleId IdType="pubmed">938196</ArticleId></ArticleIdList></Reference><Reference><Citation>Compr Psychiatry. 1995 Sep-Oct;36(5):367-76</Citation><ArticleIdList><ArticleId IdType="pubmed">7497711</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nerv Ment Dis. 2002 Dec;190(12):847-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12486373</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2006 Sep;189:204-12</Citation><ArticleIdList><ArticleId IdType="pubmed">16946354</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2000 Sep 29;45(1-2):29-36</Citation><ArticleIdList><ArticleId IdType="pubmed">10978870</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2003 Feb;5(1):14-21</Citation><ArticleIdList><ArticleId IdType="pubmed">12656933</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 1996 Nov 15;65(2):113-20</Citation><ArticleIdList><ArticleId IdType="pubmed">9122285</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2004 Jun 1;68(2-3):319-29</Citation><ArticleIdList><ArticleId IdType="pubmed">15099613</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nerv Ment Dis. 2008 Jan;196(1):16-21</Citation><ArticleIdList><ArticleId IdType="pubmed">18195637</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychol. 2008 Apr;64(4):466-81</Citation><ArticleIdList><ArticleId IdType="pubmed">18357575</ArticleId></ArticleIdList></Reference><Reference><Citation>Encephale. 2008 Dec;34(6):597-605</Citation><ArticleIdList><ArticleId IdType="pubmed">19081457</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nerv Ment Dis. 2008 Apr;196(4):333-5</Citation><ArticleIdList><ArticleId IdType="pubmed">18414129</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1993 Jun;150(6):873-9</Citation><ArticleIdList><ArticleId IdType="pubmed">8494061</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2005 Nov;162(11):2195; author reply 2195</Citation><ArticleIdList><ArticleId IdType="pubmed">16263874</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2003 Jul 15;119(1-2):81-8</Citation><ArticleIdList><ArticleId IdType="pubmed">12860362</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nerv Ment Dis. 1995 Dec;183(12):752-5</Citation><ArticleIdList><ArticleId IdType="pubmed">8522936</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2007 Nov;9(7):737-42</Citation><ArticleIdList><ArticleId IdType="pubmed">17988364</ArticleId></ArticleIdList></Reference><Reference><Citation>Compr Psychiatry. 1997 Sep-Oct;38(5):283-8</Citation><ArticleIdList><ArticleId IdType="pubmed">9298321</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1999 Jul;156(7):1094-6</Citation><ArticleIdList><ArticleId IdType="pubmed">10401459</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1994 Oct;51(10):826-36</Citation><ArticleIdList><ArticleId IdType="pubmed">7944872</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2006 Mar;91(1):1-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16442637</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2003 Mar 1;60(1):71-80</Citation><ArticleIdList><ArticleId IdType="pubmed">12505140</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2003 Apr;5(2):115-22</Citation><ArticleIdList><ArticleId IdType="pubmed">12680901</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Clin Pract. 2009 Jun;63(6):889-99</Citation><ArticleIdList><ArticleId IdType="pubmed">19490199</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nerv Ment Dis. 2008 Jun;196(6):462-7</Citation><ArticleIdList><ArticleId IdType="pubmed">18552623</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 1996 Feb 10;312(7027):345-9</Citation><ArticleIdList><ArticleId IdType="pubmed">8611831</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2010 Jun;12(4):364-75</Citation><ArticleIdList><ArticleId IdType="pubmed">20636633</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2001 Jan;158(1):122-5</Citation><ArticleIdList><ArticleId IdType="pubmed">11136644</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25800950</PMID><DateCompleted><Year>2016</Year><Month>05</Month><Day>06</Day></DateCompleted><DateRevised><Year>2018</Year><Month>01</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1814-1412</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>5</Issue><PubDate><Year>2015</Year></PubDate></JournalIssue><Title>The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry</Title><ISOAbbreviation>World J Biol Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Distinguishing bipolar II depression from unipolar major depressive disorder: Differences in heart rate variability.</ArticleTitle><Pagination><MedlinePgn>351-60</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3109/15622975.2015.1017606</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Bipolar II (BPII) depression is commonly misdiagnosed as unipolar depression (UD); however, an objective and reliable tool to differentiate between these disorders is lacking. Whether cardiac autonomic function can be used as a biomarker to distinguish BPII from UD is unknown.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We recruited 116 and 591 physically healthy patients with BPII depression and UD, respectively, and 421 healthy volunteers aged 20-65 years. Interviewer and self-reported measures of depression/anxiety severity were obtained. Cardiac autonomic function was evaluated by heart rate variability (HRV) and frequency-domain indices of HRV.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Patients with BPII depression exhibited significantly lower mean R-R intervals, variance (total HRV), low frequency (LF)-HRV, and high frequency (HF)-HRV but higher LF/HF ratio compared to those with UD. The significant differences remained after adjusting for age. Compared to the controls, the patients with BPII depression showed cardiac sympathetic excitation with reciprocal vagal impairment, whereas the UD patients showed only vagal impairment. Depression severity independently contributed to decreased HRV and vagal tone in both the patients with BPII depression and UD, but increased sympathetic tone only in those with BPII depression.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">HRV may aid in the differential diagnosis of BPII depression and UD as an adjunct to diagnostic interviews.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Hsin-An</ForeName><Initials>HA</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Tri-Service General Hospital, National Defense Medical Center , Taipei , Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Chuan-Chia</ForeName><Initials>CC</Initials></Author><Author ValidYN="Y"><LastName>Kuo</LastName><ForeName>Terry B J</ForeName><Initials>TB</Initials></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>San-Yuan</ForeName><Initials>SY</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>03</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>World J Biol Psychiatry</MedlineTA><NlmUniqueID>101120023</NlmUniqueID><ISSNLinking>1562-2975</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>World J Biol Psychiatry. 2017 Feb;18(1):82-83</RefSource><PMID Version="1">26452455</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001342" MajorTopicYN="N">Autonomic Nervous System Diseases</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006339" MajorTopicYN="N">Heart Rate</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">bipolar II depression</Keyword><Keyword MajorTopicYN="N">cardiac autonomic function</Keyword><Keyword MajorTopicYN="N">differentiation</Keyword><Keyword MajorTopicYN="N">heart rate variability</Keyword><Keyword MajorTopicYN="N">unipolar depression</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>3</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>3</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>5</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25800950</ArticleId><ArticleId IdType="doi">10.3109/15622975.2015.1017606</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30124585</PMID><DateCompleted><Year>2018</Year><Month>12</Month><Day>11</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1533-712X</ISSN><JournalIssue CitedMedium="Internet"><Volume>38</Volume><Issue>5</Issue><PubDate><Year>2018</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Journal of clinical psychopharmacology</Title><ISOAbbreviation>J Clin Psychopharmacol</ISOAbbreviation></Journal><ArticleTitle>Melancholic Symptoms in Bipolar II Depression and Responsiveness to Lamotrigine in an Exploratory Pilot Study.</ArticleTitle><Pagination><MedlinePgn>509-512</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/JCP.0000000000000947</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">In this exploratory pilot study we reanalyzed data from a previous randomized, double-blind, placebo-controlled trial of lamotrigine for bipolar II depression in which lamotrigine was not superior to placebo to determine if splitting the sample into melancholic and nonmelancholic subgroups revealed a significant treatment effect.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Adult outpatients (n = 150) in an acute bipolar II depressive episode completed 8 weeks of treatment with lamotrigine (titrated to 200 mg/d) or placebo. Depressive symptoms were assessed at baseline and weekly with the 17-item Hamilton Depression Rating Scale (HAMD-17) and the Montgomery-Åsberg Depression Rating Scale (MADRS). The presence of melancholic depression was determined by baseline responses to the HAMD-17 and MADRS according to the Diagnostic and Statistical Manual of Mental Disorders criteria. Cox regression models stratified by melancholic status were used to predict HAMD-17 and MADRS treatment response. Analysis-of-variance models were used to compare HAMD-17 and MADRS change scores between lamotrigine and placebo groups while testing for interactions by melancholic status.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Lamotrigine was associated with higher odds of treatment response compared with placebo in the melancholic subgroup but not in the nonmelancholic subgroup. However, the melancholic subgroup-treatment interactions from the analysis-of-variance models were nonsignificant.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Further research is warranted to test the hypothesis that bipolar depression with melancholic symptoms is more responsive to lamotrigine over placebo than nonmelancholic bipolar depression.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Peters</LastName><ForeName>Evyn M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>From the Department of Psychiatry, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bowen</LastName><ForeName>Rudy</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Balbuena</LastName><ForeName>Lloyd</ForeName><Initials>L</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychopharmacol</MedlineTA><NlmUniqueID>8109496</NlmUniqueID><ISSNLinking>0271-0749</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>U3H27498KS</RegistryNumber><NameOfSubstance UI="D000077213">Lamotrigine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077213" MajorTopicYN="N">Lamotrigine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>8</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>12</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>8</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30124585</ArticleId><ArticleId IdType="doi">10.1097/JCP.0000000000000947</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">8834431</PMID><DateCompleted><Year>1996</Year><Month>11</Month><Day>27</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0271-0749</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><Issue>1</Issue><PubDate><Year>1996</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Journal of clinical psychopharmacology</Title><ISOAbbreviation>J Clin Psychopharmacol</ISOAbbreviation></Journal><ArticleTitle>Clozapine in rapid cycling bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>87-90</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Frye</LastName><ForeName>M A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Altshuler</LastName><ForeName>L L</ForeName><Initials>LL</Initials></Author><Author ValidYN="Y"><LastName>Bitran</LastName><ForeName>J A</ForeName><Initials>JA</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychopharmacol</MedlineTA><NlmUniqueID>8109496</NlmUniqueID><ISSNLinking>0271-0749</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>J60AR2IKIC</RegistryNumber><NameOfSubstance UI="D003024">Clozapine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003024" MajorTopicYN="N">Clozapine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017831" MajorTopicYN="N">Diagnosis, Dual (Psychiatry)</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019966" MajorTopicYN="N">Substance-Related Disorders</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1996</Year><Month>2</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1996</Year><Month>2</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1996</Year><Month>2</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8834431</ArticleId><ArticleId IdType="doi">10.1097/00004714-199602000-00022</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15117397</PMID><DateCompleted><Year>2004</Year><Month>09</Month><Day>07</Day></DateCompleted><DateRevised><Year>2007</Year><Month>11</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1398-5647</ISSN><JournalIssue CitedMedium="Print"><Volume>6</Volume><Issue>3</Issue><PubDate><Year>2004</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>A functional magnetic resonance imaging study of cortical asymmetry in bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>183-96</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Individuals with bipolar disorder (BPD) exhibit motor, perceptual, and cognitive disturbances involving predominantly right hemisphere dysfunction. This asymmetry has been used to advance the hypothesis that the pathogenesis of bipolar disorder may be related to disturbances of the right cerebral hemisphere. We employed functional magnetic resonance imaging to examine hemispheric asymmetries in manic and depressed BPD. A secondary goal of the study was to examine effects of psychotropic medications on blood volume changes in the motor cortices.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We studied 18 right-handed BPD and 13 right-handed normal healthy comparison subjects. Blood oxygen level dependent (BOLD) responses in the primary motor area (M1) and supplementary motor area (SMA) of both hemispheres were elicited during reaction time (RT) tasks.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Healthy subjects activated the SMA in a reciprocal fashion with significantly greater activity in the left SMA for right hand trials and the right SMA for left hand trials. Depressed BPD subjects failed to show this normal reciprocity indicating a failure to suppress unwanted activity in the ipsilateral right SMA, whereas manic BPD subjects failed to suppress unwanted ipsilateral SMA activity in both hemispheres. Manic and depressed BPD subjects exhibited greater activity in the left primary motor area suggesting increased cortical excitability. BPD subjects treated with antipsychotics or mood-stabilizing medications exhibited longer RTs, lower BOLD responses in M1 and SMA, and a loss of normal hemispheric asymmetry in the SMA than untreated subjects.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The presence of a right hemisphere disturbance in BPD is consistent with the hypothesis that the right hemisphere may be dominant in mood regulation. The presence of both left and right hemisphere disturbances in mania may explain the coexisting psychotic and affective symptoms observed in this condition.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Caligiuri</LastName><ForeName>Michael P</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of California at San Diego, and VISN-22 Mental Illness Research, Education, and Clinical Center, VA San Diego Healthcare System, USA. mcaliguiuri@ucsd.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>Gregory G</ForeName><Initials>GG</Initials></Author><Author ValidYN="Y"><LastName>Meloy</LastName><ForeName>M J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Eyler</LastName><ForeName>Lisa T</ForeName><Initials>LT</Initials></Author><Author ValidYN="Y"><LastName>Kindermann</LastName><ForeName>Sandra S</ForeName><Initials>SS</Initials></Author><Author ValidYN="Y"><LastName>Eberson</LastName><ForeName>Sonja</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Frank</LastName><ForeName>Lawrence R</ForeName><Initials>LR</Initials></Author><Author ValidYN="Y"><LastName>Lohr</LastName><ForeName>James B</ForeName><Initials>JB</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01-MH-57140</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004565" MajorTopicYN="N">Electroconvulsive Therapy</DescriptorName><QualifierName UI="Q000295" MajorTopicYN="N">instrumentation</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007839" MajorTopicYN="N">Functional Laterality</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="Y">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009044" MajorTopicYN="N">Motor Cortex</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011930" MajorTopicYN="N">Reaction Time</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>5</Month><Day>1</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>9</Month><Day>8</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>5</Month><Day>1</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15117397</ArticleId><ArticleId IdType="doi">10.1111/j.1399-5618.2004.00116.x</ArticleId><ArticleId IdType="pii">BDI116</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32212517</PMID><DateCompleted><Year>2020</Year><Month>04</Month><Day>01</Day></DateCompleted><DateRevised><Year>2020</Year><Month>04</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1533-4406</ISSN><JournalIssue CitedMedium="Internet"><Volume>382</Volume><Issue>13</Issue><PubDate><Year>2020</Year><Month>Mar</Month><Day>26</Day></PubDate></JournalIssue><Title>The New England journal of medicine</Title><ISOAbbreviation>N Engl J Med</ISOAbbreviation></Journal><ArticleTitle>Suicide - Rewriting My Story.</ArticleTitle><Pagination><MedlinePgn>1196-1197</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1056/NEJMp1917203</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bullock</LastName><ForeName>Justin L</ForeName><Initials>JL</Initials><Identifier Source="ORCID">0000-0003-4240-9798</Identifier><AffiliationInfo><Affiliation>From the Department of Internal Medicine, University of California, San Francisco, School of Medicine, San Francisco.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D062210">Personal Narrative</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>N Engl J Med</MedlineTA><NlmUniqueID>0255562</NlmUniqueID><ISSNLinking>0028-4793</ISSNLinking></MedlineJournalInfo><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000223" MajorTopicYN="N">Adaptation, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="Y">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007396" MajorTopicYN="Y">Internship and Residency</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010815" MajorTopicYN="N">Physician Impairment</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059020" MajorTopicYN="Y">Suicidal Ideation</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>3</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>3</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>4</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32212517</ArticleId><ArticleId IdType="doi">10.1056/NEJMp1917203</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">26062406</PMID><DateCompleted><Year>2016</Year><Month>03</Month><Day>09</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1399-5618</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>5</Issue><PubDate><Year>2015</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>Association between history of psychosis and cardiovascular disease in bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>518-27</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/bdi.12302</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To determine whether clinical features of bipolar disorder, such as history of psychosis, and cardiovascular disease (CVD) risk factors contribute to a higher risk of CVD among patients with bipolar disorder.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This cross-sectional study included a sample of 988 patients with bipolar I or bipolar II disorder or schizoaffective bipolar type confirmed by the Structured Clinical Interview for DSM-IV-TR disorders (SCID). Medical comorbidity burden was quantified utilizing the Cumulative Illness Severity Rating Scale (CIRS). This 13-item organ-based scale includes cardiac disease severity quantification. Confirmed by medical record review, patients who scored 1 (current mild or past significant problem) or higher in the cardiac item were compared by logistic regression to patients who scored 0 (no impairment), adjusting for CVD risk factors that were selected using a backwards stepwise approach or were obtained from the literature.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In a multivariate model, age [odds ratio (OR) = 3.03, 95% confidence interval (CI): 1.66-5.54, p &lt; 0.0001], hypertension (OR = 2.43, 95% CI: 1.69-3.55, p &lt; 0.0001), and history of psychosis (OR = 1.48, 95% CI: 1.03-2.13, p = 0.03) were associated with CVD. When CVD risk factors from the literature were added to the analysis, age (OR = 3.19, 95% CI: 1.67-6.10, p = 0.0005) and hypertension (OR = 2.46, 95% CI: 1.61-3.76, p &lt; 0.01) remained significant, with psychosis being at the trend level (OR = 1.43, 95% CI: 0.96-2.13, p = 0.08).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The phenotype of psychotic bipolar disorder may reflect higher illness severity with associated cardiac comorbidity. Further studies are encouraged to clarify the effect of the disease burden (i.e., depression), lifestyle, and treatment interventions (i.e., atypical antipsychotics) on this risk association.</AbstractText><CopyrightInformation>© 2015 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Prieto</LastName><ForeName>Miguel L</ForeName><Initials>ML</Initials><Identifier Source="ORCID">http://orcid.org/0000-0001-5578-4605</Identifier><AffiliationInfo><Affiliation>Mayo Clinic Depression Center, Department of Psychiatry and Psychology, Rochester, MN, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departamento de Psiquiatría, Facultad de Medicina, Universidad de los Andes, Santiago, Chile.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McElroy</LastName><ForeName>Susan L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Lindner Center of HOPE, Mason, OH, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hayes</LastName><ForeName>Sharonne N</ForeName><Initials>SN</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Diseases, Department of Medicine, Mayo Clinic College of Medicine, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sutor</LastName><ForeName>Bruce</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Mayo Clinic Depression Center, Department of Psychiatry and Psychology, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kung</LastName><ForeName>Simon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Mayo Clinic Depression Center, Department of Psychiatry and Psychology, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bobo</LastName><ForeName>William V</ForeName><Initials>WV</Initials><AffiliationInfo><Affiliation>Mayo Clinic Depression Center, Department of Psychiatry and Psychology, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fuentes</LastName><ForeName>Manuel E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Facultad de Medicina Clínica Alemana/Universidad del Desarrollo, Santiago, Chile.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cuellar-Barboza</LastName><ForeName>Alfredo B</ForeName><Initials>AB</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Universidad Autónoma de Nuevo León, Monterrey, México.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crow</LastName><ForeName>Scott</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Minnesota, Minneapolis, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ösby</LastName><ForeName>Urban</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chauhan</LastName><ForeName>Mohit</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Mayo Clinic Depression Center, Department of Psychiatry and Psychology, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Westman</LastName><ForeName>Jeanette</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Geske</LastName><ForeName>Jennifer R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Colby</LastName><ForeName>Colin L</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryu</LastName><ForeName>Euijung</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Biernacka</LastName><ForeName>Joanna M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Mayo Clinic Depression Center, Department of Psychiatry and Psychology, Rochester, MN, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frye</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Mayo Clinic Depression Center, Department of Psychiatry and Psychology, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>06</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002318" MajorTopicYN="N">Cardiovascular Diseases</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006973" MajorTopicYN="N">Hypertension</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016015" MajorTopicYN="N">Logistic Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016017" MajorTopicYN="N">Odds Ratio</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">bipolar disorder</Keyword><Keyword MajorTopicYN="N">cardiovascular diseases</Keyword><Keyword MajorTopicYN="N">hypertension</Keyword><Keyword MajorTopicYN="N">phenotype</Keyword><Keyword MajorTopicYN="N">risk</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>09</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>01</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>6</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>6</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>3</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26062406</ArticleId><ArticleId IdType="doi">10.1111/bdi.12302</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27128720</PMID><DateCompleted><Year>2017</Year><Month>03</Month><Day>02</Day></DateCompleted><DateRevised><Year>2017</Year><Month>03</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1533-4112</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>3</Issue><PubDate><Year>2016</Year><Month>Sep</Month></PubDate></JournalIssue><Title>The journal of ECT</Title><ISOAbbreviation>J ECT</ISOAbbreviation></Journal><ArticleTitle>Effects of Electroconvulsive Therapy on Patients With Temporomandibular Joint Disorder.</ArticleTitle><Pagination><MedlinePgn>e14-5</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/YCT.0000000000000318</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rajan</LastName><ForeName>Royce</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Rutgers University New Jersey Medical School Newark, NJ sunye@rutgers.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Ye-Ming</ForeName><Initials>YM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J ECT</MedlineTA><NlmUniqueID>9808943</NlmUniqueID><ISSNLinking>1095-0680</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004565" MajorTopicYN="N">Electroconvulsive Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061214" MajorTopicYN="N">Patient Safety</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013705" MajorTopicYN="N">Temporomandibular Joint Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>4</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>4</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>3</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27128720</ArticleId><ArticleId IdType="doi">10.1097/YCT.0000000000000318</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12091194</PMID><DateCompleted><Year>2002</Year><Month>07</Month><Day>25</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0002-953X</ISSN><JournalIssue CitedMedium="Print"><Volume>159</Volume><Issue>7</Issue><PubDate><Year>2002</Year><Month>Jul</Month></PubDate></JournalIssue><Title>The American journal of psychiatry</Title><ISOAbbreviation>Am J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Suicide attempts in patients with bipolar I disorder during acute and maintenance phases of intensive treatment with pharmacotherapy and adjunctive psychotherapy.</ArticleTitle><Pagination><MedlinePgn>1160-4</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Lifetime rates of suicide attempts among patients with bipolar I disorder were compared to rates during a 2-year period of intensive treatment with pharmacotherapy and with one of two adjunctive psychosocial interventions.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Subjects entered the study during an acute mood episode. Subjects were treated with primarily lithium pharmacotherapy and with either psychotherapy specific to bipolar disorder, which included help in regularizing daily routines, or nonspecific, intensive clinical management involving regular visits with empathic clinicians. Data on prior suicide attempts were obtained retrospectively from interviews with the NIMH-Life-Chart method. Data on suicide attempts during the clinical trial were collected systematically throughout the protocol.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The rate of suicide attempts was 1.05 per 100 person-months before patients entered the trial. Patients experienced a threefold reduction in the rate of suicide attempts during the acute treatment phase (until the patient achieved stabilization, defined by completion of 4 weeks during which the patient had a mean score of &lt; or =7 on the 17-item Hamilton Depression Rating Scale and &lt; or =7 on the Bech-Rafaelsen Mania Scale) and a 17.5-fold reduction during maintenance treatment. Poisson loglinear regression analysis modeling the relationship between the observed rates and the three protocol stages (pretreatment, acute, and maintenance) showed that the reductions were significant in the acute and maintenance phases, compared with the pretreatment phase. No patient with one or more suicide attempts before entering the trial attempted suicide during the protocol.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">A treatment program in a maximally supportive clinical environment can significantly reduce suicidal behavior in high-risk patients with bipolar I disorder.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rucci</LastName><ForeName>Paola</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Western Psychiatric Institite and Clinic, 3811 O'Hara Street, Pittsburgh, PA 15213, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frank</LastName><ForeName>Ellen</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Kostelnik</LastName><ForeName>Bryan</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Fagiolini</LastName><ForeName>Andrea</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Mallinger</LastName><ForeName>Alan G</ForeName><Initials>AG</Initials></Author><Author ValidYN="Y"><LastName>Swartz</LastName><ForeName>Holly A</ForeName><Initials>HA</Initials></Author><Author ValidYN="Y"><LastName>Thase</LastName><ForeName>Michael E</ForeName><Initials>ME</Initials></Author><Author ValidYN="Y"><LastName>Siegel</LastName><ForeName>Lori</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Wilson</LastName><ForeName>Dorothy</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Kupfer</LastName><ForeName>David J</ForeName><Initials>DJ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MH 29618</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH 30915</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Psychiatry</MedlineTA><NlmUniqueID>0370512</NlmUniqueID><ISSNLinking>0002-953X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011613" MajorTopicYN="N">Psychotherapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013406" MajorTopicYN="N">Suicide, Attempted</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>7</Month><Day>2</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>7</Month><Day>26</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>7</Month><Day>2</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12091194</ArticleId><ArticleId IdType="doi">10.1176/appi.ajp.159.7.1160</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">6439056</PMID><DateCompleted><Year>1984</Year><Month>12</Month><Day>28</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0002-953X</ISSN><JournalIssue CitedMedium="Print"><Volume>141</Volume><Issue>12</Issue><PubDate><Year>1984</Year><Month>Dec</Month></PubDate></JournalIssue><Title>The American journal of psychiatry</Title><ISOAbbreviation>Am J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Psychomotor epileptic symptoms in six patients with bipolar mood disorders.</ArticleTitle><Pagination><MedlinePgn>1583-6</MedlinePgn></Pagination><Abstract><AbstractText>Of 12 consecutive patients with bipolar mood disorders satisfying DSM-III criteria, six were discovered to have five or more psychomotor epileptic symptoms. All of the six had olfactory hallucinations, metamorphopsias, and multiple déjà vu or mystical experiences. Each of them responded to lithium carbonate and had a first-degree relative with a bipolar disorder. The authors suggest that psychomotor symptoms may be more prevalent in bipolar patients than has hitherto been recognized.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lewis</LastName><ForeName>D O</ForeName><Initials>DO</Initials></Author><Author ValidYN="Y"><LastName>Feldman</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Greene</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Martinez-Mustardo</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Psychiatry</MedlineTA><NlmUniqueID>0370512</NlmUniqueID><ISSNLinking>0002-953X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>2BMD2GNA4V</RegistryNumber><NameOfSubstance UI="D016651">Lithium Carbonate</NameOfSubstance></Chemical><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003690" MajorTopicYN="N">Deja Vu</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004569" MajorTopicYN="N">Electroencephalography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004833" MajorTopicYN="N">Epilepsy, Temporal Lobe</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006212" MajorTopicYN="N">Hallucinations</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016651" MajorTopicYN="N">Lithium Carbonate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012903" MajorTopicYN="N">Smell</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014796" MajorTopicYN="N">Visual Perception</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1984</Year><Month>12</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1984</Year><Month>12</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1984</Year><Month>12</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">6439056</ArticleId><ArticleId IdType="doi">10.1176/ajp.141.12.1583</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19752647</PMID><DateCompleted><Year>2009</Year><Month>09</Month><Day>24</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1539-736X</ISSN><JournalIssue CitedMedium="Internet"><Volume>197</Volume><Issue>9</Issue><PubDate><Year>2009</Year><Month>Sep</Month></PubDate></JournalIssue><Title>The Journal of nervous and mental disease</Title><ISOAbbreviation>J Nerv Ment Dis</ISOAbbreviation></Journal><ArticleTitle>Specificities of defense mechanisms in bipolar affective disorder: relations with symptoms and therapeutic alliance.</ArticleTitle><Pagination><MedlinePgn>675-81</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/NMD.0b013e3181b3b224</ELocationID><Abstract><AbstractText>Defense mechanisms as a central notion of psychoanalysis have inspired various levels of interest in research in psychotherapy and psychopathology. Defense specificities have only recently been investigated systematically with regard to several clinical diagnoses, such as affective and personality disorders. For the present study, 30 inpatients diagnosed with Bipolar Affective Disorder I (BD) were interviewed. An observer-rater method, the Defense Mechanisms Rating Scales (DMRS), applied to session-transcripts, of assessment of defenses was used. A matched, nonclinical control group was introduced. Defense specificities in BD encompass a set of 5 immature defenses, of which omnipotence is linked with symptom level. The level of the therapeutic alliance is predicted by mature defenses. These results are discussed with regard to the psychological vulnerability of BD, and treatment implications for psychodynamic psychotherapy with such challenging patients are evoked.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kramer</LastName><ForeName>Ueli</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Departments of Psychology, University Hospitals of Lausanne, University of Lausanne, Switzerland. Ueli.Kramer@chuv.ch</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Roten</LastName><ForeName>Yves</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Perry</LastName><ForeName>J Christopher</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Despland</LastName><ForeName>Jean-Nicolas</ForeName><Initials>JN</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Nerv Ment Dis</MedlineTA><NlmUniqueID>0375402</NlmUniqueID><ISSNLinking>0022-3018</ISSNLinking></MedlineJournalInfo><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003674" MajorTopicYN="Y">Defense Mechanisms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016014" MajorTopicYN="N">Linear Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010554" MajorTopicYN="N">Personality Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010555" MajorTopicYN="N">Personality Inventory</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011369" MajorTopicYN="Y">Professional-Patient Relations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013811" MajorTopicYN="N">Psychotherapeutic Processes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011613" MajorTopicYN="N">Psychotherapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>9</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>9</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>9</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19752647</ArticleId><ArticleId IdType="doi">10.1097/NMD.0b013e3181b3b224</ArticleId><ArticleId IdType="pii">00005053-200909000-00006</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15225148</PMID><DateCompleted><Year>2004</Year><Month>10</Month><Day>28</Day></DateCompleted><DateRevised><Year>2007</Year><Month>03</Month><Day>22</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1398-5647</ISSN><JournalIssue CitedMedium="Print"><Volume>6</Volume><Issue>4</Issue><PubDate><Year>2004</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>Pediatric bipolar disorder: phenomenology and course of illness.</ArticleTitle><Pagination><MedlinePgn>305-13</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Specific features and diagnostic boundaries of childhood bipolar disorder (BD) remain controversial, and its differentiation from other disorders challenging, owing to high comorbidity with other common childhood disorders, and frequent lack of an episodic course typical of adult BD.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We repeatedly examined children meeting DSM-IV criteria for BD (excluding episode-duration requirements) and analyzed their clinical records to evaluate age-at-onset, family history, symptoms, course, and comorbidity.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of 82 juveniles (aged 10.6 +/- 3.6 years) diagnosed with BD, 90% had a family history of mood or substance-use disorders, but only 10% of patients had been diagnosed with BD. In 74%, psychopathology was recognized before age 3, usually as mood and sleep disturbances, hyperactivity, aggression, and anxiety. At onset, dysphoric-manic and mixed presentations were most common (48%), euphoric mania less (35%), and depression least (17%). Subtype diagnoses were: BP-I (52%) &gt; BP-II (40%) &gt; cyclothymia (7%). DSM episode-duration criteria were met in 52% of cases, and frequent shifts of mood and energy were common.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">Partly retrospective study of clinically diagnosed referred outpatients without a comparison group.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Pediatric BD is often mis- or undiagnosed, although it often manifests with mood lability and sleep disturbances early in life. DSM BD criteria inconsistent with clinical findings require revision for pediatric application.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Faedda</LastName><ForeName>Gianni L</ForeName><Initials>GL</Initials><AffiliationInfo><Affiliation>Lucio Bini Mood Disorders Center, New York, NY 10022, USA. gianni.faedda@moodcenter.org</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baldessarini</LastName><ForeName>Ross J</ForeName><Initials>RJ</Initials></Author><Author ValidYN="Y"><LastName>Glovinsky</LastName><ForeName>Ira P</ForeName><Initials>IP</Initials></Author><Author ValidYN="Y"><LastName>Austin</LastName><ForeName>Nancy B</ForeName><Initials>NB</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>7</Month><Day>1</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>10</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>7</Month><Day>1</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15225148</ArticleId><ArticleId IdType="doi">10.1111/j.1399-5618.2004.00128.x</ArticleId><ArticleId IdType="pii">BDI128</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">7410328</PMID><DateCompleted><Year>1980</Year><Month>11</Month><Day>25</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0160-6689</ISSN><JournalIssue CitedMedium="Print"><Volume>41</Volume><Issue>9</Issue><PubDate><Year>1980</Year><Month>Sep</Month></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Case report: manic depressive psychosis following infectious mononucleosis.</ArticleTitle><Pagination><MedlinePgn>322-3</MedlinePgn></Pagination><Abstract><AbstractText>The onset of manic depressive psychosis following infectious mononucleosis is reported. The patient appeared to be predisposed to develop such an illness, and it is postulated that the initial hypomanic episode may have been precipitated by an alteration in cerebral biogenic amines due to the infectious mononucleosis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Goldney</LastName><ForeName>R D</ForeName><Initials>RD</Initials></Author><Author ValidYN="Y"><LastName>Temme</LastName><ForeName>P B</ForeName><Initials>PB</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical><Chemical><RegistryNumber>J6292F8L3D</RegistryNumber><NameOfSubstance UI="D006220">Haloperidol</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006220" MajorTopicYN="N">Haloperidol</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007244" MajorTopicYN="N">Infectious Mononucleosis</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1980</Year><Month>9</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1980</Year><Month>9</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1980</Year><Month>9</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">7410328</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">8993155</PMID><DateCompleted><Year>1997</Year><Month>02</Month><Day>21</Day></DateCompleted><DateRevised><Year>2006</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0037-5675</ISSN><JournalIssue CitedMedium="Print"><Volume>37</Volume><Issue>4</Issue><PubDate><Year>1996</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Singapore medical journal</Title><ISOAbbreviation>Singapore Med J</ISOAbbreviation></Journal><ArticleTitle>Mania following left hemisphere injury.</ArticleTitle><Pagination><MedlinePgn>448-50</MedlinePgn></Pagination><Abstract><AbstractText>A case of mania following closed head injury to the left hemisphere is reported. The patient presented with a self-limiting manic episode that recovered without treatment. It is postulated that the head injury is the causative factor in this case. This was supported by laboratory results as well as psychological investigations. It is believed that non-dominant right hemisphere injury is related to the development of mania. However, a search of the literature revealed five other cases of mania following left hemispheric injury. Although the mechanisms implicated in the pathogenesis of secondary mania have not been established, this case adds to the growing evidence that head injury may be directly causative in affective psychoses. Therefore, it is premature to conclude that mania is a pathology of the non-dominant right hemisphere.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lim</LastName><ForeName>L C</ForeName><Initials>LC</Initials><AffiliationInfo><Affiliation>Department of Psychological Medicine National University Hospital, Singapore.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Singapore</Country><MedlineTA>Singapore Med J</MedlineTA><NlmUniqueID>0404516</NlmUniqueID><ISSNLinking>0037-5675</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000063" MajorTopicYN="Y">Accidents, Traffic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000033" MajorTopicYN="N">anatomy &amp; histology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004569" MajorTopicYN="N">Electroencephalography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007839" MajorTopicYN="Y">Functional Laterality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016489" MajorTopicYN="N">Head Injuries, Closed</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012075" MajorTopicYN="N">Remission, Spontaneous</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014057" MajorTopicYN="N">Tomography, X-Ray Computed</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>18</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1996</Year><Month>8</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1996</Year><Month>8</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1996</Year><Month>8</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8993155</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">26651011</PMID><DateCompleted><Year>2016</Year><Month>07</Month><Day>18</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1473-6578</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>1</Issue><PubDate><Year>2016</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Current opinion in psychiatry</Title><ISOAbbreviation>Curr Opin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>The complexity of bipolar and borderline personality: an expression of 'emotional frailty'?</ArticleTitle><Pagination><MedlinePgn>84-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/YCO.0000000000000214</ELocationID><Abstract><AbstractText Label="PURPOSE OF REVIEW" NlmCategory="OBJECTIVE">The purpose of this article is to review recent findings regarding the comorbidity of bipolar disorder with borderline personality disorder (BPD). The conceptualization of the comorbid condition is explored in the context of complexity theory.</AbstractText><AbstractText Label="RECENT FINDINGS" NlmCategory="RESULTS">Recent studies highlight distinguishing features between the two disorders. The course of illness of the comorbid condition is generally considered to be more debilitating than bipolar disorder alone.</AbstractText><AbstractText Label="SUMMARY" NlmCategory="CONCLUSIONS">Some of the differentiating features of bipolar disorder and BPD are highlighted. It is also crucial to consider a co-morbid diagnosis as worse outcomes may be anticipated than for bipolar disorder alone. The concept of 'emotional frailty' is introduced and the comorbid bipolar disorder-BPD condition is considered an expression of this syndrome.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>McDermid</LastName><ForeName>Joanna</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>aDepartment of PsychiatrybDepartment of Medicine, Division of Critical Care, University of British Columbia, Vancouver, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McDermid</LastName><ForeName>Robert C</ForeName><Initials>RC</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Curr Opin Psychiatry</MedlineTA><NlmUniqueID>8809880</NlmUniqueID><ISSNLinking>0951-7367</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001883" MajorTopicYN="N">Borderline Personality Disorder</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004644" MajorTopicYN="Y">Emotions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010551" MajorTopicYN="N">Personality</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>12</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>12</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>7</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26651011</ArticleId><ArticleId IdType="doi">10.1097/YCO.0000000000000214</ArticleId><ArticleId IdType="pii">00001504-201601000-00014</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16641832</PMID><DateCompleted><Year>2006</Year><Month>08</Month><Day>02</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>22</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1092-8529</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><Issue>4</Issue><PubDate><Year>2006</Year><Month>Apr</Month></PubDate></JournalIssue><Title>CNS spectrums</Title><ISOAbbreviation>CNS Spectr</ISOAbbreviation></Journal><ArticleTitle>Bipolar disorder and advances in neuroimaging: a progressive match.</ArticleTitle><Pagination><MedlinePgn>267-8</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Strakowski</LastName><ForeName>Stephen M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Center for Imaging Research, University of Cincinnati College of Medicine, Cincinnati, OH, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>CNS Spectr</MedlineTA><NlmUniqueID>9702877</NlmUniqueID><ISSNLinking>1092-8529</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001931" MajorTopicYN="N">Brain Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D038524" MajorTopicYN="N">Diffusion Magnetic Resonance Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007091" MajorTopicYN="Y">Image Processing, Computer-Assisted</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009415" MajorTopicYN="N">Nerve Net</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>4</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>8</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>4</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16641832</ArticleId><ArticleId IdType="doi">10.1017/s1092852900020769</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19500097</PMID><DateCompleted><Year>2009</Year><Month>08</Month><Day>17</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1399-5618</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>4</Issue><PubDate><Year>2009</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>Earliest symptoms discriminating juvenile-onset bipolar illness from ADHD.</ArticleTitle><Pagination><MedlinePgn>441-51</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1399-5618.2009.00684.x</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Controversy surrounds the diagnosis and earliest symptoms of childhood-onset bipolar illness, emphasizing the importance of prospective longitudinal studies. To acquire a preliminary, more immediate view of symptom evolution, we examined the course of individual symptoms over the first 10 years of life in juvenile-onset bipolar illness (JO-BP) compared with attention-deficit hyperactivity disorder (ADHD).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Parents of formally diagnosed children retrospectively rated 37 symptoms in each year of the child's life based on the degree of dysfunction in their child's usual family, social, or educational roles. A subset of children with onset of bipolar disorder prior to age 9 (JO-BP) compared with those with ADHD was the focus of this analysis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Brief and extended periods of mood elevation and decreased sleep were strong early differentiators of JO-BP and ADHD children. Depressive and somatic symptoms were later differentiators. Irritability and poor frustration tolerance differentiated the two groups only in their greater incidence and severity in JO-BP compared with a moderate occurrence in ADHD. In contrast, hyperactivity, impulsivity, and decreased attention showed highly similar trajectories in the two groups.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Elevated mood and decreased sleep discriminated JO-BP and ADHD as early as age 3, while classic ADHD symptoms were parallel in the groups. These retrospective results provide preliminary insights into symptom differences and their temporal evolution between bipolar disorder and ADHD in the first 10 years of life.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Luckenbaugh</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Mood and Anxiety Disorders Program, NIMH, NIH, Department of Health and Human Services, Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Findling</LastName><ForeName>Robert L</ForeName><Initials>RL</Initials></Author><Author ValidYN="Y"><LastName>Leverich</LastName><ForeName>Gabriele S</ForeName><Initials>GS</Initials></Author><Author ValidYN="Y"><LastName>Pizzarello</LastName><ForeName>Scott M</ForeName><Initials>SM</Initials></Author><Author ValidYN="Y"><LastName>Post</LastName><ForeName>Robert M</ForeName><Initials>RM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001289" MajorTopicYN="N">Attention Deficit Disorder with Hyperactivity</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012893" MajorTopicYN="N">Sleep Wake Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>6</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>6</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>8</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19500097</ArticleId><ArticleId IdType="pii">BDI684</ArticleId><ArticleId IdType="doi">10.1111/j.1399-5618.2009.00684.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">7545160</PMID><DateCompleted><Year>1995</Year><Month>10</Month><Day>11</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0160-6689</ISSN><JournalIssue CitedMedium="Print"><Volume>56</Volume><Issue>9</Issue><PubDate><Year>1995</Year><Month>Sep</Month></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Risperidone treatment of refractory acute mania.</ArticleTitle><Pagination><MedlinePgn>431-2</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Goodnick</LastName><ForeName>P J</ForeName><Initials>PJ</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007555">Isoxazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010880">Piperidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>L6UH7ZF8HC</RegistryNumber><NameOfSubstance UI="D018967">Risperidone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007555" MajorTopicYN="N">Isoxazoles</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010880" MajorTopicYN="N">Piperidines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018967" MajorTopicYN="N">Risperidone</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1995</Year><Month>9</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1995</Year><Month>9</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1995</Year><Month>9</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">7545160</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">4041696</PMID><DateCompleted><Year>1985</Year><Month>10</Month><Day>31</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0007-1250</ISSN><JournalIssue CitedMedium="Print"><Volume>147</Volume><PubDate><Year>1985</Year><Month>Aug</Month></PubDate></JournalIssue><Title>The British journal of psychiatry : the journal of mental science</Title><ISOAbbreviation>Br J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>1,250 electroconvulsive treatments without evidence of brain injury.</ArticleTitle><Pagination><MedlinePgn>203-4</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lippman</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Manshadi</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Wehry</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Byrd</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Past</LastName><ForeName>W</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Keller</LastName><ForeName>W</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Schuster</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Elam</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Meyer</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>O'Daniel</LastName><ForeName>R</ForeName><Initials>R</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Br J Psychiatry</MedlineTA><NlmUniqueID>0342367</NlmUniqueID><ISSNLinking>0007-1250</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001930" MajorTopicYN="N">Brain Injuries</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004565" MajorTopicYN="N">Electroconvulsive Therapy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1985</Year><Month>8</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1985</Year><Month>8</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1985</Year><Month>8</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">4041696</ArticleId><ArticleId IdType="pii">S0007125000206971</ArticleId><ArticleId IdType="doi">10.1192/bjp.147.2.203</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">5041534</PMID><DateCompleted><Year>1972</Year><Month>09</Month><Day>12</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0007-1250</ISSN><JournalIssue CitedMedium="Print"><Volume>120</Volume><Issue>558</Issue><PubDate><Year>1972</Year><Month>May</Month></PubDate></JournalIssue><Title>The British journal of psychiatry : the journal of mental science</Title><ISOAbbreviation>Br J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>The incidence of depressive symptoms during recovery from hypomania.</ArticleTitle><Pagination><MedlinePgn>537-9</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Morgan</LastName><ForeName>H G</ForeName><Initials>HG</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Br J Psychiatry</MedlineTA><NlmUniqueID>0342367</NlmUniqueID><ISSNLinking>0007-1250</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>J6292F8L3D</RegistryNumber><NameOfSubstance UI="D006220">Haloperidol</NameOfSubstance></Chemical><Chemical><RegistryNumber>U42B7VYA4P</RegistryNumber><NameOfSubstance UI="D002746">Chlorpromazine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002746" MajorTopicYN="N">Chlorpromazine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003289" MajorTopicYN="N">Convalescence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006220" MajorTopicYN="N">Haloperidol</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1972</Year><Month>5</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1972</Year><Month>5</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1972</Year><Month>5</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">5041534</ArticleId><ArticleId IdType="pii">S0007125000109638</ArticleId><ArticleId IdType="doi">10.1192/bjp.120.558.537</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">27324989</PMID><DateCompleted><Year>2017</Year><Month>09</Month><Day>13</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1399-5618</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>4</Issue><PubDate><Year>2016</Year><Month>06</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>Brain-derived neurotrophic factor, impaired glucose metabolism, and bipolar disorder course.</ArticleTitle><Pagination><MedlinePgn>373-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/bdi.12399</ELocationID><Abstract><AbstractText Label="OBJECTIVES">The neurotrophin brain-derived neurotrophic factor (BDNF) has been proposed as a potential biomarker in bipolar disorder (BD). However, current evidence is limited and results have been highly heterogeneous. This study aimed to assess the moderating effect of impaired glucose metabolism (IGM) on plasma levels of BDNF in individuals with BD, and on the relationship between BDNF and variables of illness course.</AbstractText><AbstractText Label="METHODS">We measured and compared the plasma levels of BDNF in individuals with BD (n=57) and healthy controls (n=26). IGM was operationalized as pre-diabetes or type 2 diabetes mellitus. Information related to current and past psychiatric/medical history, as well as prescription of pharmacological treatments was also captured.</AbstractText><AbstractText Label="RESULTS">Individuals with BD had lower levels of BDNF, relative to healthy controls, after adjustment for age, gender, current medications, smoking, alcohol use, and IGM (P=.046). There was no effect of IGM (P=.860) and no interaction between BD diagnosis and IGM (P=.893). Peripheral BDNF levels were positively correlated with lifetime depressive episodes (P&lt;.001), psychiatric hospitalizations (P=.001) and suicide attempts (P=.021). IGM moderated the association between BDNF and the number of previous mood episodes (P&lt;.001), wherein there was a positive correlation in euglycemic participants and a negative correlation in individuals with IGM.</AbstractText><AbstractText Label="CONCLUSIONS">BD is independently associated with lower levels of BDNF; IGM may modify the relationship between BDNF and BD course, suggesting an interactive effect of BDNF with metabolic status on illness progression.</AbstractText><CopyrightInformation>© 2016 John Wiley &amp; Sons A/S Published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mansur</LastName><ForeName>Rodrigo B</ForeName><Initials>RB</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Research Group in Behavioral Neuroscience of Bipolar Disorder (GP-TB), Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Mood Disorders Psychopharmacology Unit (MDPU), University Health Network, University of Toronto, Toronto, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Santos</LastName><ForeName>Camila M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Research Group in Behavioral Neuroscience of Bipolar Disorder (GP-TB), Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rizzo</LastName><ForeName>Lucas B</ForeName><Initials>LB</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Research Group in Behavioral Neuroscience of Bipolar Disorder (GP-TB), Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Clinic for Psychiatry and Psychotherapy, University of Tübingen, Tübingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Asevedo</LastName><ForeName>Elson</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Research Group in Behavioral Neuroscience of Bipolar Disorder (GP-TB), Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cunha</LastName><ForeName>Graccielle R</ForeName><Initials>GR</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Research Group in Behavioral Neuroscience of Bipolar Disorder (GP-TB), Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Noto</LastName><ForeName>Mariane N</ForeName><Initials>MN</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Research Group in Behavioral Neuroscience of Bipolar Disorder (GP-TB), Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Vila Maria Outpatient Clinic, São Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pedrini</LastName><ForeName>Mariana</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Research Group in Behavioral Neuroscience of Bipolar Disorder (GP-TB), Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zeni-Graiff</LastName><ForeName>Maiara</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Research Group in Behavioral Neuroscience of Bipolar Disorder (GP-TB), Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cordeiro</LastName><ForeName>Quirino</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Irmandade da Santa Casa de Misericórdia de São Paulo (ISCMSP), São Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vinberg</LastName><ForeName>Maj</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Psychiatric Center Copenhagen, University of Copenhagen, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kapczinski</LastName><ForeName>Flavio</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Bipolar Disorder Program and Laboratory of Molecular Psychiatry, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McIntyre</LastName><ForeName>Roger S</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>Mood Disorders Psychopharmacology Unit (MDPU), University Health Network, University of Toronto, Toronto, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brietzke</LastName><ForeName>Elisa</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Research Group in Behavioral Neuroscience of Bipolar Disorder (GP-TB), Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>06</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019208">Brain-Derived Neurotrophic Factor</NameOfSubstance></Chemical><Chemical><RegistryNumber>IY9XDZ35W2</RegistryNumber><NameOfSubstance UI="D005947">Glucose</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000428" MajorTopicYN="N">Alcohol Drinking</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="Y">Bipolar Disorder</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019208" MajorTopicYN="N">Brain-Derived Neurotrophic Factor</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001938" MajorTopicYN="N">Brazil</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="Y">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005947" MajorTopicYN="N">Glucose</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011236" MajorTopicYN="Y">Prediabetic State</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012907" MajorTopicYN="N">Smoking</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013223" MajorTopicYN="N">Statistics as Topic</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">bipolar disorder</Keyword><Keyword MajorTopicYN="Y">brain-derived neurotrophic factor</Keyword><Keyword MajorTopicYN="Y">diabetes</Keyword><Keyword MajorTopicYN="Y">impaired glucose metabolism</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>01</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>04</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>04</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>6</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>6</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>9</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27324989</ArticleId><ArticleId IdType="doi">10.1111/bdi.12399</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">162485</PMID><DateCompleted><Year>1982</Year><Month>06</Month><Day>14</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0165-0327</ISSN><JournalIssue CitedMedium="Print"><Volume>1</Volume><Issue>4</Issue><PubDate><Year>1979</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Psychosis as a predictor of response to lithium maintenance treatment in bipolar affective disorder.</ArticleTitle><Pagination><MedlinePgn>237-45</MedlinePgn></Pagination><Abstract><AbstractText>Sixty-six bipolar I lithium clinic patients were studied for a history of psychotic symptoms at some time during the course of their illness. Agreement between different sources of information was calculated, and the patient population was divided into psychotic and non-psychotic subgroups. Probability of remaining well on lithium for the different subgroups was analyzed by the life table method. Psychosis during mania appeared to be associated with especially good early lithium prophylaxis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rosenthal</LastName><ForeName>N E</ForeName><Initials>NE</Initials></Author><Author ValidYN="Y"><LastName>Rosenthal</LastName><ForeName>L N</ForeName><Initials>LN</Initials></Author><Author ValidYN="Y"><LastName>Stallone</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Fleiss</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Dunner</LastName><ForeName>D L</ForeName><Initials>DL</Initials></Author><Author ValidYN="Y"><LastName>Fieve</LastName><ForeName>R R</ForeName><Initials>RR</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MH-21586</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>2BMD2GNA4V</RegistryNumber><NameOfSubstance UI="D016651">Lithium Carbonate</NameOfSubstance></Chemical><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000206" MajorTopicYN="N">Actuarial Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003702" MajorTopicYN="N">Delusions</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006212" MajorTopicYN="N">Hallucinations</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016651" MajorTopicYN="N">Lithium Carbonate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011336" MajorTopicYN="N">Probability</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1979</Year><Month>12</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1979</Year><Month>12</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1979</Year><Month>12</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">162485</ArticleId><ArticleId IdType="pii">0165-0327(79)90010-7</ArticleId><ArticleId IdType="doi">10.1016/0165-0327(79)90010-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">835747</PMID><DateCompleted><Year>1977</Year><Month>03</Month><Day>15</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0002-953X</ISSN><JournalIssue CitedMedium="Print"><Volume>134</Volume><Issue>2</Issue><PubDate><Year>1977</Year><Month>Feb</Month></PubDate></JournalIssue><Title>The American journal of psychiatry</Title><ISOAbbreviation>Am J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Physical violence in the concept of dangerousness: a case report.</ArticleTitle><Pagination><MedlinePgn>203-4</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Adebimpe</LastName><ForeName>V B</ForeName><Initials>VB</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Psychiatry</MedlineTA><NlmUniqueID>0370512</NlmUniqueID><ISSNLinking>0002-953X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003134" MajorTopicYN="Y">Commitment of Mentally Ill</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005555" MajorTopicYN="Y">Forensic Psychiatry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014754" MajorTopicYN="Y">Violence</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1977</Year><Month>2</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1977</Year><Month>2</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1977</Year><Month>2</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">835747</ArticleId><ArticleId IdType="doi">10.1176/ajp.134.2.203</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">8640201</PMID><DateCompleted><Year>1996</Year><Month>07</Month><Day>12</Day></DateCompleted><DateRevised><Year>2004</Year><Month>11</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0276-3478</ISSN><JournalIssue CitedMedium="Print"><Volume>19</Volume><Issue>1</Issue><PubDate><Year>1996</Year><Month>Jan</Month></PubDate></JournalIssue><Title>The International journal of eating disorders</Title><ISOAbbreviation>Int J Eat Disord</ISOAbbreviation></Journal><ArticleTitle>Comorbidity of binge eating disorder and the partial binge eating syndrome with bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>45-52</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The authors examined the prevalence of binge eating disorder (BED), partial binge eating syndrome, and night binge eating syndrome in subjects with bipolar disorder (BD).</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Sixty-one subjects in whom BD was established using DSM-III-R criteria received a semistructured clinical interview including a detailed description of binge eating behavior and of night binge eating. Frequencies were compared to prevalence estimates in community samples.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Eight subjects (13%) met DSM-IV criteria for the diagnosis of BED. An additional 15 subjects (25%) exhibited a partial binge eating syndrome. These two otherwise identical groups of binge eaters were separated only by the DSM-IV frequency criterion. The rates found were higher than rates found in community samples. Ten subjects reported night binge eating in addition to their usual binge eating behavior. This occurred consistently between 2:00 and 4:00 a.m.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Possible underlying mechanisms for the high frequency of binge eating among bipolar subjects are discussed including a model of serotonin-mediated self-modulation of mood. The finding of two groups of binge eaters separated only by the frequency criterion raises questions as to whether the frequency criterion as presently defined in DSM-IV is valid or should be modified.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Krüger</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Westfälisches Zentrum für Psychiatrie, University of Bochum, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shugar</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Cooke</LastName><ForeName>R G</ForeName><Initials>RG</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Int J Eat Disord</MedlineTA><NlmUniqueID>8111226</NlmUniqueID><ISSNLinking>0276-3478</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002032" MajorTopicYN="N">Bulimia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006963" MajorTopicYN="N">Hyperphagia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009864" MajorTopicYN="N" Type="Geographic">Ontario</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013577" MajorTopicYN="N">Syndrome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1996</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>6</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1996</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8640201</ArticleId><ArticleId IdType="pii">10.1002/(SICI)1098-108X(199601)19:1&lt;45::AID-EAT6&gt;3.0.CO;2-W</ArticleId><ArticleId IdType="doi">10.1002/(SICI)1098-108X(199601)19:1&lt;45::AID-EAT6&gt;3.0.CO;2-W</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">30022520</PMID><DateCompleted><Year>2019</Year><Month>05</Month><Day>06</Day></DateCompleted><DateRevised><Year>2019</Year><Month>05</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1099-1166</ISSN><JournalIssue CitedMedium="Internet"><Volume>33</Volume><Issue>10</Issue><PubDate><Year>2018</Year><Month>10</Month></PubDate></JournalIssue><Title>International journal of geriatric psychiatry</Title><ISOAbbreviation>Int J Geriatr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Statins and cognition in late-life bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>1355-1360</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/gps.4956</ELocationID><Abstract><AbstractText Label="OBJECTIVES">Recent data suggests that statins have positive effects on cognition in older adults. Studies in patients with mood disorders have found contradicting positive and negative effects of statins on mood and cognition, with limited data in bipolar disorder (BD). The objective of this study was to assess the association between statin use and cognition in older adults with BD.</AbstractText><AbstractText Label="METHODS">In a cross-sectional sample of 143 euthymic older adults with BD (age ≥ 50), statin users (n = 48) and nonusers (n = 95) were compared for cognitive outcomes: Global and cognitive domain z-scores were calculated from detailed neuropsychological batteries using normative data from healthy comparators (n = 87).</AbstractText><AbstractText Label="RESULTS">The sample had a mean age of 64.3 (±8.9) years, 65.0% were female, with an average of 15.1 (±2.79) years of education. Statin users did not differ from nonusers on global (-0.60 [±0.69] vs -0.49 [±0.68], t[127] = 0.80, P = .42) or individual cognitive domains z-score.</AbstractText><AbstractText Label="CONCLUSIONS">In older patients with BD, statin use is not independently associated with cognitive impairment. This suggests that in older BD patients, the cognitive dysfunction associated with BD trumps the potential cognitive benefit that is associated with statins in older adults without a psychiatric disorder. Further, statins do not seem to exacerbate this cognitive dysfunction. Future longitudinal studies are needed to confirm these findings.</AbstractText><CopyrightInformation>© 2018 John Wiley &amp; Sons, Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rej</LastName><ForeName>Soham</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-3908-9124</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, University of Toronto, Toronto, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Centre for Addiction and Mental Health, Toronto, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Jewish General Hospital, McGill University, Montreal, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schulte</LastName><ForeName>Sarah Waters</ForeName><Initials>SW</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Toronto, Toronto, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Centre for Addiction and Mental Health, Toronto, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rajji</LastName><ForeName>Tarek K</ForeName><Initials>TK</Initials><Identifier Source="ORCID">0000-0002-8324-2560</Identifier><AffiliationInfo><Affiliation>Department of Psychiatry, University of Toronto, Toronto, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Centre for Addiction and Mental Health, Toronto, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gildengers</LastName><ForeName>Ariel G</ForeName><Initials>AG</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miranda</LastName><ForeName>Dielle</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Toronto, Toronto, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Centre for Addiction and Mental Health, Toronto, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Menon</LastName><ForeName>Mahesh</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of British Columbia, Vancouver, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Butters</LastName><ForeName>Meryl A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mulsant</LastName><ForeName>Benoit H</ForeName><Initials>BH</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Toronto, Toronto, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry, Centre for Addiction and Mental Health, Toronto, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 MH90333</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH084921</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><Agency>CIHR</Agency><Country>Canada</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>07</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Geriatr Psychiatry</MedlineTA><NlmUniqueID>8710629</NlmUniqueID><ISSNLinking>0885-6230</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019161">Hydroxymethylglutaryl-CoA Reductase Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019161" MajorTopicYN="N">Hydroxymethylglutaryl-CoA Reductase Inhibitors</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">bipolar disorder</Keyword><Keyword MajorTopicYN="Y">cognition</Keyword><Keyword MajorTopicYN="Y">mood disorders</Keyword><Keyword MajorTopicYN="Y">statins</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>03</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>06</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>7</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>5</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>7</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30022520</ArticleId><ArticleId IdType="doi">10.1002/gps.4956</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25497296</PMID><DateCompleted><Year>2015</Year><Month>09</Month><Day>25</Day></DateCompleted><DateRevised><Year>2018</Year><Month>07</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1472-1465</ISSN><JournalIssue CitedMedium="Internet"><Volume>206</Volume><Issue>2</Issue><PubDate><Year>2015</Year><Month>Feb</Month></PubDate></JournalIssue><Title>The British journal of psychiatry : the journal of mental science</Title><ISOAbbreviation>Br J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Brain functional changes across the different phases of bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>136-44</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1192/bjp.bp.114.152033</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Little is known about how functional imaging changes in bipolar disorder relate to different phases of the illness.</AbstractText><AbstractText Label="AIMS" NlmCategory="OBJECTIVE">To compare cognitive task activation in participants with bipolar disorder examined in different phases of illness.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Participants with bipolar disorder in mania (n = 38), depression (n = 38) and euthymia (n = 38), as well as healthy controls (n = 38), underwent functional magnetic resonance imaging during performance of the n-back working memory task. Activations and de-activations were compared between the bipolar subgroups and the controls, and among the bipolar subgroups. All participants were also entered into a linear mixed-effects model.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Compared with the controls, the mania and depression subgroups, but not the euthymia subgroup, showed reduced activation in the dorsolateral prefrontal cortex, the parietal cortex and other areas. Compared with the euthymia subgroup, the mania and depression subgroups showed hypoactivation in the parietal cortex. All three bipolar subgroups showed failure of de-activation in the ventromedial frontal cortex. Linear mixed-effects modelling revealed a further cluster of reduced activation in the left dorsolateral prefrontal cortex in the patients; this was significantly more marked in the mania than in the euthymia subgroup.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Bipolar disorder is characterised by mood state-dependent hypoactivation in the parietal cortex. Reduced dorsolateral prefrontal activation is a further feature of mania and depression, which may improve partially in euthymia. Failure of de-activation in the medial frontal cortex shows trait-like characteristics.</AbstractText><CopyrightInformation>Royal College of Psychiatrists.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pomarol-Clotet</LastName><ForeName>Edith</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Edith Pomarol-Clotet, MD, PhD, Silvia Alonso-Lana, BSc, FIDMAG, Germanes Hospitalàries, Barcelona and Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain; Noemi Moro, MD, FIDMAG, Germanes Hospitalàries and Benito Menni Complex Assistencial en Salut Mental, Barcelona, Spain; Salvador Sarró, MD, FIDMAG, Germanes Hospitalàries, Barcelona and Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain; Mar C. Bonnin, BSc, José M. Goikolea, MD, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM) and Bipolar Disorder Program, Institute of Neuroscience, Hospital Clínic, University of Barcelona, IDIBAPS, Barcelona, Spain; Paloma Fernandez-Corcuera, MD, Germanes Hospitalàries and Benito Menni Complex Assistencial en Salut Mental, Barcelona, Spain; Benedikt L. Amann, MD, PhD, Anna Romaguera, MD, FIDMAG, Germanes Hospitalàries, Barcelona, Spain and Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain; Eduard Vieta, MD, PhD, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM) and Bipolar Disorder Program, Institute of Neuroscience, Hospital Clínic, University of Barcelona, IDIBAPS, Barcelona, Spain; Josep Blanch, MD, Hospital Sant Joan de Déu Infantil, Barcelona, Spain; Peter J. McKenna, MRCPsych, Raymond Salvador, PhD, FIDMAG, Germanes Hospitalàries, Barcelona, Spain and Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alonso-Lana</LastName><ForeName>Silvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Edith Pomarol-Clotet, MD, PhD, Silvia Alonso-Lana, BSc, FIDMAG, Germanes Hospitalàries, Barcelona and Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain; Noemi Moro, MD, FIDMAG, Germanes Hospitalàries and Benito Menni Complex Assistencial en Salut Mental, Barcelona, Spain; Salvador Sarró, MD, FIDMAG, Germanes Hospitalàries, Barcelona and Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain; Mar C. Bonnin, BSc, José M. Goikolea, MD, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM) and Bipolar Disorder Program, Institute of Neuroscience, Hospital Clínic, University of Barcelona, IDIBAPS, Barcelona, Spain; Paloma Fernandez-Corcuera, MD, Germanes Hospitalàries and Benito Menni Complex Assistencial en Salut Mental, Barcelona, Spain; Benedikt L. Amann, MD, PhD, Anna Romaguera, MD, FIDMAG, Germanes Hospitalàries, Barcelona, Spain and Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain; Eduard Vieta, MD, PhD, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM) and Bipolar Disorder Program, Institute of Neuroscience, Hospital Clínic, University of Barcelona, IDIBAPS, Barcelona, Spain; Josep Blanch, MD, Hospital Sant Joan de Déu Infantil, Barcelona, Spain; Peter J. McKenna, MRCPsych, Raymond Salvador, PhD, FIDMAG, Germanes Hospitalàries, Barcelona, Spain and Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moro</LastName><ForeName>Noemi</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Edith Pomarol-Clotet, MD, PhD, Silvia Alonso-Lana, BSc, FIDMAG, Germanes Hospitalàries, Barcelona and Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain; Noemi Moro, MD, FIDMAG, Germanes Hospitalàries and Benito Menni Complex Assistencial en Salut Mental, Barcelona, Spain; Salvador Sarró, MD, FIDMAG, Germanes Hospitalàries, Barcelona and Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain; Mar C. Bonnin, BSc, José M. Goikolea, MD, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM) and Bipolar Disorder Program, Institute of Neuroscience, Hospital Clínic, University of Barcelona, IDIBAPS, Barcelona, Spain; Paloma Fernandez-Corcuera, MD, Germanes Hospitalàries and Benito Menni Complex Assistencial en Salut Mental, Barcelona, Spain; Benedikt L. Amann, MD, PhD, Anna Romaguera, MD, FIDMAG, Germanes Hospitalàries, Barcelona, Spain and Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain; Eduard Vieta, MD, PhD, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM) and Bipolar Disorder Program, Institute of Neuroscience, Hospital Clínic, University of Barcelona, IDIBAPS, Barcelona, Spain; Josep Blanch, MD, Hospital Sant Joan de Déu Infantil, Barcelona, Spain; Peter J. McKenna, MRCPsych, Raymond Salvador, PhD, FIDMAG, Germanes Hospitalàries, Barcelona, Spain and Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sarró</LastName><ForeName>Salvador</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Edith Pomarol-Clotet, MD, PhD, Silvia Alonso-Lana, BSc, FIDMAG, Germanes Hospitalàries, Barcelona and Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain; Noemi Moro, MD, FIDMAG, Germanes Hospitalàries and Benito Menni Complex Assistencial en Salut Mental, Barcelona, Spain; Salvador Sarró, MD, FIDMAG, Germanes Hospitalàries, Barcelona and Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain; Mar C. Bonnin, BSc, José M. Goikolea, MD, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM) and Bipolar Disorder Program, Institute of Neuroscience, Hospital Clínic, University of Barcelona, IDIBAPS, Barcelona, Spain; Paloma Fernandez-Corcuera, MD, Germanes Hospitalàries and Benito Menni Complex Assistencial en Salut Mental, Barcelona, Spain; Benedikt L. Amann, MD, PhD, Anna Romaguera, MD, FIDMAG, Germanes Hospitalàries, Barcelona, Spain and Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain; Eduard Vieta, MD, PhD, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM) and Bipolar Disorder Program, Institute of Neuroscience, Hospital Clínic, University of Barcelona, IDIBAPS, Barcelona, Spain; Josep Blanch, MD, Hospital Sant Joan de Déu Infantil, Barcelona, Spain; Peter J. McKenna, MRCPsych, Raymond Salvador, PhD, FIDMAG, Germanes Hospitalàries, Barcelona, Spain and Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bonnin</LastName><ForeName>Mar C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Edith Pomarol-Clotet, MD, PhD, Silvia Alonso-Lana, BSc, FIDMAG, Germanes Hospitalàries, Barcelona and Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain; Noemi Moro, MD, FIDMAG, Germanes Hospitalàries and Benito Menni Complex Assistencial en Salut Mental, Barcelona, Spain; Salvador Sarró, MD, FIDMAG, Germanes Hospitalàries, Barcelona and Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain; Mar C. Bonnin, BSc, José M. Goikolea, MD, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM) and Bipolar Disorder Program, Institute of Neuroscience, Hospital Clínic, University of Barcelona, IDIBAPS, Barcelona, Spain; Paloma Fernandez-Corcuera, MD, Germanes Hospitalàries and Benito Menni Complex Assistencial en Salut Mental, Barcelona, Spain; Benedikt L. Amann, MD, PhD, Anna Romaguera, MD, FIDMAG, Germanes Hospitalàries, Barcelona, Spain and Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain; Eduard Vieta, MD, PhD, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM) and Bipolar Disorder Program, Institute of Neuroscience, Hospital Clínic, University of Barcelona, IDIBAPS, Barcelona, Spain; Josep Blanch, MD, Hospital Sant Joan de Déu Infantil, Barcelona, Spain; Peter J. McKenna, MRCPsych, Raymond Salvador, PhD, FIDMAG, Germanes Hospitalàries, Barcelona, Spain and Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goikolea</LastName><ForeName>José M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Edith Pomarol-Clotet, MD, PhD, Silvia Alonso-Lana, BSc, FIDMAG, Germanes Hospitalàries, Barcelona and Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain; Noemi Moro, MD, FIDMAG, Germanes Hospitalàries and Benito Menni Complex Assistencial en Salut Mental, Barcelona, Spain; Salvador Sarró, MD, FIDMAG, Germanes Hospitalàries, Barcelona and Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain; Mar C. Bonnin, BSc, José M. Goikolea, MD, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM) and Bipolar Disorder Program, Institute of Neuroscience, Hospital Clínic, University of Barcelona, IDIBAPS, Barcelona, Spain; Paloma Fernandez-Corcuera, MD, Germanes Hospitalàries and Benito Menni Complex Assistencial en Salut Mental, Barcelona, Spain; Benedikt L. Amann, MD, PhD, Anna Romaguera, MD, FIDMAG, Germanes Hospitalàries, Barcelona, Spain and Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain; Eduard Vieta, MD, PhD, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM) and Bipolar Disorder Program, Institute of Neuroscience, Hospital Clínic, University of Barcelona, IDIBAPS, Barcelona, Spain; Josep Blanch, MD, Hospital Sant Joan de Déu Infantil, Barcelona, Spain; Peter J. McKenna, MRCPsych, Raymond Salvador, PhD, FIDMAG, Germanes Hospitalàries, Barcelona, Spain and Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fernández-Corcuera</LastName><ForeName>Paloma</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Edith Pomarol-Clotet, MD, PhD, Silvia Alonso-Lana, BSc, FIDMAG, Germanes Hospitalàries, Barcelona and Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain; Noemi Moro, MD, FIDMAG, Germanes Hospitalàries and Benito Menni Complex Assistencial en Salut Mental, Barcelona, Spain; Salvador Sarró, MD, FIDMAG, Germanes Hospitalàries, Barcelona and Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain; Mar C. Bonnin, BSc, José M. Goikolea, MD, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM) and Bipolar Disorder Program, Institute of Neuroscience, Hospital Clínic, University of Barcelona, IDIBAPS, Barcelona, Spain; Paloma Fernandez-Corcuera, MD, Germanes Hospitalàries and Benito Menni Complex Assistencial en Salut Mental, Barcelona, Spain; Benedikt L. Amann, MD, PhD, Anna Romaguera, MD, FIDMAG, Germanes Hospitalàries, Barcelona, Spain and Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain; Eduard Vieta, MD, PhD, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM) and Bipolar Disorder Program, Institute of Neuroscience, Hospital Clínic, University of Barcelona, IDIBAPS, Barcelona, Spain; Josep Blanch, MD, Hospital Sant Joan de Déu Infantil, Barcelona, Spain; Peter J. McKenna, MRCPsych, Raymond Salvador, PhD, FIDMAG, Germanes Hospitalàries, Barcelona, Spain and Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amann</LastName><ForeName>Benedikt L</ForeName><Initials>BL</Initials><AffiliationInfo><Affiliation>Edith Pomarol-Clotet, MD, PhD, Silvia Alonso-Lana, BSc, FIDMAG, Germanes Hospitalàries, Barcelona and Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain; Noemi Moro, MD, FIDMAG, Germanes Hospitalàries and Benito Menni Complex Assistencial en Salut Mental, Barcelona, Spain; Salvador Sarró, MD, FIDMAG, Germanes Hospitalàries, Barcelona and Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain; Mar C. Bonnin, BSc, José M. Goikolea, MD, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM) and Bipolar Disorder Program, Institute of Neuroscience, Hospital Clínic, University of Barcelona, IDIBAPS, Barcelona, Spain; Paloma Fernandez-Corcuera, MD, Germanes Hospitalàries and Benito Menni Complex Assistencial en Salut Mental, Barcelona, Spain; Benedikt L. Amann, MD, PhD, Anna Romaguera, MD, FIDMAG, Germanes Hospitalàries, Barcelona, Spain and Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain; Eduard Vieta, MD, PhD, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM) and Bipolar Disorder Program, Institute of Neuroscience, Hospital Clínic, University of Barcelona, IDIBAPS, Barcelona, Spain; Josep Blanch, MD, Hospital Sant Joan de Déu Infantil, Barcelona, Spain; Peter J. McKenna, MRCPsych, Raymond Salvador, PhD, FIDMAG, Germanes Hospitalàries, Barcelona, Spain and Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Romaguera</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Edith Pomarol-Clotet, MD, PhD, Silvia Alonso-Lana, BSc, FIDMAG, Germanes Hospitalàries, Barcelona and Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain; Noemi Moro, MD, FIDMAG, Germanes Hospitalàries and Benito Menni Complex Assistencial en Salut Mental, Barcelona, Spain; Salvador Sarró, MD, FIDMAG, Germanes Hospitalàries, Barcelona and Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain; Mar C. Bonnin, BSc, José M. Goikolea, MD, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM) and Bipolar Disorder Program, Institute of Neuroscience, Hospital Clínic, University of Barcelona, IDIBAPS, Barcelona, Spain; Paloma Fernandez-Corcuera, MD, Germanes Hospitalàries and Benito Menni Complex Assistencial en Salut Mental, Barcelona, Spain; Benedikt L. Amann, MD, PhD, Anna Romaguera, MD, FIDMAG, Germanes Hospitalàries, Barcelona, Spain and Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain; Eduard Vieta, MD, PhD, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM) and Bipolar Disorder Program, Institute of Neuroscience, Hospital Clínic, University of Barcelona, IDIBAPS, Barcelona, Spain; Josep Blanch, MD, Hospital Sant Joan de Déu Infantil, Barcelona, Spain; Peter J. McKenna, MRCPsych, Raymond Salvador, PhD, FIDMAG, Germanes Hospitalàries, Barcelona, Spain and Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vieta</LastName><ForeName>Eduard</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Edith Pomarol-Clotet, MD, PhD, Silvia Alonso-Lana, BSc, FIDMAG, Germanes Hospitalàries, Barcelona and Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain; Noemi Moro, MD, FIDMAG, Germanes Hospitalàries and Benito Menni Complex Assistencial en Salut Mental, Barcelona, Spain; Salvador Sarró, MD, FIDMAG, Germanes Hospitalàries, Barcelona and Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain; Mar C. Bonnin, BSc, José M. Goikolea, MD, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM) and Bipolar Disorder Program, Institute of Neuroscience, Hospital Clínic, University of Barcelona, IDIBAPS, Barcelona, Spain; Paloma Fernandez-Corcuera, MD, Germanes Hospitalàries and Benito Menni Complex Assistencial en Salut Mental, Barcelona, Spain; Benedikt L. Amann, MD, PhD, Anna Romaguera, MD, FIDMAG, Germanes Hospitalàries, Barcelona, Spain and Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain; Eduard Vieta, MD, PhD, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM) and Bipolar Disorder Program, Institute of Neuroscience, Hospital Clínic, University of Barcelona, IDIBAPS, Barcelona, Spain; Josep Blanch, MD, Hospital Sant Joan de Déu Infantil, Barcelona, Spain; Peter J. McKenna, MRCPsych, Raymond Salvador, PhD, FIDMAG, Germanes Hospitalàries, Barcelona, Spain and Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blanch</LastName><ForeName>Josep</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Edith Pomarol-Clotet, MD, PhD, Silvia Alonso-Lana, BSc, FIDMAG, Germanes Hospitalàries, Barcelona and Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain; Noemi Moro, MD, FIDMAG, Germanes Hospitalàries and Benito Menni Complex Assistencial en Salut Mental, Barcelona, Spain; Salvador Sarró, MD, FIDMAG, Germanes Hospitalàries, Barcelona and Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain; Mar C. Bonnin, BSc, José M. Goikolea, MD, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM) and Bipolar Disorder Program, Institute of Neuroscience, Hospital Clínic, University of Barcelona, IDIBAPS, Barcelona, Spain; Paloma Fernandez-Corcuera, MD, Germanes Hospitalàries and Benito Menni Complex Assistencial en Salut Mental, Barcelona, Spain; Benedikt L. Amann, MD, PhD, Anna Romaguera, MD, FIDMAG, Germanes Hospitalàries, Barcelona, Spain and Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain; Eduard Vieta, MD, PhD, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM) and Bipolar Disorder Program, Institute of Neuroscience, Hospital Clínic, University of Barcelona, IDIBAPS, Barcelona, Spain; Josep Blanch, MD, Hospital Sant Joan de Déu Infantil, Barcelona, Spain; Peter J. McKenna, MRCPsych, Raymond Salvador, PhD, FIDMAG, Germanes Hospitalàries, Barcelona, Spain and Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McKenna</LastName><ForeName>Peter J</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>Edith Pomarol-Clotet, MD, PhD, Silvia Alonso-Lana, BSc, FIDMAG, Germanes Hospitalàries, Barcelona and Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain; Noemi Moro, MD, FIDMAG, Germanes Hospitalàries and Benito Menni Complex Assistencial en Salut Mental, Barcelona, Spain; Salvador Sarró, MD, FIDMAG, Germanes Hospitalàries, Barcelona and Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain; Mar C. Bonnin, BSc, José M. Goikolea, MD, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM) and Bipolar Disorder Program, Institute of Neuroscience, Hospital Clínic, University of Barcelona, IDIBAPS, Barcelona, Spain; Paloma Fernandez-Corcuera, MD, Germanes Hospitalàries and Benito Menni Complex Assistencial en Salut Mental, Barcelona, Spain; Benedikt L. Amann, MD, PhD, Anna Romaguera, MD, FIDMAG, Germanes Hospitalàries, Barcelona, Spain and Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain; Eduard Vieta, MD, PhD, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM) and Bipolar Disorder Program, Institute of Neuroscience, Hospital Clínic, University of Barcelona, IDIBAPS, Barcelona, Spain; Josep Blanch, MD, Hospital Sant Joan de Déu Infantil, Barcelona, Spain; Peter J. McKenna, MRCPsych, Raymond Salvador, PhD, FIDMAG, Germanes Hospitalàries, Barcelona, Spain and Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salvador</LastName><ForeName>Raymond</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Edith Pomarol-Clotet, MD, PhD, Silvia Alonso-Lana, BSc, FIDMAG, Germanes Hospitalàries, Barcelona and Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain; Noemi Moro, MD, FIDMAG, Germanes Hospitalàries and Benito Menni Complex Assistencial en Salut Mental, Barcelona, Spain; Salvador Sarró, MD, FIDMAG, Germanes Hospitalàries, Barcelona and Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain; Mar C. Bonnin, BSc, José M. Goikolea, MD, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM) and Bipolar Disorder Program, Institute of Neuroscience, Hospital Clínic, University of Barcelona, IDIBAPS, Barcelona, Spain; Paloma Fernandez-Corcuera, MD, Germanes Hospitalàries and Benito Menni Complex Assistencial en Salut Mental, Barcelona, Spain; Benedikt L. Amann, MD, PhD, Anna Romaguera, MD, FIDMAG, Germanes Hospitalàries, Barcelona, Spain and Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain; Eduard Vieta, MD, PhD, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM) and Bipolar Disorder Program, Institute of Neuroscience, Hospital Clínic, University of Barcelona, IDIBAPS, Barcelona, Spain; Josep Blanch, MD, Hospital Sant Joan de Déu Infantil, Barcelona, Spain; Peter J. McKenna, MRCPsych, Raymond Salvador, PhD, FIDMAG, Germanes Hospitalàries, Barcelona, Spain and Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>12</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Br J Psychiatry</MedlineTA><NlmUniqueID>0342367</NlmUniqueID><ISSNLinking>0007-1250</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059907" MajorTopicYN="N">Functional Neuroimaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>12</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>12</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>9</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25497296</ArticleId><ArticleId IdType="pii">S0007125000237677</ArticleId><ArticleId IdType="doi">10.1192/bjp.bp.114.152033</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11740167</PMID><DateCompleted><Year>2002</Year><Month>02</Month><Day>22</Day></DateCompleted><DateRevised><Year>2018</Year><Month>02</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0033-3190</ISSN><JournalIssue CitedMedium="Print"><Volume>71</Volume><Issue>1</Issue><PubDate><MedlineDate>2002 Jan-Feb</MedlineDate></PubDate></JournalIssue><Title>Psychotherapy and psychosomatics</Title><ISOAbbreviation>Psychother Psychosom</ISOAbbreviation></Journal><ArticleTitle>Executive function in patients with remitted bipolar disorder and schizophrenia and its relationship with functional outcome.</ArticleTitle><Pagination><MedlinePgn>39-46</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Recent studies have reported that differences in cognitive performance between schizophrenic and bipolar patients seem to be smaller than expected. Patients with schizophrenia have consistently shown frontal executive dysfunctions, but studies regarding executive abilities in bipolar patients are scarce and discrepant. As executive function has been associated with psychosocial functioning in schizophrenia, we wanted to investigate if such a relationship is also present in bipolar disorder and the differences between the two groups.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Executive function was assessed in 49 euthymic (at least 6 months in remission, Hamilton Depression Rating Scale &lt; or = 8 and Young Mania Rating Scale &lt; or = 6) bipolar and in 49 schizophrenic, residual-type (with at least 1 year without acute exacerbation and predominant negative symptomatology) patients, by the Wisconsin Card Sorting Test (WCST), FAS Test (COWAT) and Trail Making Test. Baseline clinical and psychosocial variables were controlled and psychopathology evaluated by means of the Positive and Negative Syndrome Scale (PANSS).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The two groups showed a similar pattern of cognitive deficits in tests of executive function, except for the number of categories achieved in the WCST, which was significantly lower in the schizophrenic group (F = 7.26; p = 0.009). Functional outcome was predicted by the negative syndrome (PANSSN) and perseverative errors (WCST) in schizophrenic patients, and general psychopathology (PANSSG) was the best predictor of functional outcome in the bipolar group.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Executive function was a good predictor of functional outcome in the schizophrenic group, whereas clinical variables were more predictive of the bipolar one. Patterns of cognitive disturbances in tasks of executive function are similar in both groups but quantitatively more marked in schizophrenia.</AbstractText><CopyrightInformation>Copyright 2001 S. Karger AG, Basel</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Martínez-Arán</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Bipolar Disorders Program, Clinical Institute of Psychiatry and Psychology, Hospital Clinic, Barcelona Stanley Foundation Research Center, University of Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Penadés</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Vieta</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Colom</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Reinares</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Benabarre</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Salamero</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Gastó</LastName><ForeName>C</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Psychother Psychosom</MedlineTA><NlmUniqueID>0024046</NlmUniqueID><ISSNLinking>0033-3190</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="Y">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="Y">Schizophrenic Psychology</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>12</Month><Day>12</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>2</Month><Day>23</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>12</Month><Day>12</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11740167</ArticleId><ArticleId IdType="pii">pps71039</ArticleId><ArticleId IdType="doi">10.1159/000049342</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">4425782</PMID><DateCompleted><Year>1975</Year><Month>01</Month><Day>31</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0007-1250</ISSN><JournalIssue CitedMedium="Print"><Volume>125</Volume><Issue>0</Issue><PubDate><Year>1974</Year><Month>Oct</Month></PubDate></JournalIssue><Title>The British journal of psychiatry : the journal of mental science</Title><ISOAbbreviation>Br J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Letter: Genetics of manic-depressive disease: Iceland revisited.</ArticleTitle><Pagination><MedlinePgn>429-31</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hendrie</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Klinge</LastName><ForeName>V</ForeName><Initials>V</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Br J Psychiatry</MedlineTA><NlmUniqueID>0342367</NlmUniqueID><ISSNLinking>0007-1250</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003469" MajorTopicYN="N">Culture</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005799" MajorTopicYN="N">Genes, Dominant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007055" MajorTopicYN="N" Type="Geographic">Iceland</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012380" MajorTopicYN="N">Role</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012423" MajorTopicYN="N">Rural Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012730" MajorTopicYN="N">Sex Chromosomes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013405" MajorTopicYN="N">Suicide</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014505" MajorTopicYN="N">Urban Population</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1974</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1974</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1974</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">4425782</ArticleId><ArticleId IdType="pii">S0007125000041143</ArticleId><ArticleId IdType="doi">10.1192/bjp.125.4.429</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22968227</PMID><DateCompleted><Year>2013</Year><Month>03</Month><Day>01</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2158-3188</ISSN><JournalIssue CitedMedium="Internet"><Volume>2</Volume><PubDate><Year>2012</Year><Month>Sep</Month><Day>11</Day></PubDate></JournalIssue><Title>Translational psychiatry</Title><ISOAbbreviation>Transl Psychiatry</ISOAbbreviation></Journal><ArticleTitle>A longitudinal pilot proton MRS investigation of the manic and euthymic states of bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>e160</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/tp.2012.84</ELocationID><Abstract><AbstractText>Several lines of evidence implicate dysfunction in brain energy production as a key component of bipolar disorder. In particular, elevated brain lactate levels observed in this condition suggest a shift from aerobic to anaerobic metabolism, possibly as a result of mitochondrial abnormalities. Most prior imaging studies of brain metabolites were performed in either euthymic or depressed bipolar patients or compared different populations in different mood states. We sought to measure brain metabolite concentrations in the same patients in both manic and euthymic states. Given the dramatic changes in clinical state of bipolar disorder patients, we hypothesized that previously observed abnormalities in lactate concentrations in bipolar disorder might show state dependent changes. In this study 15 patients (mean age 36.1 years) diagnosed with bipolar I disorder underwent proton magnetic resonance spectroscopy of the anterior cingulate cortex and parieto-occipital cortex during hospitalization for acute mania (mean Young Mania Rating Scale (YMRS) 22.1). Seven of these subjects returned (mean interval 21.16 months) to have imaging repeated while euthymic (mean YMRS 2.0). A group of age- and gender-matched control participants (N=6) were scanned as well. We report that during mania, bipolar disorder subjects had lactate levels comparable to healthy control subjects but during euthymia these levels were significantly reduced. No significant change was observed for other metabolites. These results implicate mood dependent alterations in energy metabolism in the biology of bipolar disorder. Additionally, this finding has potential use as a biomarker for both evaluating novel treatments as well as diagnostic clarification between mood disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Brady</LastName><ForeName>R O</ForeName><Initials>RO</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>Department of Psychiatry, Beth-Israel Deaconess Medical Center, Boston, MA, USA. robrady@bidmc.harvard.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cooper</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Jensen</LastName><ForeName>J E</ForeName><Initials>JE</Initials></Author><Author ValidYN="Y"><LastName>Tandon</LastName><ForeName>N</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Cohen</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Renshaw</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Keshavan</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Öngür</LastName><ForeName>D</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K23 MH079982</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23MH079982</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>09</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Transl Psychiatry</MedlineTA><NlmUniqueID>101562664</NlmUniqueID><ISSNLinking>2158-3188</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>33X04XA5AT</RegistryNumber><NameOfSubstance UI="D019344">Lactic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000339" MajorTopicYN="N">Affect</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004734" MajorTopicYN="N">Energy Metabolism</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006179" MajorTopicYN="N">Gyrus Cinguli</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007091" MajorTopicYN="N">Image Processing, Computer-Assisted</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019344" MajorTopicYN="N">Lactic Acid</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009682" MajorTopicYN="N">Magnetic Resonance Spectroscopy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>9</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>9</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>3</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22968227</ArticleId><ArticleId IdType="pii">tp201284</ArticleId><ArticleId IdType="doi">10.1038/tp.2012.84</ArticleId><ArticleId IdType="pmc">PMC3565206</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>NMR Biomed. 2009 Aug;22(7):762-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19388001</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2000 Sep;2(3 Pt 1):180-90</Citation><ArticleIdList><ArticleId IdType="pubmed">11256685</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res Rev. 2008 Nov;59(1):9-21</Citation><ArticleIdList><ArticleId IdType="pubmed">18539335</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1990 Dec;47(12):1106-11</Citation><ArticleIdList><ArticleId IdType="pubmed">2244795</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2001 Aug;158(8):1265-70</Citation><ArticleIdList><ArticleId IdType="pubmed">11481161</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2009 May;14(5):537-45</Citation><ArticleIdList><ArticleId IdType="pubmed">18180759</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2001 May 30;106(3):181-91</Citation><ArticleIdList><ArticleId IdType="pubmed">11382540</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2004 May;61(5):450-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15123489</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2002 Dec;4(6):357-65</Citation><ArticleIdList><ArticleId IdType="pubmed">12519095</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1992 Dec;26(4):223-30</Citation><ArticleIdList><ArticleId IdType="pubmed">1479134</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2004 Feb;6(1):62-6</Citation><ArticleIdList><ArticleId IdType="pubmed">14996142</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopharmacology (Berl). 2003 Jul;168(3):344-6</Citation><ArticleIdList><ArticleId IdType="pubmed">12684737</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1989 Nov-Dec;17(3):237-41</Citation><ArticleIdList><ArticleId IdType="pubmed">2529291</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2008 Oct 15;64(8):718-26</Citation><ArticleIdList><ArticleId IdType="pubmed">18602089</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2009 Apr 30;172(1):44-8</Citation><ArticleIdList><ArticleId IdType="pubmed">19239984</ArticleId></ArticleIdList></Reference><Reference><Citation>Top Magn Reson Imaging. 2008 Apr;19(2):81-96</Citation><ArticleIdList><ArticleId IdType="pubmed">19363431</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1993 Jan;27(1):53-9</Citation><ArticleIdList><ArticleId IdType="pubmed">8432961</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2005 Oct;10(10):900-19</Citation><ArticleIdList><ArticleId IdType="pubmed">16027739</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Pathol. 2010 Aug;177(2):575-85</Citation><ArticleIdList><ArticleId IdType="pubmed">20566748</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neuropsychopharmacol Biol Psychiatry. 2007 Aug 15;31(6):1182-8</Citation><ArticleIdList><ArticleId IdType="pubmed">17532107</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23312884</PMID><DateCompleted><Year>2014</Year><Month>05</Month><Day>30</Day></DateCompleted><DateRevised><Year>2013</Year><Month>02</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-1379</ISSN><JournalIssue CitedMedium="Internet"><Volume>47</Volume><Issue>3</Issue><PubDate><Year>2013</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Journal of psychiatric research</Title><ISOAbbreviation>J Psychiatr Res</ISOAbbreviation></Journal><ArticleTitle>In vivo glutathione levels in young persons with bipolar disorder: a magnetic resonance spectroscopy study.</ArticleTitle><Pagination><MedlinePgn>412-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jpsychires.2012.12.006</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0022-3956(12)00376-7</ELocationID><Abstract><AbstractText>Oxidative stress has recently been reported to assume a significant role in the pathophysiology of bipolar disorder. Several studies have demonstrated the replenishment of glutathione (GSH) diminishes oxidative cellular damage and ameliorates depressive symptoms in this disorder. Whilst the mechanism by which GSH exerts any clinical effect is unknown it has been proposed that it involves the bolstering of antioxidant defences by increasing the bioavailability of GSH, which in turn reverses clinical symptoms of depression. Such a proposal is predicated on the implicit assumption that GSH is diminished in these patients prior to GSH supplementation. However hitherto no study has reported in vivo measures of GSH in patients with bipolar disorder. Using magnetic resonance spectroscopy we obtained in vivo measures of GSH in young people with bipolar disorder and contrasted these with matched healthy controls. Young people with bipolar disorder were found to have no diminution in baseline GSH concentration and, furthermore, no significant correlations were found between GSH and clinical scores of depression or mania. The results do not support the hypothesis that oxidative stress is involved in the primary pathophysiology of bipolar disorder.</AbstractText><CopyrightInformation>Copyright © 2012 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lagopoulos</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Clinical Research Unit, Brain and Mind Research Institute, The University of Sydney, 94 Mallett Street, Camperdown, NSW 2050, Australia. Electronic address: jim.lagopoulos@sydney.edu.au.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hermens</LastName><ForeName>D F</ForeName><Initials>DF</Initials></Author><Author ValidYN="Y"><LastName>Tobias-Webb</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Duffy</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Naismith</LastName><ForeName>S L</ForeName><Initials>SL</Initials></Author><Author ValidYN="Y"><LastName>White</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Scott</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Hickie</LastName><ForeName>I B</ForeName><Initials>IB</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>01</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Psychiatr Res</MedlineTA><NlmUniqueID>0376331</NlmUniqueID><ISSNLinking>0022-3956</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>30KYC7MIAI</RegistryNumber><NameOfSubstance UI="D001224">Aspartic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>997-55-7</RegistryNumber><NameOfSubstance UI="C000179">N-acetylaspartate</NameOfSubstance></Chemical><Chemical><RegistryNumber>GAN16C9B8O</RegistryNumber><NameOfSubstance UI="D005978">Glutathione</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001224" MajorTopicYN="N">Aspartic Acid</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005978" MajorTopicYN="N">Glutathione</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009682" MajorTopicYN="N">Magnetic Resonance Spectroscopy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>10</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2012</Year><Month>12</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2012</Year><Month>12</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>1</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>1</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>5</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23312884</ArticleId><ArticleId IdType="pii">S0022-3956(12)00376-7</ArticleId><ArticleId IdType="doi">10.1016/j.jpsychires.2012.12.006</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12450629</PMID><DateCompleted><Year>2003</Year><Month>04</Month><Day>17</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>26</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0165-1781</ISSN><JournalIssue CitedMedium="Print"><Volume>112</Volume><Issue>3</Issue><PubDate><Year>2002</Year><Month>Nov</Month><Day>15</Day></PubDate></JournalIssue><Title>Psychiatry research</Title><ISOAbbreviation>Psychiatry Res</ISOAbbreviation></Journal><ArticleTitle>Clinical and demographic features of mood disorder subtypes.</ArticleTitle><Pagination><MedlinePgn>195-210</MedlinePgn></Pagination><Abstract><AbstractText>The aim of this study was to investigate demographic, clinical and symptomatologic features of the following mood disorder subtypes: bipolar disorder I (BP-I); bipolar disorder II (BP-II); major depressive disorder, recurrent (MDR); and major depressive episode, single episode (MDSE). A total of 1832 patients with mood disorders (BP-I=863, BP-II=141, MDR=708, and MDSE=120) were included in our study. The patients were assessed using structured diagnostic interviews and the operational criteria for psychotic illness checklist (n=885), the Hamilton depression rating scale (n=167), and the social adjustment scale (n=305). The BP-I patients were younger; had more hospital admissions; presented a more severe form of symptomatology in terms of psychotic symptoms, disorganization, and atypical features; and showed less insight into their disorder than patients in the other groups. Compared with the major depressive subgroups, BP-I patients were more likely to have an earlier age at onset, an earlier first lifetime psychiatric treatment, and a greater number of illness episodes. BP-II patients had a higher suicide risk than both BP-I and MDSE patients. MDSE patients presented less severe symptomatology, lower age at observation, and a higher number of males. The retrospective approach and the selection constraints due to the inclusion criteria are the main limitations of the study. Our data support the view that BP-I disorder is quite different from the remaining mood disorders from a demographic and clinical perspective, with BP-II disorder having an intermediate position to MDR and MDSE, that is, as a less severe disorder. This finding may help in the search for the biological basis of mood disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Serretti</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Vita-Salute University, San Raffaele Institute, Via Luigi Prinetti 29, Milan, Italy. serretti.alessandro@hsr.it</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mandelli</LastName><ForeName>Laura</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Lattuada</LastName><ForeName>Enrico</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Cusin</LastName><ForeName>Cristina</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Smeraldi</LastName><ForeName>Enrico</ForeName><Initials>E</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Psychiatry Res</MedlineTA><NlmUniqueID>7911385</NlmUniqueID><ISSNLinking>0165-1781</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007558" MajorTopicYN="N" Type="Geographic">Italy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010359" MajorTopicYN="N">Patient Readmission</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010555" MajorTopicYN="N">Personality Inventory</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011599" MajorTopicYN="N">Psychopathology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013405" MajorTopicYN="N">Suicide</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>11</Month><Day>27</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>4</Month><Day>18</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>11</Month><Day>27</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12450629</ArticleId><ArticleId IdType="pii">S0165178102002275</ArticleId><ArticleId IdType="doi">10.1016/s0165-1781(02)00227-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18362874</PMID><DateCompleted><Year>2012</Year><Month>03</Month><Day>13</Day></DateCompleted><DateRevised><Year>2008</Year><Month>03</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0048-5764</ISSN><JournalIssue CitedMedium="Print"><Volume>41</Volume><Issue>1</Issue><PubDate><Year>2008</Year></PubDate></JournalIssue><Title>Psychopharmacology bulletin</Title><ISOAbbreviation>Psychopharmacol Bull</ISOAbbreviation></Journal><ArticleTitle>Patterns of pharmacotherapy and treatment response in elderly adults with bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>102-14</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Bipolar disorder is a difficult disease to treat because of its cycling nature, frequent residual symptoms, and poor compliance to treatment. Several guidelines have been proposed for treatment, but there is limited data on best treatment practices in elderly, bipolar patients. This study assessed patterns of psychopharmacological treatment and treatment response in acutely ill, bipolar patients over the age of 60.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Naturalistic pharmacologic data was obtained on 138 acutely ill, elderly bipolar patients from the Duke University Medical Center electronic psychiatric record. Clinical Global Impression (CGI) severity and improvement scale ratings were performed at each visit, and time to response was measured. Pharmacological treatment selected was reviewed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Standard mood stabilizers (lithium, valproate, carbamazepine, and lamotrigine) were the most prescribed medications (68%), followed by antipsychotics (54%) and antidepressants (34%). Combination therapy was more common than monotherapy (57% vs. 38%). Remission was achieved in 35% of subjects, while 32% showed no significant improvement. There was no difference in antipsychotic prescription between old old and young old patients.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In this naturalistic, real-setting study of pharmacologic treatment, acutely ill, elderly bipolar patients were treated primarily with mood-stabilizing agents, followed by antipsychotics and antidepressants. Combination therapy is much more common than monotherapy. Results can be useful in understanding the current clinical standard of care in elderly bipolar patients, and are consistent with current clinical guidelines for mixed-age bipolar patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Beyer</LastName><ForeName>John L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Duke University Medical Center, Durham, NC, USA. beyer001@mc.duke.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burchitt</LastName><ForeName>Bruce</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Gersing</LastName><ForeName>Kenneth</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Krishnan</LastName><ForeName>K Ranga</ForeName><Initials>KR</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Psychopharmacol Bull</MedlineTA><NlmUniqueID>0101123</NlmUniqueID><ISSNLinking>0048-5764</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000339" MajorTopicYN="N">Affect</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>3</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>3</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>3</Month><Day>26</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18362874</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16917682</PMID><DateCompleted><Year>2007</Year><Month>02</Month><Day>26</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0940-1334</ISSN><JournalIssue CitedMedium="Print"><Volume>256</Volume><Issue>7</Issue><PubDate><Year>2006</Year><Month>Oct</Month></PubDate></JournalIssue><Title>European archives of psychiatry and clinical neuroscience</Title><ISOAbbreviation>Eur Arch Psychiatry Clin Neurosci</ISOAbbreviation></Journal><ArticleTitle>Is the association of alcohol use disorders with major depressive disorder a consequence of undiagnosed bipolar-II disorder?</ArticleTitle><Pagination><MedlinePgn>452-7</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">There is emerging evidence that there is a spectrum of expression of bipolar disorder. This paper uses the well-established patterns of comorbidity of mood and alcohol use disorder to test the hypothesis that application of an expanded concept of bipolar-II (BP-II) disorder might largely explain the association of alcohol use disorders (AUD) with major depressive disorder (MDD).</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Data from the Zurich study, a community cohort assessed over 6 waves from ages 20/21 to 40/41, were used to investigate the comorbidity between mood disorders and AUD. Systematic diagnostic criteria were used for alcohol abuse, alcohol dependence, MDD, and BP-II. In addition to DSM criteria, two increasingly broad definitions of BP-II were employed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">There was substantially greater comorbidity for the BP-II compared to major depression and for alcohol dependence compared to alcohol abuse. The broadest concept of BP-II explained two thirds of all cases of comorbidity of AUD with major depressive episodes (MDE). In fact, the broader the definition of BP-II applied, the smaller was the association of AUD with MDD, up to non-significance. In the majority of cases, the onset of bipolar manifestations preceded that of drinking problems by at least 5 years.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The findings that the comorbidity of mood disorders with AUD was primarily attributable to BP-II rather than MDD and that bipolar symptoms usually preceded alcohol problems may encourage new approaches to prevention and treatment of AUD.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Angst</LastName><ForeName>Jules</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Zurich University Psychiatric Hospital, Lenggstrasse 31, Mail Box 1931, 8032, Zurich, Switzerland. jangst@bli.unizh.ch</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gamma</LastName><ForeName>Alex</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Endrass</LastName><ForeName>Jérôme</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Rössler</LastName><ForeName>Wulf</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Ajdacic-Gross</LastName><ForeName>Valdeta</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Eich</LastName><ForeName>Dominique</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Herrell</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Merikangas</LastName><ForeName>Kathleen Ries</ForeName><Initials>KR</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2006</Year><Month>08</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Eur Arch Psychiatry Clin Neurosci</MedlineTA><NlmUniqueID>9103030</NlmUniqueID><ISSNLinking>0940-1334</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000437" MajorTopicYN="N">Alcoholism</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012727" MajorTopicYN="N">Sex Characteristics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013557" MajorTopicYN="N" Type="Geographic">Switzerland</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2005</Year><Month>09</Month><Day>02</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2006</Year><Month>04</Month><Day>04</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>8</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>2</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>8</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16917682</ArticleId><ArticleId IdType="doi">10.1007/s00406-006-0673-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Drug Alcohol Depend. 2003 Jul 20;71(1):7-16</Citation><ArticleIdList><ArticleId IdType="pubmed">12821201</ArticleId></ArticleIdList></Reference><Reference><Citation>Encephale. 1992 Jan;18 Spec No 1:23-9</Citation><ArticleIdList><ArticleId IdType="pubmed">1600900</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Soc Clin Psychol. 1977 Nov;16(4):347-56</Citation><ArticleIdList><ArticleId IdType="pubmed">588890</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2000 Sep;2(3 Pt 1):191-5</Citation><ArticleIdList><ArticleId IdType="pubmed">11256686</ArticleId></ArticleIdList></Reference><Reference><Citation>World J Biol Psychiatry. 2000 Apr;1(2):65-74</Citation><ArticleIdList><ArticleId IdType="pubmed">12607202</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychopharmacol. 1992 Feb;12(1 Suppl):17S-22S</Citation><ArticleIdList><ArticleId IdType="pubmed">1541713</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2003 Jan;73(1-2):133-46</Citation><ArticleIdList><ArticleId IdType="pubmed">12507746</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 1995 Apr;34(4):454-63</Citation><ArticleIdList><ArticleId IdType="pubmed">7751259</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry Suppl. 1996 Jun;(30):58-67</Citation><ArticleIdList><ArticleId IdType="pubmed">8864150</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2000 Sep;59 Suppl 1:S5-S30</Citation><ArticleIdList><ArticleId IdType="pubmed">11121824</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Arch Psychiatry Clin Neurosci. 1997;247(3):146-53</Citation><ArticleIdList><ArticleId IdType="pubmed">9224907</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 1990 Nov 21;264(19):2511-8</Citation><ArticleIdList><ArticleId IdType="pubmed">2232018</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2005 Oct;88(2):217-33</Citation><ArticleIdList><ArticleId IdType="pubmed">16125784</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1998 Sep;50(2-3):163-73</Citation><ArticleIdList><ArticleId IdType="pubmed">9858076</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcohol Res Health. 2002;26(3):208-13</Citation><ArticleIdList><ArticleId IdType="pubmed">12875049</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand Suppl. 1994;376:16-23</Citation><ArticleIdList><ArticleId IdType="pubmed">8178681</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Arch Psychiatry Clin Neurosci. 1999;249(1):45-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10195343</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 1998 Jul;28(4):773-88</Citation><ArticleIdList><ArticleId IdType="pubmed">9723135</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2000 Sep;2(3 Pt 2):281-93</Citation><ArticleIdList><ArticleId IdType="pubmed">11249806</ArticleId></ArticleIdList></Reference><Reference><Citation>J Stud Alcohol. 2002 Jul;63(4):498-502</Citation><ArticleIdList><ArticleId IdType="pubmed">12162295</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2004 Aug;61(8):807-16</Citation><ArticleIdList><ArticleId IdType="pubmed">15289279</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Clin North Am. 2005 Jun;28(2):415-25</Citation><ArticleIdList><ArticleId IdType="pubmed">15826740</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1998 Sep;50(2-3):81-9</Citation><ArticleIdList><ArticleId IdType="pubmed">9858067</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Arch Psychiatry Clin Neurosci. 2001 Oct;251(5):232-8</Citation><ArticleIdList><ArticleId IdType="pubmed">11829210</ArticleId></ArticleIdList></Reference><Reference><Citation>J Abnorm Psychol. 1990 Feb;99(1):55-63</Citation><ArticleIdList><ArticleId IdType="pubmed">2307767</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2000 Nov;157(11):1873-5</Citation><ArticleIdList><ArticleId IdType="pubmed">11058490</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 1998 Feb;37(2):171-8</Citation><ArticleIdList><ArticleId IdType="pubmed">9473913</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1997 Apr;54(4):313-21</Citation><ArticleIdList><ArticleId IdType="pubmed">9107147</ArticleId></ArticleIdList></Reference><Reference><Citation>Alcohol Clin Exp Res. 2002 Apr;26(4):471-7</Citation><ArticleIdList><ArticleId IdType="pubmed">11981122</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20696479</PMID><DateCompleted><Year>2011</Year><Month>04</Month><Day>25</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2517</ISSN><JournalIssue CitedMedium="Internet"><Volume>128</Volume><Issue>3</Issue><PubDate><Year>2011</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Three studies on self-report scales to detect bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>199-210</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jad.2010.07.012</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">This study investigated the usefulness of self-report scales for detecting bipolar disorder in several settings.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Study 1 developed a short form of the Hypomanic Personality Scale (the HPS-6) based on clinic/community and undergraduate samples. Study 2 used this scale for recruiting participants with bipolar disorder from the community. Study 3 administered the full-length Hypomanic Personality Scale, the Mood Disorder Questionnaire, and a short form of the General Behavior Inventory (the GBI-15) to an undergraduate sample. Each study featured a reference standard diagnostic interview.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In Study 2, about half of those responding to the advertisement (based on the HPS-6 developed in Study 1) reported a history of at least one hypomanic episode on a telephone-based SCID. In Study 3, the most robust findings emerged for the GBI-15: about one-third of participants screening positive on that measure met criteria for bipolar disorder using the Structured Clinical Interview for the DSM-IV (SCID).</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">Despite large sample sizes and stratified sampling, this study was limited by a low number of participants with bipolar I disorder.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These three studies produced mixed findings regarding the detection of bipolar disorder via self-report. The HPS-6 was reasonably successful in recruiting participants with a history of at least one manic or hypomanic episode into a study on bipolar disorder. The GBI-15 showed some promise as a screening tool in an undergraduate setting, but there is a need for more sensitive and specific scales. Discussion focuses on potential strategies for developing such scales.</AbstractText><CopyrightInformation>© 2010 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>Christopher J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Department of Psychology, University of Miami, 5665 Ponce de Leon Blvd., Coral Gables, FL 33146, USA. cmiller@psy.miami.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Sheri L</ForeName><Initials>SL</Initials></Author><Author ValidYN="Y"><LastName>Kwapil</LastName><ForeName>Thomas R</ForeName><Initials>TR</Initials></Author><Author ValidYN="Y"><LastName>Carver</LastName><ForeName>Charles S</ForeName><Initials>CS</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 MH076021-03</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH076021-02</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH076021-04</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH076021-01A1</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH076021</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH076021-05</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01-MH075021</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>08</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007406" MajorTopicYN="N">Interview, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018579" MajorTopicYN="N">Patient Selection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010556" MajorTopicYN="N">Personality Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057566" MajorTopicYN="Y">Self Report</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>03</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2010</Year><Month>06</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>07</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>8</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>8</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>4</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20696479</ArticleId><ArticleId IdType="pii">S0165-0327(10)00493-3</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2010.07.012</ArticleId><ArticleId IdType="pmc">PMC2992802</ArticleId><ArticleId IdType="mid">NIHMS225312</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2004 Jul;43(7):847-58</Citation><ArticleIdList><ArticleId IdType="pubmed">15213586</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Clin Psychol. 1990 May;29(2):235-7</Citation><ArticleIdList><ArticleId IdType="pubmed">2364203</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Epidemiol. 1992 Jun;45(6):581-6</Citation><ArticleIdList><ArticleId IdType="pubmed">1607897</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2004 Nov;110(5):374-82</Citation><ArticleIdList><ArticleId IdType="pubmed">15458561</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2005 Oct;88(2):217-33</Citation><ArticleIdList><ArticleId IdType="pubmed">16125784</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2004 Oct;6(5):395-405</Citation><ArticleIdList><ArticleId IdType="pubmed">15383132</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Psychiatry. 2003 Jul 10;3:8</Citation><ArticleIdList><ArticleId IdType="pubmed">12854971</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2007 May;64(5):543-52</Citation><ArticleIdList><ArticleId IdType="pubmed">17485606</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1994 Aug;31(4):281-94</Citation><ArticleIdList><ArticleId IdType="pubmed">7989643</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2003 Jul;160(7):1286-90</Citation><ArticleIdList><ArticleId IdType="pubmed">12832243</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 1995 Apr;34(4):454-63</Citation><ArticleIdList><ArticleId IdType="pubmed">7751259</ArticleId></ArticleIdList></Reference><Reference><Citation>J Abnorm Psychol. 2000 May;109(2):222-6</Citation><ArticleIdList><ArticleId IdType="pubmed">10895560</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2008 Jul;118(1):81-5</Citation><ArticleIdList><ArticleId IdType="pubmed">18595178</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1999 Jan-Mar;52(1-3):135-44</Citation><ArticleIdList><ArticleId IdType="pubmed">10357026</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Psychol Rev. 2005 May;25(3):307-39</Citation><ArticleIdList><ArticleId IdType="pubmed">15792852</ArticleId></ArticleIdList></Reference><Reference><Citation>J Consult Clin Psychol. 1989 Feb;57(1):106-11</Citation><ArticleIdList><ArticleId IdType="pubmed">2925959</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1993 Feb;50(2):85-94</Citation><ArticleIdList><ArticleId IdType="pubmed">8427558</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Neurol. 2005 Jun;12 Suppl 1:34-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15877776</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Care. 1989 Jun;27(6):593-607</Citation><ArticleIdList><ArticleId IdType="pubmed">2725088</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 1997 Sep;27(5):1079-89</Citation><ArticleIdList><ArticleId IdType="pubmed">9300513</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2008 Jun;10(4):520-9</Citation><ArticleIdList><ArticleId IdType="pubmed">18452448</ArticleId></ArticleIdList></Reference><Reference><Citation>J Abnorm Psychol. 1986 Aug;95(3):214-22</Citation><ArticleIdList><ArticleId IdType="pubmed">3745642</ArticleId></ArticleIdList></Reference><Reference><Citation>J Abnorm Psychol. 1981 Oct;90(5):381-437</Citation><ArticleIdList><ArticleId IdType="pubmed">7298991</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2005 Jun;35(6):855-63</Citation><ArticleIdList><ArticleId IdType="pubmed">15997605</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Board Fam Pract. 2005 Jul-Aug;18(4):233-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15994469</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2005 May 25;293(20):2528-30</Citation><ArticleIdList><ArticleId IdType="pubmed">15914754</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2003 Jan;160(1):178-80</Citation><ArticleIdList><ArticleId IdType="pubmed">12505821</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2005 Jun;62(6):617-27</Citation><ArticleIdList><ArticleId IdType="pubmed">15939839</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2003 Dec;5(6):456-63</Citation><ArticleIdList><ArticleId IdType="pubmed">14636371</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2000 Nov;157(11):1873-5</Citation><ArticleIdList><ArticleId IdType="pubmed">11058490</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2005 Feb;84(2-3):273-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15708426</ArticleId></ArticleIdList></Reference><Reference><Citation>Biometrics. 1994 Mar;50(1):149-63</Citation><ArticleIdList><ArticleId IdType="pubmed">8086598</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1981 Apr;38(4):400-5</Citation><ArticleIdList><ArticleId IdType="pubmed">7212970</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 1986 Dec;19(4):285-96</Citation><ArticleIdList><ArticleId IdType="pubmed">3809326</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2004 Jan;161(1):163-5</Citation><ArticleIdList><ArticleId IdType="pubmed">14702267</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2004 Nov;65(11):1499-504</Citation><ArticleIdList><ArticleId IdType="pubmed">15554762</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2005 Mar;85(1-2):3-16</Citation><ArticleIdList><ArticleId IdType="pubmed">15780671</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2003 Sep 17;290(11):1517-9</Citation><ArticleIdList><ArticleId IdType="pubmed">13129995</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1996 Jun 5;38(2-3):135-43</Citation><ArticleIdList><ArticleId IdType="pubmed">8791182</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2003 Jan;73(1-2):123-31</Citation><ArticleIdList><ArticleId IdType="pubmed">12507745</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2003 Jul;75(2):149-54</Citation><ArticleIdList><ArticleId IdType="pubmed">12798254</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1992 Aug;49(8):630-6</Citation><ArticleIdList><ArticleId IdType="pubmed">1637253</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1983 Mar;40(3):249-57</Citation><ArticleIdList><ArticleId IdType="pubmed">6830404</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1994 Jan;51(1):8-19</Citation><ArticleIdList><ArticleId IdType="pubmed">8279933</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 1996 Jul 24-31;276(4):293-9</Citation><ArticleIdList><ArticleId IdType="pubmed">8656541</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Serv. 2002 Mar;53(3):349</Citation><ArticleIdList><ArticleId IdType="pubmed">11875241</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2004 Aug;81(2):167-71</Citation><ArticleIdList><ArticleId IdType="pubmed">15306144</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2005;7 Suppl 4:4-12</Citation><ArticleIdList><ArticleId IdType="pubmed">15948762</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1995 Mar;152(3):385-90</Citation><ArticleIdList><ArticleId IdType="pubmed">7864264</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pers Disord. 1999 Spring;13(1):75-89</Citation><ArticleIdList><ArticleId IdType="pubmed">10228929</ArticleId></ArticleIdList></Reference><Reference><Citation>Assessment. 1999 Sep;6(3):235-42</Citation><ArticleIdList><ArticleId IdType="pubmed">10445961</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2001 Aug;58(8):787-94</Citation><ArticleIdList><ArticleId IdType="pubmed">11483146</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1978 Jul;35(7):837-44</Citation><ArticleIdList><ArticleId IdType="pubmed">678037</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2004 Nov 15;56(10):728-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15556116</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pers Disord. 2001 Aug;15(4):351-7</Citation><ArticleIdList><ArticleId IdType="pubmed">11556701</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Psychiatry. 2004 Apr;19(2):85-90</Citation><ArticleIdList><ArticleId IdType="pubmed">15051107</ArticleId></ArticleIdList></Reference><Reference><Citation>J Abnorm Psychol. 1989 May;98(2):117-26</Citation><ArticleIdList><ArticleId IdType="pubmed">2708652</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2002 Feb;59(2):115-23</Citation><ArticleIdList><ArticleId IdType="pubmed">11825131</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26360451</PMID><DateCompleted><Year>2017</Year><Month>01</Month><Day>06</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2215-0374</ISSN><JournalIssue CitedMedium="Internet"><Volume>2</Volume><Issue>6</Issue><PubDate><Year>2015</Year><Month>Jun</Month></PubDate></JournalIssue><Title>The lancet. Psychiatry</Title><ISOAbbreviation>Lancet Psychiatry</ISOAbbreviation></Journal><ArticleTitle>An evidence map of psychosocial interventions for the earliest stages of bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>548-63</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S2215-0366(15)00156-X</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2215-0366(15)00156-X</ELocationID><Abstract><AbstractText>Depression, schizophrenia, and bipolar disorder are three of the four most burdensome problems in people aged under 25 years. In psychosis and depression, psychological interventions are effective, low-risk, and high-benefit approaches for patients at high risk of first-episode or early-onset disorders. We review the use of psychological interventions for early-stage bipolar disorder in patients aged 15-25 years. Because previous systematic reviews had struggled to identify information about this emerging sphere of research, we used evidence mapping to help us identify the extent, distribution, and methodological quality of evidence because the gold standard approaches were only slightly informative or appropriate. This strategy identified 29 studies in three target groups: ten studies in populations at high risk for bipolar disorder, five studies in patients with a first episode, and 14 studies in patients with early-onset bipolar disorder. Of the 20 completed studies, eight studies were randomised trials, but only two had sample sizes of more than 100 individuals. The main interventions used were family, cognitive behavioural, and interpersonal therapies. Only behavioural family therapies were tested across all of our three target groups. Although the available interventions were well adapted to the level of maturity and social environment of young people, few interventions target specific developmental psychological or physiological processes (eg, ruminative response style or delayed sleep phase), or offer detailed strategies for the management of substance use or physical health. </AbstractText><CopyrightInformation>Copyright © 2015 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vallarino</LastName><ForeName>Martine</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy; Laboratory of Epidemiology and Social Psychiatry, IRCCS Istituto di Ricerche Farmacologiche 'Mario Negri', Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Henry</LastName><ForeName>Chantal</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Faculté de médecine, Université Paris Est, Créteil, France; Pôle de Psychiatrie, APHP, Hôpital H Mondor-A Chenevier, Créteil, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Etain</LastName><ForeName>Bruno</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Faculté de médecine, Université Paris Est, Créteil, France; Pôle de Psychiatrie, APHP, Hôpital H Mondor-A Chenevier, Créteil, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gehue</LastName><ForeName>Lillian J</ForeName><Initials>LJ</Initials><AffiliationInfo><Affiliation>Brain and Mind Research Institute, University of Sydney, Camperdown, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Macneil</LastName><ForeName>Craig</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Early Psychosis Prevention &amp; Intervention Centre, Orygen Youth Health, Melbourne, VIC, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scott</LastName><ForeName>Elizabeth M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Brain and Mind Research Institute, University of Sydney, Camperdown, NSW, Australia; School of Medicine, University of Notre Dame, Sydney, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barbato</LastName><ForeName>Angelo</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Laboratory of Epidemiology and Social Psychiatry, IRCCS Istituto di Ricerche Farmacologiche 'Mario Negri', Milan, Italy; IRIS Postgraduate Psychotherapy School, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Conus</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Département Universitaire de Psychiatrie CHUV, Service de Psychiatrie Générale, Lausanne University, Clinique de Cery, Prilly, Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hlastala</LastName><ForeName>Stefanie A</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, Division of Child and Adolescent Psychiatry, University of Washington, WA, Seattle, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fristad</LastName><ForeName>Mary</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Health, The Ohio State University Wexner Medical Center, and Ohio State University Harding Hospital, Columbus, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miklowitz</LastName><ForeName>David J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, University of California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scott</LastName><ForeName>Jan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Academic Psychiatry, Institute of Neuroscience, Newcastle University, Newcastle upon Tyne, UK; Centre for Affective Disorders, IPPN, King's College, London, UK. Electronic address: jan.scott@newcastle.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 MH093676</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 MH097007</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R33 MH097007</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>05</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Psychiatry</MedlineTA><NlmUniqueID>101638123</NlmUniqueID><ISSNLinking>2215-0366</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Psychiatry. 2015 Jun;2(6):483-5</RefSource><PMID Version="1">26360429</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018479" MajorTopicYN="N">Early Intervention, Educational</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011613" MajorTopicYN="N">Psychotherapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>12</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>03</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>03</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>9</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>9</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>1</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26360451</ArticleId><ArticleId IdType="pii">S2215-0366(15)00156-X</ArticleId><ArticleId IdType="doi">10.1016/S2215-0366(15)00156-X</ArticleId><ArticleId IdType="pmc">PMC4629930</ArticleId><ArticleId IdType="mid">NIHMS729961</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Arch Gen Psychiatry. 2003 Apr;60(4):402-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12695318</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2013 Jun;74(6):595-602</Citation><ArticleIdList><ArticleId IdType="pubmed">23842011</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2014 Jun;53(6):614-24</Citation><ArticleIdList><ArticleId IdType="pubmed">24839880</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 1984 Feb 3;251(5):637-44</Citation><ArticleIdList><ArticleId IdType="pubmed">6418903</ArticleId></ArticleIdList></Reference><Reference><Citation>Child Adolesc Psychiatr Clin N Am. 2012 Oct;21(4):739-51</Citation><ArticleIdList><ArticleId IdType="pubmed">23040899</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2011 Feb;13(1):67-75</Citation><ArticleIdList><ArticleId IdType="pubmed">21320254</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2008 Sep;65(9):1053-61</Citation><ArticleIdList><ArticleId IdType="pubmed">18762591</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2014 Nov;130(5):354-63</Citation><ArticleIdList><ArticleId IdType="pubmed">24961757</ArticleId></ArticleIdList></Reference><Reference><Citation>Dev Psychopathol. 2006 Fall;18(4):1247-65</Citation><ArticleIdList><ArticleId IdType="pubmed">17064437</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2010 Jun;123(1-3):81-6</Citation><ArticleIdList><ArticleId IdType="pubmed">19853922</ArticleId></ArticleIdList></Reference><Reference><Citation>Early Interv Psychiatry. 2013 Feb;7(1):31-43</Citation><ArticleIdList><ArticleId IdType="pubmed">22672533</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Psychol Psychother. 2008 Nov-Dec;15(6):367-77</Citation><ArticleIdList><ArticleId IdType="pubmed">19115455</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2011 Jun 18;377(9783):2093-102</Citation><ArticleIdList><ArticleId IdType="pubmed">21652063</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2015 Mar;17(2):128-38</Citation><ArticleIdList><ArticleId IdType="pubmed">25346391</ArticleId></ArticleIdList></Reference><Reference><Citation>Depress Res Treat. 2012;2012:820735</Citation><ArticleIdList><ArticleId IdType="pubmed">22496974</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2013 Feb;127(2):136-44</Citation><ArticleIdList><ArticleId IdType="pubmed">22901015</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2002 Oct;59(10):921-8</Citation><ArticleIdList><ArticleId IdType="pubmed">12365879</ArticleId></ArticleIdList></Reference><Reference><Citation>Aust N Z J Psychiatry. 2006 Aug;40(8):616-22</Citation><ArticleIdList><ArticleId IdType="pubmed">16866756</ArticleId></ArticleIdList></Reference><Reference><Citation>J Eval Clin Pract. 2010 Dec;16(6):1025-30</Citation><ArticleIdList><ArticleId IdType="pubmed">20337833</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2005 Sep;62(9):996-1004</Citation><ArticleIdList><ArticleId IdType="pubmed">16143731</ArticleId></ArticleIdList></Reference><Reference><Citation>Early Interv Psychiatry. 2016 Oct;10(5):426-34</Citation><ArticleIdList><ArticleId IdType="pubmed">25582800</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2006 Apr;188:313-20</Citation><ArticleIdList><ArticleId IdType="pubmed">16582056</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Child Adolesc Psychol. 2014;43(3):339-55</Citation><ArticleIdList><ArticleId IdType="pubmed">23927375</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2013 Feb;52(2):121-31</Citation><ArticleIdList><ArticleId IdType="pubmed">23357439</ArticleId></ArticleIdList></Reference><Reference><Citation>Depress Anxiety. 2010 May;27(5):457-64</Citation><ArticleIdList><ArticleId IdType="pubmed">20186968</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2006 Oct;8(5 Pt 1):508-15</Citation><ArticleIdList><ArticleId IdType="pubmed">17042890</ArticleId></ArticleIdList></Reference><Reference><Citation>Early Interv Psychiatry. 2014 Feb;8(1):3-11</Citation><ArticleIdList><ArticleId IdType="pubmed">23968367</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Intern Med. 2009 Aug 18;151(4):W65-94</Citation><ArticleIdList><ArticleId IdType="pubmed">19622512</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2010 Oct;126(1-2):88-95</Citation><ArticleIdList><ArticleId IdType="pubmed">20434220</ArticleId></ArticleIdList></Reference><Reference><Citation>Early Interv Psychiatry. 2012 Nov;6(4):380-8</Citation><ArticleIdList><ArticleId IdType="pubmed">22225628</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Pract. 2014 May;20(3):237-48</Citation><ArticleIdList><ArticleId IdType="pubmed">24847999</ArticleId></ArticleIdList></Reference><Reference><Citation>Actas Esp Psiquiatr. 2012 Mar-Apr;40(2):51-6</Citation><ArticleIdList><ArticleId IdType="pubmed">22508069</ArticleId></ArticleIdList></Reference><Reference><Citation>Early Interv Psychiatry. 2007 Nov;1(4):333-9</Citation><ArticleIdList><ArticleId IdType="pubmed">21352121</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2013 Feb 20;145(2):260-3</Citation><ArticleIdList><ArticleId IdType="pubmed">22877966</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2012 Dec;14(8):797-808</Citation><ArticleIdList><ArticleId IdType="pubmed">22963164</ArticleId></ArticleIdList></Reference><Reference><Citation>J Behav Ther Exp Psychiatry. 2012 Jun;43(2):770-9</Citation><ArticleIdList><ArticleId IdType="pubmed">22104659</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2013 Jan;143(1):143-9</Citation><ArticleIdList><ArticleId IdType="pubmed">23146146</ArticleId></ArticleIdList></Reference><Reference><Citation>Trials. 2014 May 08;15:161</Citation><ArticleIdList><ArticleId IdType="pubmed">24886581</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2014 Jan;152-154:403-8</Citation><ArticleIdList><ArticleId IdType="pubmed">24268595</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2013 Sep;149(1-3):56-62</Citation><ArticleIdList><ArticleId IdType="pubmed">23870806</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2011 Mar;68(3):241-51</Citation><ArticleIdList><ArticleId IdType="pubmed">21383262</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Psychiatry. 2013 Sep;28(7):423-6</Citation><ArticleIdList><ArticleId IdType="pubmed">23968892</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2007 Jul;46(7):820-30</Citation><ArticleIdList><ArticleId IdType="pubmed">17581446</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2014 Feb;16(1):5-15</Citation><ArticleIdList><ArticleId IdType="pubmed">24305108</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2009 Oct;39(10):1627-36</Citation><ArticleIdList><ArticleId IdType="pubmed">19335932</ArticleId></ArticleIdList></Reference><Reference><Citation>Dev Psychopathol. 2006 Fall;18(4):939-69</Citation><ArticleIdList><ArticleId IdType="pubmed">17064424</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2014 Jun;171(6):658-67</Citation><ArticleIdList><ArticleId IdType="pubmed">24626789</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2010 Aug;12(5):494-503</Citation><ArticleIdList><ArticleId IdType="pubmed">20712750</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychotherapy (Chic). 2014 Mar;51(1):180-9</Citation><ArticleIdList><ArticleId IdType="pubmed">24377402</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Child Adolesc Psychiatry. 2006 Aug;15(5):300-7</Citation><ArticleIdList><ArticleId IdType="pubmed">16572276</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2010 Oct;123(1):37-44</Citation><ArticleIdList><ArticleId IdType="pubmed">20558043</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2007 Nov;9(7):671-8</Citation><ArticleIdList><ArticleId IdType="pubmed">17988356</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2004 May;43(5):528-37</Citation><ArticleIdList><ArticleId IdType="pubmed">15100559</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2013 Apr;202(4):243-5</Citation><ArticleIdList><ArticleId IdType="pubmed">23549937</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19520435</PMID><DateCompleted><Year>2010</Year><Month>04</Month><Day>14</Day></DateCompleted><DateRevised><Year>2017</Year><Month>11</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2517</ISSN><JournalIssue CitedMedium="Internet"><Volume>121</Volume><Issue>1-2</Issue><PubDate><Year>2010</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Acute antidepressant response to sleep deprivation combined with light therapy is influenced by the catechol-O-methyltransferase Val(108/158)Met polymorphism.</ArticleTitle><Pagination><MedlinePgn>68-72</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jad.2009.05.017</ELocationID><Abstract><AbstractText>Catechol-O-methyltransferase (COMT) inactivates norepinephrine and dopamine via methyl conjugation, and a G-A transition in the COMT gene (rs4680) influences the enzyme activity. It is a current area of debate whether rs4680 can influence antidepressant response in major depressive disorder, and whether this influence extends to bipolar depression. Chronotherapeutic interventions, such as sleep deprivation and light therapy, are multi-target in nature and are effective in bipolar depression. Here we studied the effect of rs4680 on response to sleep deprivation combined with light therapy (36 h awake followed by a night of undisturbed sleep, with 10,000 lx light administered for 30 min during the night awake and upon awakening) in 87 bipolar depressed inpatients. Patients who were homozygotic for the Val/Val variant showed a significantly less efficient antidepressant effect after the night awake than those who were heterozygotic and homozygotic for the Met variant. This effect of rs4680 is similar to its observed influence on response to serotonergic and noradrenergic drug treatments in major depressive disorder. This is the first study reporting an influence of rs4680 on antidepressant response in bipolar depression. This finding supports the hypothesis of a major role for catecholamines in the mechanism of action of chronotherapeutics, and for rs4680 in modulating this effect.</AbstractText><CopyrightInformation>2009 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Benedetti</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Division of Neurosciences, Scientific Institute and University Vita-Salute San Raffaele, Milan, Italy. benedetti.francesco@hsr.it</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barbini</LastName><ForeName>Barbara</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Bernasconi</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Fulgosi</LastName><ForeName>Mara Cigala</ForeName><Initials>MC</Initials></Author><Author ValidYN="Y"><LastName>Dallaspezia</LastName><ForeName>Sara</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Gavinelli</LastName><ForeName>Chiara</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Locatelli</LastName><ForeName>Clara</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Lorenzi</LastName><ForeName>Cristina</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Pirovano</LastName><ForeName>Adele</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Radaelli</LastName><ForeName>Daniele</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Smeraldi</LastName><ForeName>Enrico</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Colombo</LastName><ForeName>Cristina</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>06</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 2.1.1.6</RegistryNumber><NameOfSubstance UI="D002394">Catechol O-Methyltransferase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="Y">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002394" MajorTopicYN="N">Catechol O-Methyltransferase</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006580" MajorTopicYN="N">Genetic Carrier Screening</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006720" MajorTopicYN="N">Homozygote</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010789" MajorTopicYN="Y">Phototherapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011110" MajorTopicYN="N">Polymorphism, Genetic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012892" MajorTopicYN="Y">Sleep Deprivation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>03</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2009</Year><Month>05</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2009</Year><Month>05</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>6</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>6</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>4</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19520435</ArticleId><ArticleId IdType="pii">S0165-0327(09)00225-0</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2009.05.017</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12141273</PMID><DateCompleted><Year>2003</Year><Month>01</Month><Day>02</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>26</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0033-3158</ISSN><JournalIssue CitedMedium="Print"><Volume>162</Volume><Issue>1</Issue><PubDate><Year>2002</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Psychopharmacology</Title><ISOAbbreviation>Psychopharmacology (Berl)</ISOAbbreviation></Journal><ArticleTitle>Risperidone may induce mania.</ArticleTitle><Pagination><MedlinePgn>85-6</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Güzelcan</LastName><ForeName>Y</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Academic Medical Center, University of Amsterdam, P.O. Box 22700, 1100 DE Amsterdam, The Netrherlands. y.guzelcan@amc.uva.nl</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Haan</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Scholte</LastName><ForeName>W F</ForeName><Initials>WF</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Psychopharmacology (Berl)</MedlineTA><NlmUniqueID>7608025</NlmUniqueID><ISSNLinking>0033-3158</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>L6UH7ZF8HC</RegistryNumber><NameOfSubstance UI="D018967">Risperidone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018967" MajorTopicYN="N">Risperidone</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>7</Month><Day>27</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>1</Month><Day>3</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>7</Month><Day>27</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12141273</ArticleId><ArticleId IdType="doi">10.1007/s00213-002-1061-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Clin Psychopharmacol. 1998 Apr;18(2):172-4</Citation><ArticleIdList><ArticleId IdType="pubmed">9555604</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 1992 Apr;85(4):295-305</Citation><ArticleIdList><ArticleId IdType="pubmed">1375801</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1996 Apr;153(4):466-76</Citation><ArticleIdList><ArticleId IdType="pubmed">8599393</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 1994 Feb 19;343(8895):457-60</Citation><ArticleIdList><ArticleId IdType="pubmed">7508541</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Neuropsychopharmacol. 2001 Apr;11(2):97-8</Citation><ArticleIdList><ArticleId IdType="pubmed">11313153</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1999 Feb;156(2):286-93</Citation><ArticleIdList><ArticleId IdType="pubmed">9989565</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Pharmacother. 1999 Mar;33(3):380-1</Citation><ArticleIdList><ArticleId IdType="pubmed">10200867</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1978 Nov;133:429-35</Citation><ArticleIdList><ArticleId IdType="pubmed">728692</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 1995 Sep;56(9):431-2</Citation><ArticleIdList><ArticleId IdType="pubmed">7545160</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 1999 Aug;38(8):960-5</Citation><ArticleIdList><ArticleId IdType="pubmed">10434487</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2000 Sep;61(9):649-55</Citation><ArticleIdList><ArticleId IdType="pubmed">11030485</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 1998 Feb;59(2):85-6</Citation><ArticleIdList><ArticleId IdType="pubmed">9501895</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11247181</PMID><DateCompleted><Year>2001</Year><Month>04</Month><Day>26</Day></DateCompleted><DateRevised><Year>2016</Year><Month>10</Month><Day>18</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1997-7298</ISSN><JournalIssue CitedMedium="Print"><Volume>100</Volume><Issue>11</Issue><PubDate><Year>2000</Year></PubDate></JournalIssue><Title>Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova</Title><ISOAbbreviation>Zh Nevrol Psikhiatr Im S S Korsakova</ISOAbbreviation></Journal><ArticleTitle>[Alcoholic hypomanic syndrome].</ArticleTitle><Pagination><MedlinePgn>21-3</MedlinePgn></Pagination><Abstract><AbstractText>There were examined 115 patients with I and II stages alcoholism who had hypomaniacal syndrome. This syndrome was observed in form of "jolly hypomania" in the I stage of alcoholism and by more complex forms--"angry" or "obsessive" hypomania--in the II stage. The correlation of psychopathologic peculiarities of hypomania and psychological personality traits and EEG data was found.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Serebrennikova</LastName><ForeName>O A</ForeName><Initials>OA</Initials></Author></AuthorList><Language>rus</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Alkogol'nyĭ gipomaniakal'nyĭ sindrom.</VernacularTitle></Article><MedlineJournalInfo><Country>Russia (Federation)</Country><MedlineTA>Zh Nevrol Psikhiatr Im S S Korsakova</MedlineTA><NlmUniqueID>9712194</NlmUniqueID><ISSNLinking>1997-7298</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000437" MajorTopicYN="N">Alcoholism</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008950" MajorTopicYN="N">MMPI</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2001</Year><Month>3</Month><Day>15</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>5</Month><Day>1</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2001</Year><Month>3</Month><Day>15</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11247181</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">2690167</PMID><DateCompleted><Year>1990</Year><Month>02</Month><Day>08</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0048-5764</ISSN><JournalIssue CitedMedium="Print"><Volume>25</Volume><Issue>2</Issue><PubDate><Year>1989</Year></PubDate></JournalIssue><Title>Psychopharmacology bulletin</Title><ISOAbbreviation>Psychopharmacol Bull</ISOAbbreviation></Journal><ArticleTitle>A double-blind, placebo-controlled trial of clonidine in the treatment of acute mania.</ArticleTitle><Pagination><MedlinePgn>243-5</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Janicak</LastName><ForeName>P G</ForeName><Initials>PG</Initials></Author><Author ValidYN="Y"><LastName>Sharma</LastName><ForeName>R P</ForeName><Initials>RP</Initials></Author><Author ValidYN="Y"><LastName>Easton</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Comaty</LastName><ForeName>J E</ForeName><Initials>JE</Initials></Author><Author ValidYN="Y"><LastName>Davis</LastName><ForeName>J M</ForeName><Initials>JM</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Psychopharmacol Bull</MedlineTA><NlmUniqueID>0101123</NlmUniqueID><ISSNLinking>0048-5764</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>MN3L5RMN02</RegistryNumber><NameOfSubstance UI="D003000">Clonidine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003000" MajorTopicYN="N">Clonidine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1989</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1989</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1989</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2690167</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">4937544</PMID><DateCompleted><Year>1971</Year><Month>12</Month><Day>01</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0012-3714</ISSN><JournalIssue CitedMedium="Print"><Volume>32</Volume><Issue>8</Issue><PubDate><Year>1971</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Diseases of the nervous system</Title><ISOAbbreviation>Dis Nerv Syst</ISOAbbreviation></Journal><ArticleTitle>Production of cortisol in patients with manic-depressive psychosis treated with Lithium Carbonate.</ArticleTitle><Pagination><MedlinePgn>542-4</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Platman</LastName><ForeName>S R</ForeName><Initials>SR</Initials></Author><Author ValidYN="Y"><LastName>Hilton</LastName><ForeName>J G</ForeName><Initials>JG</Initials></Author><Author ValidYN="Y"><LastName>Koss</LastName><ForeName>M C</ForeName><Initials>MC</Initials></Author><Author ValidYN="Y"><LastName>Kelly</LastName><ForeName>W G</ForeName><Initials>WG</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D018848">Controlled Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Nerv Syst</MedlineTA><NlmUniqueID>0370666</NlmUniqueID><ISSNLinking>0012-3714</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015065">17-Hydroxycorticosteroids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002254">Carbonates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010919">Placebos</NameOfSubstance></Chemical><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical><Chemical><RegistryNumber>WI4X0X7BPJ</RegistryNumber><NameOfSubstance UI="D006854">Hydrocortisone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015065" MajorTopicYN="N">17-Hydroxycorticosteroids</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000652" MajorTopicYN="N">urine</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002254" MajorTopicYN="N">Carbonates</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006854" MajorTopicYN="N">Hydrocortisone</DescriptorName><QualifierName UI="Q000652" MajorTopicYN="N">urine</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010919" MajorTopicYN="N">Placebos</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1971</Year><Month>8</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1971</Year><Month>8</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1971</Year><Month>8</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">4937544</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">7848051</PMID><DateCompleted><Year>1995</Year><Month>03</Month><Day>03</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0003-990X</ISSN><JournalIssue CitedMedium="Print"><Volume>52</Volume><Issue>2</Issue><PubDate><Year>1995</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Archives of general psychiatry</Title><ISOAbbreviation>Arch Gen Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Tryptophan depletion in stable lithium-treated patients with bipolar disorder in remission.</ArticleTitle><Pagination><MedlinePgn>154-6</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Benkelfat</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Seletti</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Palmour</LastName><ForeName>R M</ForeName><Initials>RM</Initials></Author><Author ValidYN="Y"><LastName>Hillel</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Ellenbogen</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Young</LastName><ForeName>S N</ForeName><Initials>SN</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016420">Comment</PublicationType><PublicationType UI="D018848">Controlled Clinical Trial</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Gen Psychiatry</MedlineTA><NlmUniqueID>0372435</NlmUniqueID><ISSNLinking>0003-990X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>2BMD2GNA4V</RegistryNumber><NameOfSubstance UI="D016651">Lithium Carbonate</NameOfSubstance></Chemical><Chemical><RegistryNumber>333DO1RDJY</RegistryNumber><NameOfSubstance UI="D012701">Serotonin</NameOfSubstance></Chemical><Chemical><RegistryNumber>8DUH1N11BX</RegistryNumber><NameOfSubstance UI="D014364">Tryptophan</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Arch Gen Psychiatry. 1990 May;47(5):411-8</RefSource><PMID Version="1">2184795</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004032" MajorTopicYN="N">Diet</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016651" MajorTopicYN="N">Lithium Carbonate</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012701" MajorTopicYN="N">Serotonin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014364" MajorTopicYN="N">Tryptophan</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000172" MajorTopicYN="Y">deficiency</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1995</Year><Month>2</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1995</Year><Month>2</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1995</Year><Month>2</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">7848051</ArticleId><ArticleId IdType="doi">10.1001/archpsyc.1995.03950140072010</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30870472</PMID><DateCompleted><Year>2019</Year><Month>12</Month><Day>27</Day></DateCompleted><DateRevised><Year>2020</Year><Month>03</Month><Day>09</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>3</Issue><PubDate><Year>2019</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Handwriting movements for assessment of motor symptoms in schizophrenia spectrum disorders and bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>e0213657</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0213657</ELocationID><Abstract><AbstractText>The main aim of the present study was to explore the value of several measures of handwriting in the study of motor abnormalities in patients with bipolar or psychotic disorders. 54 adult participants with a schizophrenia spectrum disorder or bipolar disorder and 44 matched healthy controls, participated in the study. Participants were asked to copy a handwriting pattern consisting of four loops, with an inking pen on a digitizing tablet. We collected a number of classical, non-linear and geometrical measures of handwriting. The handwriting of patients was characterized by a significant decrease in velocity and acceleration and an increase in the length, disfluency and pressure with respect to controls. Concerning non-linear measures, we found significant differences between patients and controls in the Sample Entropy of velocity and pressure, Lempel-Ziv of velocity and pressure, and Higuchi Fractal Dimension of pressure. Finally, Lacunarity, a measure of geometrical heterogeneity, was significantly greater in handwriting patterns from patients than from controls. We did not find differences in any handwriting measure on function of the specific diagnosis or the antipsychotic dose. Results indicate that participants with a schizophrenia spectrum disorder or bipolar disorder exhibit significant motor impairments and that these impairments can be readily quantified using measures of handwriting movements. Besides, they suggest that motor abnormalities are a core feature of several mental disorders and they seem to be unrelated to the pharmacological treatment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Crespo</LastName><ForeName>Yasmina</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-4872-0977</Identifier><AffiliationInfo><Affiliation>Psychology Department, University of Jaén, Jaén, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Mental Health Unit, St. Agustín Universitary Hospital, Linares, Jaén, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ibañez</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Psychology Department, University of Jaén, Jaén, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soriano</LastName><ForeName>María Felipa</ForeName><Initials>MF</Initials><AffiliationInfo><Affiliation>Mental Health Unit, St. Agustín Universitary Hospital, Linares, Jaén, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iglesias</LastName><ForeName>Sergio</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Psychology Department, University of Jaén, Jaén, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aznarte</LastName><ForeName>Jose Ignacio</ForeName><Initials>JI</Initials><AffiliationInfo><Affiliation>Mental Health Unit, St. Agustín Universitary Hospital, Linares, Jaén, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>03</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000465" MajorTopicYN="N">Algorithms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001696" MajorTopicYN="N">Biomechanical Phenomena</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019277" MajorTopicYN="N">Entropy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017709" MajorTopicYN="N">Fractals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006236" MajorTopicYN="Y">Handwriting</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009068" MajorTopicYN="N">Movement</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>09</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>02</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>3</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>3</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>12</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30870472</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0213657</ArticleId><ArticleId IdType="pii">PONE-D-18-27776</ArticleId><ArticleId IdType="pmc">PMC6417658</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Schizophr Res. 2016 Jan;170(1):137-42</Citation><ArticleIdList><ArticleId IdType="pubmed">26492987</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2014 Mar;40 Suppl 2:S138-46</Citation><ArticleIdList><ArticleId IdType="pubmed">24371326</ArticleId></ArticleIdList></Reference><Reference><Citation>J Formos Med Assoc. 2013 Jun;112(6):332-7</Citation><ArticleIdList><ArticleId IdType="pubmed">23787010</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Rep. 2017 Dec 18;7(1):17730</Citation><ArticleIdList><ArticleId IdType="pubmed">29255220</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2014 Jan;40(1):111-9</Citation><ArticleIdList><ArticleId IdType="pubmed">23661632</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 1987;13(2):261-76</Citation><ArticleIdList><ArticleId IdType="pubmed">3616518</ArticleId></ArticleIdList></Reference><Reference><Citation>Cortex. 2013 Nov-Dec;49(10):2772-87</Citation><ArticleIdList><ArticleId IdType="pubmed">23831432</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2000 Sep 29;45(1-2):133-43</Citation><ArticleIdList><ArticleId IdType="pubmed">10978881</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2018 Apr 24;13(4):e0196098</Citation><ArticleIdList><ArticleId IdType="pubmed">29689111</ArticleId></ArticleIdList></Reference><Reference><Citation>Phys Rev A. 1991 Sep 15;44(6):3552-3558</Citation><ArticleIdList><ArticleId IdType="pubmed">9906372</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Dyslexia. 2012 Jul;62(2):100-19</Citation><ArticleIdList><ArticleId IdType="pubmed">22460607</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2014 May 22;9(5):e97614</Citation><ArticleIdList><ArticleId IdType="pubmed">24854199</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatry Neurosci. 1999 Sep;24(4):304-14</Citation><ArticleIdList><ArticleId IdType="pubmed">10516797</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Rep. 2016 Oct 05;6:34468</Citation><ArticleIdList><ArticleId IdType="pubmed">27703257</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychol (Amst). 2018 Jan;182:200-211</Citation><ArticleIdList><ArticleId IdType="pubmed">29229183</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacopsychiatry. 1991 Jul;24(4):132-7</Citation><ArticleIdList><ArticleId IdType="pubmed">1754609</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Occup Ther. 2003 Mar-Apr;57(2):129-38</Citation><ArticleIdList><ArticleId IdType="pubmed">12674304</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2011 Mar;129(1-3):252-60</Citation><ArticleIdList><ArticleId IdType="pubmed">20947174</ArticleId></ArticleIdList></Reference><Reference><Citation>Nervenarzt. 2000 May;71(5):373-9</Citation><ArticleIdList><ArticleId IdType="pubmed">10846712</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2015 Oct;45(13):2685-9</Citation><ArticleIdList><ArticleId IdType="pubmed">26005109</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Arch Psychiatry Clin Neurosci. 2006 Jun;256(4):201-6</Citation><ArticleIdList><ArticleId IdType="pubmed">16283597</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neuropsychopharmacol Biol Psychiatry. 2016 Jan 4;64:96-101</Citation><ArticleIdList><ArticleId IdType="pubmed">26241859</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Physiol Heart Circ Physiol. 2000 Jun;278(6):H2039-49</Citation><ArticleIdList><ArticleId IdType="pubmed">10843903</ArticleId></ArticleIdList></Reference><Reference><Citation>Phys Rev E Stat Nonlin Soft Matter Phys. 2005 Feb;71(2 Pt 1):021906</Citation><ArticleIdList><ArticleId IdType="pubmed">15783351</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2012 May;137(1-3):230-3</Citation><ArticleIdList><ArticleId IdType="pubmed">22309978</ArticleId></ArticleIdList></Reference><Reference><Citation>Percept Mot Skills. 2016 Apr;122(2):560-77</Citation><ArticleIdList><ArticleId IdType="pubmed">27166334</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Psychiatry. 2017 May;4(5):353-354</Citation><ArticleIdList><ArticleId IdType="pubmed">28344043</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand Suppl. 1970;212:11-9</Citation><ArticleIdList><ArticleId IdType="pubmed">4917967</ArticleId></ArticleIdList></Reference><Reference><Citation>Actas Luso Esp Neurol Psiquiatr Cienc Afines. 1994 Jul-Aug;22(4):171-7</Citation><ArticleIdList><ArticleId IdType="pubmed">7810373</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Alzheimer Res. 2017;14(9):960-968</Citation><ArticleIdList><ArticleId IdType="pubmed">28290244</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Mov Sci. 2009 Oct;28(5):633-42</Citation><ArticleIdList><ArticleId IdType="pubmed">19692133</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2009 Jan 17;373(9659):234-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19150704</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2016 Apr 1;173(4):373-84</Citation><ArticleIdList><ArticleId IdType="pubmed">26651391</ArticleId></ArticleIdList></Reference><Reference><Citation>Behav Res Methods. 2010 Feb;42(1):326-32</Citation><ArticleIdList><ArticleId IdType="pubmed">20160312</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2008 Feb;65(2):165-71</Citation><ArticleIdList><ArticleId IdType="pubmed">18250254</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2010 Jul;36(4):723-31</Citation><ArticleIdList><ArticleId IdType="pubmed">18990712</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2010 Feb 1;67(3):255-62</Citation><ArticleIdList><ArticleId IdType="pubmed">19897178</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2017 Dec;258:207-216</Citation><ArticleIdList><ArticleId IdType="pubmed">28899614</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2014 May;40(3):504-15</Citation><ArticleIdList><ArticleId IdType="pubmed">24567502</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2002 Aug;181:135-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12151284</ArticleId></ArticleIdList></Reference><Reference><Citation>Artif Intell Med. 2016 Feb;67:39-46</Citation><ArticleIdList><ArticleId IdType="pubmed">26874552</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2004 Dec 1;71(2-3):405-16</Citation><ArticleIdList><ArticleId IdType="pubmed">15474912</ArticleId></ArticleIdList></Reference><Reference><Citation>J Mot Behav. 2018 Nov-Dec;50(6):643-652</Citation><ArticleIdList><ArticleId IdType="pubmed">29192870</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Belg. 1978 Jan-Feb;78(1):19-36</Citation><ArticleIdList><ArticleId IdType="pubmed">645405</ArticleId></ArticleIdList></Reference><Reference><Citation>Cognition. 2009 Mar;110(3):440-4</Citation><ArticleIdList><ArticleId IdType="pubmed">19150536</ArticleId></ArticleIdList></Reference><Reference><Citation>Phys Rev E Stat Phys Plasmas Fluids Relat Interdiscip Topics. 1996 May;53(5):5461-5468</Citation><ArticleIdList><ArticleId IdType="pubmed">9964879</ArticleId></ArticleIdList></Reference><Reference><Citation>Behav Res Methods. 2017 Jun;49(3):913-922</Citation><ArticleIdList><ArticleId IdType="pubmed">27325167</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2010 May;118(1-3):168-75</Citation><ArticleIdList><ArticleId IdType="pubmed">20071147</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Psychiatry. 2017 May;4(5):400-408</Citation><ArticleIdList><ArticleId IdType="pubmed">28344044</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Biomed Eng. 2009 Mar;37(3):586-94</Citation><ArticleIdList><ArticleId IdType="pubmed">19130227</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2010 May 15;177(1-2):77-83</Citation><ArticleIdList><ArticleId IdType="pubmed">20381875</ArticleId></ArticleIdList></Reference><Reference><Citation>J Neuropsychiatry Clin Neurosci. 2006 Summer;18(3):342-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16963583</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2008 Jan;105(1-3):291-5</Citation><ArticleIdList><ArticleId IdType="pubmed">17573121</ArticleId></ArticleIdList></Reference><Reference><Citation>Physiol Meas. 2006 Nov;27(11):1091-106</Citation><ArticleIdList><ArticleId IdType="pubmed">17028404</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2017 Sep 1;43(5):956-971</Citation><ArticleIdList><ArticleId IdType="pubmed">28911050</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2000 Sep;157(9):1416-22</Citation><ArticleIdList><ArticleId IdType="pubmed">10964857</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2013 Nov;170(11):1263-74</Citation><ArticleIdList><ArticleId IdType="pubmed">23846857</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2004 Jun;80(2-3):221-30</Citation><ArticleIdList><ArticleId IdType="pubmed">15207935</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nerv Ment Dis. 1997 Oct;185(10):641-4</Citation><ArticleIdList><ArticleId IdType="pubmed">9345256</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1982 Jul;39(7):789-94</Citation><ArticleIdList><ArticleId IdType="pubmed">7165478</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2014 May;40(3):523-31</Citation><ArticleIdList><ArticleId IdType="pubmed">24609453</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neuropsychopharmacol Biol Psychiatry. 2013 Jun 3;43:72-8</Citation><ArticleIdList><ArticleId IdType="pubmed">23266480</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1999 May;56(5):457-63</Citation><ArticleIdList><ArticleId IdType="pubmed">10232301</ArticleId></ArticleIdList></Reference><Reference><Citation>Res Dev Disabil. 2013 Dec;34(12):4375-84</Citation><ArticleIdList><ArticleId IdType="pubmed">24139714</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Psychiatry. 2014 Oct 09;14:280</Citation><ArticleIdList><ArticleId IdType="pubmed">25298069</ArticleId></ArticleIdList></Reference><Reference><Citation>Can J Psychiatry. 2005 Jun;50(7):429-31</Citation><ArticleIdList><ArticleId IdType="pubmed">16086541</ArticleId></ArticleIdList></Reference><Reference><Citation>J Forensic Sci. 2014 Jul;59(4):1020-4</Citation><ArticleIdList><ArticleId IdType="pubmed">24673648</ArticleId></ArticleIdList></Reference><Reference><Citation>Front Neurol. 2013 Jun 05;4:67</Citation><ArticleIdList><ArticleId IdType="pubmed">23761780</ArticleId></ArticleIdList></Reference><Reference><Citation>J Vis Exp. 2013 Nov 21;(81):e50852</Citation><ArticleIdList><ArticleId IdType="pubmed">24300590</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopharmacology (Berl). 2002 Jan;159(2):211-5</Citation><ArticleIdList><ArticleId IdType="pubmed">11862351</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2010 May;12(3):230-43</Citation><ArticleIdList><ArticleId IdType="pubmed">20565430</ArticleId></ArticleIdList></Reference><Reference><Citation>Open Biomed Eng J. 2010;4:223-35</Citation><ArticleIdList><ArticleId IdType="pubmed">21625647</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2015 Dec;169(1-3):217-233</Citation><ArticleIdList><ArticleId IdType="pubmed">26547881</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Neuropsychopharmacol. 2001 Dec;4(4):347-60</Citation><ArticleIdList><ArticleId IdType="pubmed">11806860</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">7973464</PMID><DateCompleted><Year>1994</Year><Month>12</Month><Day>20</Day></DateCompleted><DateRevised><Year>2019</Year><Month>05</Month><Day>12</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0586-7614</ISSN><JournalIssue CitedMedium="Print"><Volume>20</Volume><Issue>3</Issue><PubDate><Year>1994</Year></PubDate></JournalIssue><Title>Schizophrenia bulletin</Title><ISOAbbreviation>Schizophr Bull</ISOAbbreviation></Journal><ArticleTitle>Minor physical anomalies in schizophrenia patients, bipolar patients, and their siblings.</ArticleTitle><Pagination><MedlinePgn>433-40</MedlinePgn></Pagination><Abstract><AbstractText>Minor physical anomalies (MPAs) are believed to reflect abnormalities in fetal neurodevelopment. Several studies have shown that schizophrenia patients have more MPAs than normal controls, but little is known about the meaning of this increased rate of MPAs. The current study first attempted to determine whether the increased MPAs are associated with schizophrenia in particular or with psychosis in general. Second, the study tested whether the patients' siblings also show an increased rate of MPAs by assessing MPAs in schizophrenia patients, bipolar manic patients, the siblings from each group of patients, and normal controls. The schizophrenia patients had significantly more MPAs than normal controls and bipolar patients. The rate of MPAs in bipolar patients did not differ from normal controls. This pattern suggests that MPAs have some degree of specificity to schizophrenia. Both sibling groups had fewer MPAs than the patients, and this difference was significant for the comparison between schizophrenia patients and their siblings. When viewed within a vulnerability-stress model, the results are consistent with the theory that MPAs may reflect early, largely extra-genetic, stressful events.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Green</LastName><ForeName>M F</ForeName><Initials>MF</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Biobehavioral Sciences, University of California at Los Angeles (UCLA).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Satz</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Christenson</LastName><ForeName>C</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MH-43292</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Schizophr Bull</MedlineTA><NlmUniqueID>0236760</NlmUniqueID><ISSNLinking>0586-7614</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002908" MajorTopicYN="N">Chronic Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000013" MajorTopicYN="N">Congenital Abnormalities</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008016" MajorTopicYN="N">Life Change Events</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010553" MajorTopicYN="N">Personality Development</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011247" MajorTopicYN="N">Pregnancy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011297" MajorTopicYN="Y">Prenatal Exposure Delayed Effects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="Y">Schizophrenic Psychology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012569" MajorTopicYN="N">Schizotypal Personality Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1994</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1994</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1994</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">7973464</ArticleId><ArticleId IdType="doi">10.1093/schbul/20.3.433</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">4118559</PMID><DateCompleted><Year>1973</Year><Month>02</Month><Day>22</Day></DateCompleted><DateRevised><Year>2019</Year><Month>06</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0140-6736</ISSN><JournalIssue CitedMedium="Print"><Volume>1</Volume><Issue>7793</Issue><PubDate><Year>1973</Year><Month>Jan</Month><Day>06</Day></PubDate></JournalIssue><Title>Lancet (London, England)</Title><ISOAbbreviation>Lancet</ISOAbbreviation></Journal><ArticleTitle>Increased lithium erythrocyte-plasma ratio in manic-depressive psychosis.</ArticleTitle><Pagination><MedlinePgn>40</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lyttkens</LastName><ForeName>L</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Söderberg</LastName><ForeName>U</ForeName><Initials>U</Initials></Author><Author ValidYN="Y"><LastName>Wetterberg</LastName><ForeName>L</ForeName><Initials>L</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet</MedlineTA><NlmUniqueID>2985213R</NlmUniqueID><ISSNLinking>0140-6736</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004912" MajorTopicYN="N">Erythrocytes</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1973</Year><Month>1</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1973</Year><Month>1</Month><Day>6</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1973</Year><Month>1</Month><Day>6</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">4118559</ArticleId><ArticleId IdType="pii">S0140-6736(73)91250-6</ArticleId><ArticleId IdType="doi">10.1016/s0140-6736(73)91250-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">9853694</PMID><DateCompleted><Year>1999</Year><Month>03</Month><Day>16</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1044-5463</ISSN><JournalIssue CitedMedium="Print"><Volume>8</Volume><Issue>3</Issue><PubDate><Year>1998</Year></PubDate></JournalIssue><Title>Journal of child and adolescent psychopharmacology</Title><ISOAbbreviation>J Child Adolesc Psychopharmacol</ISOAbbreviation></Journal><ArticleTitle>An adolescent male with multiple paraphilias successfully treated with fluoxetine.</ArticleTitle><Pagination><MedlinePgn>195-7</MedlinePgn></Pagination><Abstract><AbstractText>Little is known about the psychiatric diagnosis and treatment of adolescents who sexually offend. We therefore describe an adolescent sex offender who met DSM-IV criteria for multiple paraphilias (except for the age criterion), bipolar type II disorder, and OCD, whose paraphilic urges and behaviors, depression, and violent obsessions responded to open label fluoxetine after failing to respond to long-term residential treatment. Although only a single and uncontrolled observation, this case suggests that some adolescent sex offenders may in fact have paraphilias, and that paraphilias in adolescents, like those in adults, may respond to serotonin reuptake inhibitors.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Galli</LastName><ForeName>V B</ForeName><Initials>VB</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Cincinnati College of Medicine, Ohio 45267-0559, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raute</LastName><ForeName>N J</ForeName><Initials>NJ</Initials></Author><Author ValidYN="Y"><LastName>McConville</LastName><ForeName>B J</ForeName><Initials>BJ</Initials></Author><Author ValidYN="Y"><LastName>McElroy</LastName><ForeName>S L</ForeName><Initials>SL</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Child Adolesc Psychopharmacol</MedlineTA><NlmUniqueID>9105358</NlmUniqueID><ISSNLinking>1044-5463</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018687">Antidepressive Agents, Second-Generation</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017367">Serotonin Uptake Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>01K63SUP8D</RegistryNumber><NameOfSubstance UI="D005473">Fluoxetine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018687" MajorTopicYN="N">Antidepressive Agents, Second-Generation</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005473" MajorTopicYN="N">Fluoxetine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009771" MajorTopicYN="N">Obsessive-Compulsive Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010262" MajorTopicYN="N">Paraphilic Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017367" MajorTopicYN="N">Serotonin Uptake Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1998</Year><Month>12</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1998</Year><Month>12</Month><Day>16</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1998</Year><Month>12</Month><Day>16</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">9853694</ArticleId><ArticleId IdType="doi">10.1089/cap.1998.8.195</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15147051</PMID><DateCompleted><Year>2004</Year><Month>07</Month><Day>07</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0031-5990</ISSN><JournalIssue CitedMedium="Print"><Volume>40</Volume><Issue>1</Issue><PubDate><MedlineDate>2004 Jan-Mar</MedlineDate></PubDate></JournalIssue><Title>Perspectives in psychiatric care</Title><ISOAbbreviation>Perspect Psychiatr Care</ISOAbbreviation></Journal><ArticleTitle>The case for atypical antipsychotics in bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>34-8</MedlinePgn></Pagination><Abstract><AbstractText>As the opening scenario illustrates about Mary and Bob, bipolar disorder can be devastating to individuals and families. Managing symptoms through psychotropic medications can help people with mental illness better manage their lives. Our brief review of the current research supports the effectiveness of atypical antipsychotic medications and, therefore, supports their use in treating bipolar disorder.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shattell</LastName><ForeName>Mona</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>University of Alabama at Birmingham School of Nursing, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keltner</LastName><ForeName>Norman L</ForeName><Initials>NL</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Perspect Psychiatr Care</MedlineTA><NlmUniqueID>0401133</NlmUniqueID><ISSNLinking>0031-5990</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003987">Dibenzothiazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010879">Piperazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015363">Quinolones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013844">Thiazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>12794-10-4</RegistryNumber><NameOfSubstance UI="D001569">Benzodiazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>2S3PL1B6UJ</RegistryNumber><NameOfSubstance UI="D000069348">Quetiapine Fumarate</NameOfSubstance></Chemical><Chemical><RegistryNumber>6UKA5VEJ6X</RegistryNumber><NameOfSubstance UI="C092292">ziprasidone</NameOfSubstance></Chemical><Chemical><RegistryNumber>82VFR53I78</RegistryNumber><NameOfSubstance UI="D000068180">Aripiprazole</NameOfSubstance></Chemical><Chemical><RegistryNumber>J60AR2IKIC</RegistryNumber><NameOfSubstance UI="D003024">Clozapine</NameOfSubstance></Chemical><Chemical><RegistryNumber>L6UH7ZF8HC</RegistryNumber><NameOfSubstance UI="D018967">Risperidone</NameOfSubstance></Chemical><Chemical><RegistryNumber>N7U69T4SZR</RegistryNumber><NameOfSubstance UI="D000077152">Olanzapine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>N</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000068180" MajorTopicYN="N">Aripiprazole</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001569" MajorTopicYN="N">Benzodiazepines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003024" MajorTopicYN="N">Clozapine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003987" MajorTopicYN="N">Dibenzothiazepines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077152" MajorTopicYN="N">Olanzapine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018579" MajorTopicYN="N">Patient Selection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069348" MajorTopicYN="N">Quetiapine Fumarate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015363" MajorTopicYN="N">Quinolones</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018967" MajorTopicYN="N">Risperidone</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013844" MajorTopicYN="N">Thiazoles</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>34</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>5</Month><Day>19</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>7</Month><Day>9</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>5</Month><Day>19</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15147051</ArticleId><ArticleId IdType="doi">10.1111/j.1744-6163.2004.00034.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24067291</PMID><DateCompleted><Year>2015</Year><Month>01</Month><Day>06</Day></DateCompleted><DateRevised><Year>2016</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1469-5111</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>7</Issue><PubDate><Year>2014</Year><Month>Jul</Month></PubDate></JournalIssue><Title>The international journal of neuropsychopharmacology</Title><ISOAbbreviation>Int J Neuropsychopharmacol</ISOAbbreviation></Journal><ArticleTitle>Polypharmacy and bipolar disorder: what's personality got to do with it?</ArticleTitle><Pagination><MedlinePgn>1053-61</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1017/S1461145713000953</ELocationID><Abstract><AbstractText>The majority of patients treated for bipolar disorder receive multiple psychotropic medications concurrently (polypharmacy), despite a lack of empirical evidence for any combination of three or more medications. Some patients benefit from the skillful management of a complex medication regimen, but iterative additions to a treatment regimen often do not lead to clinical improvement, are expensive, and can confound assessment of the underlying mood disorder. Given these potential problems of polypharmacy, this paper reviews the evidence supporting the use of multiple medications and seeks to identify patient personality traits that may put patients at a greater risk for ineffective complex chronic care. Patients with bipolar disorder (n = 89), ages 18 and older, were assessed on the Montgomery Asberg Depression Rating Scale (MADRS), Young Mania Rating Scale (YMRS), and the NEO Five Factor Inventory (NEO-FFI), and completed a treatment history questionnaire to report psychotropic medication use. We found that patients with lower scores on openness had significantly more current psychotropic medications than patients with higher scores on openness (3.7 ± 1.9 vs. 2.8 ± 1.8, p &lt; 0.05). Patients with the highest lifetime medication use had significantly lower extraversion (21.8 ± 8.9 vs. 25.4 ± 7.6, p &lt; 0.05) and lower conscientiousness (21.9 ± 8.2 vs. 27.9 ± 8.2, p &lt; 0.01) than those reporting lower lifetime medication use. Low levels of openness, extraversion, and conscientiousness may be associated with increased psychotropic medication use. Investigating the role of individual differences, such as patient personality traits, in moderating effective polypharmacy warrants future research.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sachs</LastName><ForeName>G S</ForeName><Initials>GS</Initials><AffiliationInfo><Affiliation>Massachusetts General Hospital,Boston, MA,USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peters</LastName><ForeName>A T</ForeName><Initials>AT</Initials><AffiliationInfo><Affiliation>Massachusetts General Hospital,Boston, MA,USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sylvia</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Massachusetts General Hospital,Boston, MA,USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grunze</LastName><ForeName>H</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Newcastle University,UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>09</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Neuropsychopharmacol</MedlineTA><NlmUniqueID>9815893</NlmUniqueID><ISSNLinking>1461-1457</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011619">Psychotropic Drugs</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007407" MajorTopicYN="N">Interviews as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010551" MajorTopicYN="Y">Personality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010555" MajorTopicYN="N">Personality Inventory</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019338" MajorTopicYN="Y">Polypharmacy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011619" MajorTopicYN="N">Psychotropic Drugs</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>9</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>9</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>1</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24067291</ArticleId><ArticleId IdType="pii">S1461145713000953</ArticleId><ArticleId IdType="doi">10.1017/S1461145713000953</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">4752681</PMID><DateCompleted><Year>1974</Year><Month>01</Month><Day>16</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0001-7604</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><Issue>2</Issue><PubDate><Year>1973</Year><Month>May</Month></PubDate></JournalIssue><Title>Activitas nervosa superior</Title><ISOAbbreviation>Act Nerv Super (Praha)</ISOAbbreviation></Journal><ArticleTitle>Genealogic study of patients suffering from primary affective disorder and treated with lithium.</ArticleTitle><Pagination><MedlinePgn>90</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zvolskỳ</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Dostàl</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Vinarovà</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Soucek</LastName><ForeName>K</ForeName><Initials>K</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Czech Republic</Country><MedlineTA>Act Nerv Super (Praha)</MedlineTA><NlmUniqueID>0400662</NlmUniqueID><ISSNLinking>0001-7604</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1973</Year><Month>5</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1973</Year><Month>5</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1973</Year><Month>5</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">4752681</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">5470285</PMID><DateCompleted><Year>1970</Year><Month>12</Month><Day>01</Day></DateCompleted><DateRevised><Year>2007</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0028-2804</ISSN><JournalIssue CitedMedium="Print"><Volume>41</Volume><Issue>9</Issue><PubDate><Year>1970</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Der Nervenarzt</Title><ISOAbbreviation>Nervenarzt</ISOAbbreviation></Journal><ArticleTitle>[Course controls in phasic psychoses].</ArticleTitle><Pagination><MedlinePgn>434-9</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wendland</LastName><ForeName>K L</ForeName><Initials>KL</Initials></Author><Author ValidYN="Y"><LastName>Ahlswede</LastName><ForeName>J</ForeName><Initials>J</Initials></Author></AuthorList><Language>ger</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Verlaufskontrollen bei phasischen Psychosen.</VernacularTitle></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Nervenarzt</MedlineTA><NlmUniqueID>0400773</NlmUniqueID><ISSNLinking>0028-2804</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001008" MajorTopicYN="N">Anxiety Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006998" MajorTopicYN="N">Hypochondriasis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009771" MajorTopicYN="N">Obsessive-Compulsive Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010259" MajorTopicYN="N">Paranoid Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011596" MajorTopicYN="N">Psychomotor Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009626" MajorTopicYN="N">Terminology as Topic</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1970</Year><Month>9</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1970</Year><Month>9</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1970</Year><Month>9</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">5470285</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28458141</PMID><DateCompleted><Year>2018</Year><Month>03</Month><Day>27</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-1379</ISSN><JournalIssue CitedMedium="Internet"><Volume>92</Volume><PubDate><Year>2017</Year><Month>09</Month></PubDate></JournalIssue><Title>Journal of psychiatric research</Title><ISOAbbreviation>J Psychiatr Res</ISOAbbreviation></Journal><ArticleTitle>A systematic review of evidence for the role of inflammatory biomarkers in bipolar patients.</ArticleTitle><Pagination><MedlinePgn>160-182</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0022-3956(16)30633-1</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jpsychires.2017.03.018</ELocationID><Abstract><AbstractText>Bipolar disorder (BD) is a neuropsychiatric disorder that is characterized by a phasic course of affective episodes interspersed with a euthymic state. Epidemiological, clinical, genetic, post-mortem and preclinical studies have shown that inflammatory reactions and immune modulation play a pivotal role in the pathophysiology of BD. It is conceptualized that biomarkers of inflammation and immune responses should be employed to monitor the disease process in bipolar patients. The objective of this systematic review is to analyse the inflammatory markers involved in human studies and to explore each individual marker for its potential clinical application and summarize evidence regarding their role in BD. A systematic review of human studies to measure inflammatory markers was conducted, and the studies were identified by searching PubMed/MEDLINE, PsycINFO, EMBASE, and Web of Science databases for peer-reviewed journals that were published until September 2015. In this review, we included peripheral markers, genetic, post-mortem and cell studies with inflammatory biomarker analysis in BD. One hundred and two (102) papers met the inclusion criteria. The pro-inflammatory cytokines were elevated and the anti-inflammatory cytokines were reduced in BD patients, particularly during manic and depressive phases when compared to the controls. These changes tend to disappear in euthymia, indicating that inflammation may be associated with acute phases of BD. Even though there are promising findings in this field, further clinical studies using more established detection techniques are needed to clearly show the benefit of using inflammatory markers in the diagnosis, follow-up and prognosis of patients with BD.</AbstractText><CopyrightInformation>Copyright © 2017 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sayana</LastName><ForeName>Pavani</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Translational Psychiatry Program, Department of Psychiatry and Behavioral Sciences, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Colpo</LastName><ForeName>Gabriela Delevati</ForeName><Initials>GD</Initials><AffiliationInfo><Affiliation>Translational Psychiatry Program, Department of Psychiatry and Behavioral Sciences, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simões</LastName><ForeName>Lutiana R</ForeName><Initials>LR</Initials><AffiliationInfo><Affiliation>Laboratory of Neurosciences, Graduate Program in Health Sciences, Health Sciences Unit, University of Southern Santa Catarina, UNESC, Criciúma, SC, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giridharan</LastName><ForeName>Vijayasree Vayalanellore</ForeName><Initials>VV</Initials><AffiliationInfo><Affiliation>Translational Psychiatry Program, Department of Psychiatry and Behavioral Sciences, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Teixeira</LastName><ForeName>Antonio Lucio</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Translational Psychiatry Program, Department of Psychiatry and Behavioral Sciences, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quevedo</LastName><ForeName>João</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Translational Psychiatry Program, Department of Psychiatry and Behavioral Sciences, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA; Center of Excellence on Mood Disorders, Department of Psychiatry and Behavioral Sciences, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA; Neuroscience Graduate Program, The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, TX, USA; Laboratory of Neurosciences, Graduate Program in Health Sciences, Health Sciences Unit, University of Southern Santa Catarina, UNESC, Criciúma, SC, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barichello</LastName><ForeName>Tatiana</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Translational Psychiatry Program, Department of Psychiatry and Behavioral Sciences, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA; Neuroscience Graduate Program, The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, TX, USA; Laboratory of Neurosciences, Graduate Program in Health Sciences, Health Sciences Unit, University of Southern Santa Catarina, UNESC, Criciúma, SC, Brazil. Electronic address: Tatiana.Barichello@uth.tmc.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>03</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Psychiatr Res</MedlineTA><NlmUniqueID>0376331</NlmUniqueID><ISSNLinking>0022-3956</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000890">Anti-Infective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000890" MajorTopicYN="N">Anti-Infective Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Biomarkers</Keyword><Keyword MajorTopicYN="Y">Bipolar disorder</Keyword><Keyword MajorTopicYN="Y">Depression</Keyword><Keyword MajorTopicYN="Y">Inflammation</Keyword><Keyword MajorTopicYN="Y">Mania</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>11</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>03</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>5</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>3</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>5</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28458141</ArticleId><ArticleId IdType="pii">S0022-3956(16)30633-1</ArticleId><ArticleId IdType="doi">10.1016/j.jpsychires.2017.03.018</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">3341463</PMID><DateCompleted><Year>1988</Year><Month>03</Month><Day>14</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0002-953X</ISSN><JournalIssue CitedMedium="Print"><Volume>145</Volume><Issue>2</Issue><PubDate><Year>1988</Year><Month>Feb</Month></PubDate></JournalIssue><Title>The American journal of psychiatry</Title><ISOAbbreviation>Am J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Rapid cycling affective disorder: contributing factors and treatment responses in 51 patients.</ArticleTitle><Pagination><MedlinePgn>179-84</MedlinePgn></Pagination><Abstract><AbstractText>For 51 patients with rapid cycling affective disorder, clinical and family history data indicated that the illness was phenotypically and genetically related to more typical forms of affective disorder, was characterized by a bipolar course (100%), and was more common in women (92%). Manic-depressive cycles were separate from menstrual cycles. At the time of onset of rapid cycling, 73% of the patients were taking antidepressant drugs; the continuation of rapid cycling was associated with antidepressant drug therapy in 51% of the patients. Although most patients had been referred to a research ward because they were considered to be refractory to treatment, 37% attained essentially complete remissions, usually during treatment with lithium and/or monoamine oxidase inhibitors.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wehr</LastName><ForeName>T A</ForeName><Initials>TA</Initials><AffiliationInfo><Affiliation>Clinical Psychobiology Branch, NIMH, Bethesda, MD 20892.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sack</LastName><ForeName>D A</ForeName><Initials>DA</Initials></Author><Author ValidYN="Y"><LastName>Rosenthal</LastName><ForeName>N E</ForeName><Initials>NE</Initials></Author><Author ValidYN="Y"><LastName>Cowdry</LastName><ForeName>R W</ForeName><Initials>RW</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Psychiatry</MedlineTA><NlmUniqueID>0370512</NlmUniqueID><ISSNLinking>0002-953X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008996">Monoamine Oxidase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008598" MajorTopicYN="N">Menstruation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008996" MajorTopicYN="N">Monoamine Oxidase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019964" MajorTopicYN="N">Mood Disorders</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012737" MajorTopicYN="N">Sex Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013959" MajorTopicYN="N">Thyroid Diseases</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1988</Year><Month>2</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1988</Year><Month>2</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1988</Year><Month>2</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">3341463</ArticleId><ArticleId IdType="doi">10.1176/ajp.145.2.179</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17994346</PMID><DateCompleted><Year>2007</Year><Month>12</Month><Day>06</Day></DateCompleted><DateRevised><Year>2007</Year><Month>11</Month><Day>12</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0742-0528</ISSN><JournalIssue CitedMedium="Print"><Volume>24</Volume><Issue>5</Issue><PubDate><Year>2007</Year></PubDate></JournalIssue><Title>Chronobiology international</Title><ISOAbbreviation>Chronobiol Int</ISOAbbreviation></Journal><ArticleTitle>Phase advance is an actimetric correlate of antidepressant response to sleep deprivation and light therapy in bipolar depression.</ArticleTitle><Pagination><MedlinePgn>921-37</MedlinePgn></Pagination><Abstract><AbstractText>The combination of total sleep deprivation (TSD) and light therapy (LT) in bipolar depression causes rapid antidepressant effects, and its mechanism of action has been hypothesized to involve the enhancement of all of the monoaminergic systems targeted by antidepressant drugs (serotonin, dopamine, norepinephrine). It is still unknown if the clinical effects are paralleled by changes in biological rhythms. In a before/after design of a study of biological correlates of response, 39 inpatients affected by Type I Bipolar Disorder whose current depressive episode was without psychotic features were treated for one week with repeated TSD combined with morning LT. Wrist actigraphy was recorded throughout the study. Two-thirds of the patients responded to treatment (50% reduction in Hamilton Depression score). Responders showed an increase in daytime activity, phase-advance of the activity-rest rhythm of 57 min compared to the pre-treatment baseline, and reduced nighttime sleep. Non-responders did not show significant changes in the parameters of their activity-rest rhythm. Phase advance of the activity-rest rhythm is an actimetric correlate of the antidepressant response to TSD and LT in bipolar depression. Results are consistent with the known effects of sleep-wake manipulations and neurotransmitter function on the suprachiasmatic nucleus.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Benedetti</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Neuropsychiatric Sciences, Scientific Institute, University Vita-Salute San Raffaele, Milano, Italy. benedetti.francesco@hsr.it</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dallaspezia</LastName><ForeName>Sara</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Fulgosi</LastName><ForeName>Mara Cigala</ForeName><Initials>MC</Initials></Author><Author ValidYN="Y"><LastName>Barbini</LastName><ForeName>Barbara</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Colombo</LastName><ForeName>Cristina</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Smeraldi</LastName><ForeName>Enrico</ForeName><Initials>E</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Chronobiol Int</MedlineTA><NlmUniqueID>8501362</NlmUniqueID><ISSNLinking>0742-0528</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000204" MajorTopicYN="N">Activity Cycles</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019454" MajorTopicYN="Y">Chronotherapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002940" MajorTopicYN="N">Circadian Rhythm</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010789" MajorTopicYN="Y">Phototherapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012892" MajorTopicYN="N">Sleep Deprivation</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>11</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>12</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>11</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17994346</ArticleId><ArticleId IdType="pii">783646353</ArticleId><ArticleId IdType="doi">10.1080/07420520701649455</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17303249</PMID><DateCompleted><Year>2007</Year><Month>07</Month><Day>16</Day></DateCompleted><DateRevised><Year>2008</Year><Month>04</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0165-1781</ISSN><JournalIssue CitedMedium="Print"><Volume>150</Volume><Issue>2</Issue><PubDate><Year>2007</Year><Month>Mar</Month><Day>30</Day></PubDate></JournalIssue><Title>Psychiatry research</Title><ISOAbbreviation>Psychiatry Res</ISOAbbreviation></Journal><ArticleTitle>Long-lasting effects of high frequency repetitive transcranial magnetic stimulation in major depressed patients.</ArticleTitle><Pagination><MedlinePgn>181-6</MedlinePgn></Pagination><Abstract><AbstractText>The majority of previous clinical studies have indicated that repetitive transcranial magnetic stimulation (rTMS) may have antidepressant effects. Herein, we investigated the longitudinal, long-term antidepressant efficacy of daily left prefrontal cortex (PFC) rTMS for a 1-week period. Nineteen patients were randomly assigned to two treatment groups at 90% of individual motor threshold (MT): Twelve received active repetitive transcranial magnetic stimulation and seven received sham treatment. Each patient underwent five sessions of twenty 2-s trains of 20 Hz rTMS with 800 stimuli/day. The Beck Depression Inventory and the Hamilton Depression Rating Scale were used to assess severity of depression at 1, 4 and 12 weeks post-therapy. A significant reduction of baseline depression scores was observed after 1 week of active treatment that lasted for 1 month, indicating improvement of depressive symptoms. No significant effects were observed in patients receiving sham treatment. The results of this controlled study are in agreement with the findings of previous studies suggesting that daily left PFC rTMS has an antidepressant effect.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bortolomasi</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Casa di Cura Villa S. Chiara, Verona, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Minelli</LastName><ForeName>Alessandra</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Fuggetta</LastName><ForeName>Giorgio</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Perini</LastName><ForeName>Michele</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Comencini</LastName><ForeName>Sandra</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Fiaschi</LastName><ForeName>Antonio</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Manganotti</LastName><ForeName>Paolo</ForeName><Initials>P</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>02</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Psychiatry Res</MedlineTA><NlmUniqueID>7911385</NlmUniqueID><ISSNLinking>0165-1781</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000929">Antidepressive Agents, Tricyclic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017367">Serotonin Uptake Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000929" MajorTopicYN="N">Antidepressive Agents, Tricyclic</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010555" MajorTopicYN="N">Personality Inventory</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017367" MajorTopicYN="N">Serotonin Uptake Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050781" MajorTopicYN="Y">Transcranial Magnetic Stimulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2005</Year><Month>11</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2006</Year><Month>04</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2006</Year><Month>04</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>2</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>7</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>2</Month><Day>17</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17303249</ArticleId><ArticleId IdType="pii">S0165-1781(06)00113-2</ArticleId><ArticleId IdType="doi">10.1016/j.psychres.2006.04.010</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17283705</PMID><DateCompleted><Year>2007</Year><Month>03</Month><Day>13</Day></DateCompleted><DateRevised><Year>2007</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1080-7543</ISSN><JournalIssue CitedMedium="Print"><Volume>24</Volume><Issue>1</Issue><PubDate><Year>2007</Year><Month>Jan</Month></PubDate></JournalIssue><Title>School nurse news</Title><ISOAbbreviation>School Nurse News</ISOAbbreviation></Journal><ArticleTitle>Bipolar disorder: an evolving understanding of the diagnosis.</ArticleTitle><Pagination><MedlinePgn>28-30</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Boehm</LastName><ForeName>Hans</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Hart</LastName><ForeName>James</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>School Nurse News</MedlineTA><NlmUniqueID>100956395</NlmUniqueID><ISSNLinking>1080-7543</ISSNLinking></MedlineJournalInfo><CitationSubset>N</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004519" MajorTopicYN="N">Education, Special</DescriptorName><QualifierName UI="Q000458" MajorTopicYN="N">organization &amp; administration</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007255" MajorTopicYN="N">Information Services</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020407" MajorTopicYN="N">Internet</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D024802" MajorTopicYN="N">Nurse's Role</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009730" MajorTopicYN="N">Nursing Assessment</DescriptorName><QualifierName UI="Q000458" MajorTopicYN="N">organization &amp; administration</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010347" MajorTopicYN="N">Patient Care Planning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010353" MajorTopicYN="N">Patient Education as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012573" MajorTopicYN="N">School Nursing</DescriptorName><QualifierName UI="Q000458" MajorTopicYN="Y">organization &amp; administration</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>2</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>3</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>2</Month><Day>8</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17283705</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">25660665</PMID><DateCompleted><Year>2015</Year><Month>10</Month><Day>21</Day></DateCompleted><DateRevised><Year>2019</Year><Month>02</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-7123</ISSN><JournalIssue CitedMedium="Internet"><Volume>226</Volume><Issue>1</Issue><PubDate><Year>2015</Year><Month>Mar</Month><Day>30</Day></PubDate></JournalIssue><Title>Psychiatry research</Title><ISOAbbreviation>Psychiatry Res</ISOAbbreviation></Journal><ArticleTitle>The Zuckerman-Kuhlman personality questionnaire in bipolar I and II disorders: a preliminary report.</ArticleTitle><Pagination><MedlinePgn>357-60</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.psychres.2015.01.019</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0165-1781(15)00061-X</ELocationID><Abstract><AbstractText>Patients with bipolar disorder have tendencies of higher impulsivity and sensation seeking, they might contribute differently to the emotional states of bipolar I (BD I) and II (BD II). We administered the Zuckerman-Kuhlman Personality Questionnaire (ZKPQ), the Plutchik-van Praag Depression Inventory (PVP), the Mood Disorder Questionnaire (MDQ), and the Hypomania Checklist (HCL-32) in 23 patients with BD I, 22 BD II, and 64 healthy volunteers. Both BD I and II scored higher on ZKPQ Impulsive sensation seeking (and its Impulsivity facet), Neuroticism-anxiety and Aggression-hostility, and on PVP and HCL-32 scales than controls did; BD I scored higher on MDQ and General sensation seeking facet than controls did. Compared to BD II, BD I scored higher on Impulsive sensation seeking (and General sensation seeking) and on MDQ. Moreover, General sensation seeking predicted MDQ, and Activity predicted HCL-32 in BD I. Aggression-hostility predicted HCL-32 in BD II. General sensation seeking predicted MDQ and HCL-32, and together with Neuroticism-anxiety, predicted PVP in controls. Our study suggests that Impulsive sensation seeking, and its General sensation seeking facet might help to delineate the two types of bipolar disorder. </AbstractText><CopyrightInformation>Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Shaofang</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Clinical Psychology and Psychiatry/School of Public Health, Zhejiang University College of Medicine, Hangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Qianqian</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Clinical Psychology and Psychiatry/School of Public Health, Zhejiang University College of Medicine, Hangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Liji</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Psychology, Zhejiang Police Vocational Academy, Hangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fan</LastName><ForeName>Hongying</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Clinical Psychology and Psychiatry/School of Public Health, Zhejiang University College of Medicine, Hangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mao</LastName><ForeName>Hongjing</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Clinical Psychology, Affiliated Psychiatric Hospital, Zhejiang University College of Medicine, Hangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Jian</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Clinical Psychology, Affiliated Psychiatric Hospital, Zhejiang University College of Medicine, Hangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Clinical Psychology and Psychiatry/School of Public Health, Zhejiang University College of Medicine, Hangzhou, China; Department of Clinical Psychology, Affiliated Psychiatric Hospital, Zhejiang University College of Medicine, Hangzhou, China. Electronic address: wangmufan@msn.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>01</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Psychiatry Res</MedlineTA><NlmUniqueID>7911385</NlmUniqueID><ISSNLinking>0165-1781</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000374" MajorTopicYN="N">Aggression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001007" MajorTopicYN="N">Anxiety</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001008" MajorTopicYN="N">Anxiety Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="Y">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019964" MajorTopicYN="N">Mood Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000075384" MajorTopicYN="N">Neuroticism</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010551" MajorTopicYN="N">Personality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010554" MajorTopicYN="N">Personality Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010555" MajorTopicYN="N">Personality Inventory</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012044" MajorTopicYN="N">Regression Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="Y">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Emotional state</Keyword><Keyword MajorTopicYN="N">Impulsive sensation seeking</Keyword><Keyword MajorTopicYN="N">Mood disorder</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>10</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2014</Year><Month>12</Month><Day>04</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>01</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>2</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>2</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>10</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25660665</ArticleId><ArticleId IdType="pii">S0165-1781(15)00061-X</ArticleId><ArticleId IdType="doi">10.1016/j.psychres.2015.01.019</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24492903</PMID><DateCompleted><Year>2015</Year><Month>02</Month><Day>13</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1557-9700</ISSN><JournalIssue CitedMedium="Internet"><Volume>65</Volume><Issue>2</Issue><PubDate><Year>2014</Year><Month>Feb</Month><Day>01</Day></PubDate></JournalIssue><Title>Psychiatric services (Washington, D.C.)</Title><ISOAbbreviation>Psychiatr Serv</ISOAbbreviation></Journal><ArticleTitle>Inadequate treatment of black Americans with bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>255-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1176/appi.ps.201200590</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">This study examined disparity in bipolar disorder treatment for black and white Americans.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The sample included 167 respondents to the National Comorbidity Survey Replication who had lifetime type I or II bipolar disorder. Treatment adequacy and potential correlates were assessed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">No black respondent received minimally adequate mood-stabilizing treatment, and blacks were less likely than whites to have taken a mood stabilizer in the prior year. Service use, sociodemographic characteristics, and symptom expression did not explain this disparity.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">There was substantial racial inequality in bipolar disorder treatment. Issues guiding this disparity may be unique to this disorder, and clarification of the source of disparity is needed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Kaja R</ForeName><Initials>KR</Initials></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Sheri L</ForeName><Initials>SL</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Psychiatr Serv</MedlineTA><NlmUniqueID>9502838</NlmUniqueID><ISSNLinking>1075-2730</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001741" MajorTopicYN="N">African Americans</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D044465" MajorTopicYN="N">European Continental Ancestry Group</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054625" MajorTopicYN="N">Healthcare Disparities</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008605" MajorTopicYN="N">Mental Health Services</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N">United States</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>2</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>2</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>2</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24492903</ArticleId><ArticleId IdType="pii">1818807</ArticleId><ArticleId IdType="doi">10.1176/appi.ps.201200590</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12507739</PMID><DateCompleted><Year>2003</Year><Month>04</Month><Day>23</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>06</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0165-0327</ISSN><JournalIssue CitedMedium="Print"><Volume>73</Volume><Issue>1-2</Issue><PubDate><Year>2003</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Validating antidepressant-associated hypomania (bipolar III): a systematic comparison with spontaneous hypomania (bipolar II).</ArticleTitle><Pagination><MedlinePgn>65-74</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">According to DSM-IV and ICD-10, hypomania which occurs solely during antidepressant treatment does not belong to the category of bipolar II (BP-II).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">As part of the EPIDEP National Multisite French Study of 493 consecutive DSM-IV major depressive patients evaluated in at least two semi-structured interviews 1 month apart, 144 (29.2%) fulfilled the criteria for bipolar II with spontaneous hypomania (BP-II Sp), and 52 (10.5%) had hypomania associated solely with antidepressants (BP-H AA).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">BP-II Sp group had earlier age at onset, more hypomanic episodes, and higher ratings on cyclothymic and hyperthymic temperaments, and abused alcohol more often. The two groups were indistinguishable on the hypomania checklist score (12.2+/-4.0 vs. 11.4+/-4.4, respectively, P=0.25) and on rates of familial bipolarity (14.1% vs. 11.8%, respectively, P=0.68). But BP-H AA had significantly more family history of suicide, had higher ratings on depressive temperament, with greater chronicity of depression, were more likely to be admitted to the hospital for suicidal depressions, and were more likely to have psychotic features; finally, clinicians were more likely to treat them with ECT, lithium and mood stabilizing anticonvulsants.</AbstractText><AbstractText Label="LIMITATION" NlmCategory="CONCLUSIONS">Naturalistic study, where treatment was uncontrolled.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">BP-H AA emerges as a disorder with depressive temperamental instability, manifesting hypomania later in life (and, by definition, during pharmacotherapy only). By the standards of clinicians who have taken care of these patients for long periods of time, BP-H AA appears as no less bipolar than those with prototypical BP-II. We submit that familial bipolarity ('genotypic' bipolarity) strongly favors their inclusion within the realm of bipolar II spectrum, as a prognostically less favorable depression-prone phenotype of this disorder, and which is susceptible to destabilization under antidepressant treatment. These considerations argue for revisions of DSM-IV and ICD-10 conventions. BP-HAA may represent a genetically less penetrant expression of BP-II; phenotypically; it might provisionally be categorized as bipolar III.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Akiskal</LastName><ForeName>Hagop S</ForeName><Initials>HS</Initials><AffiliationInfo><Affiliation>International Mood Center, University of California at San Diego and VA Psychiatry Service (116-A), 3350 La Jolla Village Drive, San Diego, CA 92161, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hantouche</LastName><ForeName>Elie-Georges</ForeName><Initials>EG</Initials></Author><Author ValidYN="Y"><LastName>Allilaire</LastName><ForeName>Jean-François</ForeName><Initials>JF</Initials></Author><Author ValidYN="Y"><LastName>Sechter</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Bourgeois</LastName><ForeName>Marc L</ForeName><Initials>ML</Initials></Author><Author ValidYN="Y"><LastName>Azorin</LastName><ForeName>Jean-Michel</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Chatenêt-Duchêne</LastName><ForeName>Liliane</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Lancrenon</LastName><ForeName>Sylvie</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013694" MajorTopicYN="N">Temperament</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>1</Month><Day>1</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>4</Month><Day>24</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>1</Month><Day>1</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12507739</ArticleId><ArticleId IdType="pii">S0165032702003257</ArticleId><ArticleId IdType="doi">10.1016/s0165-0327(02)00325-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16263857</PMID><DateCompleted><Year>2006</Year><Month>01</Month><Day>12</Day></DateCompleted><DateRevised><Year>2014</Year><Month>11</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0002-953X</ISSN><JournalIssue CitedMedium="Print"><Volume>162</Volume><Issue>11</Issue><PubDate><Year>2005</Year><Month>Nov</Month></PubDate></JournalIssue><Title>The American journal of psychiatry</Title><ISOAbbreviation>Am J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>A 20-month, double-blind, maintenance trial of lithium versus divalproex in rapid-cycling bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>2152-61</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The authors tested the hypothesis that divalproex would be more effective than lithium in the long-term management of patients with recently stabilized rapid-cycling bipolar disorder.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">A 20-month, double-blind, parallel-group comparison was carried out in recently hypomanic/manic patients who had experienced a persistent bimodal response to combined treatment with lithium and divalproex. Sixty patients were randomly assigned to lithium or divalproex monotherapy in a balanced design after stratification for illness type (bipolar I versus bipolar II disorder).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of the 254 patients enrolled in the open-label acute stabilization phase, 76% discontinued the study prematurely (poor adherence: 28%; nonresponse: 26% [of whom 74% remained depressed and 26% remained in a hypomanic/manic/mixed episode], intolerable side effects: 19%). Of the 60 patients (24%) randomly assigned to double-blind maintenance monotherapy, 53% relapsed (59% into depression and 41% into a hypomanic/manic/mixed episode), 22% completed the study, 10% had intolerable side effects, and 10% were poorly adherent. The rates of relapse into any mood episode for those given lithium versus divalproex were 56% and 50%, respectively; the rates were 34% and 29% for a depressive relapse and 19% and 22% for a hypomania/mania relapse. There were no significant differences in time to relapse. The proportion discontinuing prematurely because of side effects was 16% for lithium and 4% for divalproex.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The hypothesis that divalproex is more effective than lithium in the long-term management of rapid-cycling bipolar disorder is not supported by these data. Preliminary data suggest highly recurrent refractory depression may be the hallmark of rapid-cycling bipolar disorder.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Calabrese</LastName><ForeName>Joseph R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Case Western Reserve University, University Hospitals of Cleveland, Cleveland, OH 44106, USA. joseph.calabrese@uhhs.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shelton</LastName><ForeName>Melvin D</ForeName><Initials>MD</Initials></Author><Author ValidYN="Y"><LastName>Rapport</LastName><ForeName>Daniel J</ForeName><Initials>DJ</Initials></Author><Author ValidYN="Y"><LastName>Youngstrom</LastName><ForeName>Eric A</ForeName><Initials>EA</Initials></Author><Author ValidYN="Y"><LastName>Jackson</LastName><ForeName>Kelly</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Bilali</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Ganocy</LastName><ForeName>Stephen J</ForeName><Initials>SJ</Initials></Author><Author ValidYN="Y"><LastName>Findling</LastName><ForeName>Robert L</ForeName><Initials>RL</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 MH-50165</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Psychiatry</MedlineTA><NlmUniqueID>0370512</NlmUniqueID><ISSNLinking>0002-953X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance></Chemical><Chemical><RegistryNumber>614OI1Z5WI</RegistryNumber><NameOfSubstance UI="D014635">Valproic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000927" MajorTopicYN="N">Anticonvulsants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010352" MajorTopicYN="N">Patient Dropouts</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055502" MajorTopicYN="N">Secondary Prevention</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014635" MajorTopicYN="N">Valproic Acid</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>11</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>1</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>11</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16263857</ArticleId><ArticleId IdType="pii">162/11/2152</ArticleId><ArticleId IdType="doi">10.1176/appi.ajp.162.11.2152</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26989836</PMID><DateCompleted><Year>2017</Year><Month>08</Month><Day>25</Day></DateCompleted><DateRevised><Year>2018</Year><Month>08</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1600-0447</ISSN><JournalIssue CitedMedium="Internet"><Volume>134</Volume><Issue>3</Issue><PubDate><Year>2016</Year><Month>09</Month></PubDate></JournalIssue><Title>Acta psychiatrica Scandinavica</Title><ISOAbbreviation>Acta Psychiatr Scand</ISOAbbreviation></Journal><ArticleTitle>More inclusive bipolar mixed depression definitions by requiring fewer non-overlapping mood elevation symptoms.</ArticleTitle><Pagination><MedlinePgn>189-98</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/acps.12563</ELocationID><Abstract><AbstractText Label="OBJECTIVE">Assess strengths and limitations of mixed bipolar depression definitions made more inclusive than that of the Diagnostic and Statistical Manual of Mental Disorders Fifth Edition (DSM-5) by requiring fewer than three 'non-overlapping' mood elevation symptoms (NOMES).</AbstractText><AbstractText Label="METHOD">Among bipolar disorder (BD) out-patients assessed with Systematic Treatment Enhancement Program for BD (STEP-BD) Affective Disorders Evaluation, we assessed prevalence, demographics, and clinical correlates of mixed vs. pure depression, using less inclusive (≥3 NOMES, DSM-5), more inclusive (≥2 NOMES), and most inclusive (≥1 NOMES) definitions.</AbstractText><AbstractText Label="RESULTS">Among 153 depressed BD, compared to less inclusive DSM-5 threshold, our more and most inclusive thresholds, yielded approximately two- and five-fold higher mixed depression rates (7.2%, 15.0%, and 34.6% respectively), and important statistically significant clinical correlates for mixed compared to pure depression (e.g. more lifetime anxiety disorder comorbidity, more current irritability), which were not significant using the DSM-5 threshold.</AbstractText><AbstractText Label="CONCLUSION">Further studies assessing strengths and limitations of more inclusive mixed depression definitions are warranted, including assessing the extent to which enhanced statistical power vs. other factors contributes to more vs. less inclusive mixed bipolar depression thresholds having more statistically significant clinical correlates, and whether 'overlapping' mood elevation symptoms should be counted.</AbstractText><CopyrightInformation>© 2016 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>W</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Seoul Paik Hospital, Inje University School of Medicine, Seoul, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>H</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Ilsan Paik Hospital, Inje University School of Medicine, Goyang, South Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Citrome</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>New York Medical College, Valhalla, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akiskal</LastName><ForeName>H S</ForeName><Initials>HS</Initials><AffiliationInfo><Affiliation>International Mood Centre, University of California and Veterans Administration Hospital, San Diego, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goffin</LastName><ForeName>K C</ForeName><Initials>KC</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holtzman</LastName><ForeName>J N</ForeName><Initials>JN</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hooshmand</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>P W</ForeName><Initials>PW</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hill</LastName><ForeName>S J</ForeName><Initials>SJ</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ketter</LastName><ForeName>T A</ForeName><Initials>TA</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>03</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Acta Psychiatr Scand</MedlineTA><NlmUniqueID>0370364</NlmUniqueID><ISSNLinking>0001-690X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011595" MajorTopicYN="N">Psychomotor Agitation</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">bipolar disorder</Keyword><Keyword MajorTopicYN="Y">depression</Keyword><Keyword MajorTopicYN="Y">diagnosis</Keyword><Keyword MajorTopicYN="Y">nosology</Keyword><Keyword MajorTopicYN="Y">psychopathology</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>02</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>3</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>3</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>8</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26989836</ArticleId><ArticleId IdType="doi">10.1111/acps.12563</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11078046</PMID><DateCompleted><Year>2000</Year><Month>11</Month><Day>30</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>31</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0160-6689</ISSN><JournalIssue CitedMedium="Print"><Volume>61</Volume><Issue>10</Issue><PubDate><Year>2000</Year><Month>Oct</Month></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Diagnosing bipolar disorder and the effect of antidepressants: a naturalistic study.</ArticleTitle><Pagination><MedlinePgn>804-8; quiz 809</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To determine if bipolar disorder is accurately diagnosed in clinical practice and to assess the effects of antidepressants on the course of bipolar illness.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Charts of outpatients with affective disorder diagnoses seen in an outpatient clinic during 1 year (N = 85 with bipolar or unipolar disorders) were reviewed. Past diagnostic and treatment information was obtained by patient report and systematic psychiatric history. Bipolar diagnosis was based on DSM-IV criteria using a SCID-based interview.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Bipolar disorder was found to be misdiagnosed as unipolar depression in 37% of patients who first see a mental health professional after their first manic/hypomanic episode. Antidepressants were used earlier and more frequently than mood stabilizers, and 23% of this unselected sample experienced a new or worsening rapid-cycling course attributable to antidepressant use.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">These results suggest that bipolar disorder tends be misdiagnosed as unipolar major depressive disorder and that antidepressants seem to be associated with a worsened course of bipolar illness. However, this naturalistic trial was uncontrolled, and more controlled research is required to confirm or refute these findings.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ghaemi</LastName><ForeName>S N</ForeName><Initials>SN</Initials><AffiliationInfo><Affiliation>Cambridge Hospital, Department of Psychiatry, Harvard Medical School, Mass, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boiman</LastName><ForeName>E E</ForeName><Initials>EE</Initials></Author><Author ValidYN="Y"><LastName>Goodwin</LastName><ForeName>F K</ForeName><Initials>FK</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000553" MajorTopicYN="N">Ambulatory Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003951" MajorTopicYN="N">Diagnostic Errors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008499" MajorTopicYN="N">Medical Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>11</Month><Day>15</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>2</Month><Day>28</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>11</Month><Day>15</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11078046</ArticleId><ArticleId IdType="doi">10.4088/jcp.v61n1013</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">29952230</PMID><DateCompleted><Year>2019</Year><Month>10</Month><Day>28</Day></DateCompleted><DateRevised><Year>2019</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-5725</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>5</Issue><PubDate><MedlineDate>2018 Sep/Oct</MedlineDate></PubDate></JournalIssue><Title>Journal of the American Psychiatric Nurses Association</Title><ISOAbbreviation>J Am Psychiatr Nurses Assoc</ISOAbbreviation></Journal><ArticleTitle>The Compelling and Persistent Problem of Bipolar Disorder Disguised as Major Depression Disorder: An Integrative Review [Formula: see text].</ArticleTitle><Pagination><MedlinePgn>415-425</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/1078390318784360</ELocationID><Abstract><AbstractText Label="BACKGROUND">Up to 40% of patients with bipolar disorder are misdiagnosed, usually with major depression disorder.</AbstractText><AbstractText Label="OBJECTIVE">The purpose was to describe the current state of the science of the misdiagnosis of bipolar disorder, with the ultimate goal of improving psychiatric diagnostic workups including screening.</AbstractText><AbstractText Label="DESIGN">An integrative review was conducted using standard criteria for evaluating research articles.</AbstractText><AbstractText Label="RESULTS">Forty-nine articles met the eligibility criteria. Articles explored patient-related and health care provider-related factors contributing to the misdiagnosis of bipolar disorder as well as consequences of misdiagnosis. Clinically oriented, reliable, and valid screening tools for bipolar disorder also were reviewed.</AbstractText><AbstractText Label="CONCLUSIONS">Awareness of multiple, challenging patient-related factors and more comprehensive assessment and screening by health care providers may reduce misdiagnosis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Stiles</LastName><ForeName>Brandie M</ForeName><Initials>BM</Initials><AffiliationInfo><Affiliation>1 Brandie M. Stiles, PhD, MSN, PMHNP-BC, University of Missouri-St. Louis, St. Louis, MO, USA; Centerpointe Hospital, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fish</LastName><ForeName>Anne F</ForeName><Initials>AF</Initials><AffiliationInfo><Affiliation>2 Anne F. Fish, PhD, RN, FAHA, University of Missouri-St. Louis, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vandermause</LastName><ForeName>Roxanne</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>3 Roxanne Vandermause, PhD, RN, University of Missouri-St. Louis, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malik</LastName><ForeName>Azfar M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>4 Azfar M. Malik, MD, MBA, Centerpointe Hospital, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>06</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Am Psychiatr Nurses Assoc</MedlineTA><NlmUniqueID>9507418</NlmUniqueID><ISSNLinking>1078-3903</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CitationSubset>N</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003951" MajorTopicYN="Y">Diagnostic Errors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">bipolar disorder</Keyword><Keyword MajorTopicYN="Y">mental illness</Keyword><Keyword MajorTopicYN="Y">misdiagnosis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>6</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>10</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>6</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29952230</ArticleId><ArticleId IdType="doi">10.1177/1078390318784360</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12519097</PMID><DateCompleted><Year>2003</Year><Month>04</Month><Day>02</Day></DateCompleted><DateRevised><Year>2019</Year><Month>11</Month><Day>06</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1398-5647</ISSN><JournalIssue CitedMedium="Print"><Volume>4</Volume><Issue>6</Issue><PubDate><Year>2002</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>The Maudsley bipolar disorder project. A survey of psychotropic prescribing patterns in bipolar I disorder.</ArticleTitle><Pagination><MedlinePgn>378-85</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">The outcome of Bipolar 1 Disorder (BD1) is greatly dependent on the adequacy and appropriateness of its treatment. As the treatment choices in BD1 disorder are increasing the aim of this study was to examine the current use of the pharmacological agents in BD1 patients and its association with clinical characteristics.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Case note review of the pharmacotherapy of a sample of BD1 patients from a specified South London sector of a National Health Service Trust.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Half of the patients were on mood-stabilizers (usually lithium) and their use was associated with female gender and multiple admissions. Antipsychotics were more commonly used in patients with psychotic features and multiple manic episodes. Antidepressants were rarely prescribed alone and were not associated with increased number of manic episodes. Combination treatments were mostly used in patients in acute episodes and with multiple hospitalizations.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In ordinary care, the treatment of BD1 is often driven by symptoms and falls short of the existing practice guidelines.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Frangou</LastName><ForeName>Sophia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Section of Neurobiology of Psychosis, Division of Psychological Medicine, Institute of Psychiatry, De Crespigny Park, London, UK. s.frangou@iop.kcl.ac.uk</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raymont</LastName><ForeName>Vanessa</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Bettany</LastName><ForeName>David</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011619">Psychotropic Drugs</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016009" MajorTopicYN="N">Chi-Square Distribution</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011307" MajorTopicYN="Y">Drug Prescriptions</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019538" MajorTopicYN="N">Health Care Surveys</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008605" MajorTopicYN="N">Mental Health Services</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010818" MajorTopicYN="Y">Practice Patterns, Physicians'</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011619" MajorTopicYN="N">Psychotropic Drugs</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>1</Month><Day>10</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>4</Month><Day>4</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>1</Month><Day>10</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12519097</ArticleId><ArticleId IdType="pii">1o223</ArticleId><ArticleId IdType="doi">10.1034/j.1399-5618.2002.01223.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27978794</PMID><DateCompleted><Year>2018</Year><Month>05</Month><Day>15</Day></DateCompleted><DateRevised><Year>2018</Year><Month>05</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1996-3181</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>2</Issue><PubDate><Year>2017</Year></PubDate></JournalIssue><Title>CNS &amp; neurological disorders drug targets</Title><ISOAbbreviation>CNS Neurol Disord Drug Targets</ISOAbbreviation></Journal><ArticleTitle>Mitochondrial Dysfunctions in Bipolar Disorder: Effect of the Disease and Pharmacotherapy.</ArticleTitle><Pagination><MedlinePgn>176-186</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2174/1871527315666161213110518</ELocationID><Abstract><AbstractText>Exact pathophysiological mechanisms of bipolar disorder have not been sufficiently clarified. We review the evidence of mitochondrial dysfunctions on the relation between both disease and pharmacotherapy. Mitochondria produce the most of energy-rich molecules of adenosine triphosphate (ATP), apart from energy production they are involved in other functions: regulation of free radicals, antioxidant defenses, lipid peroxidation, calcium metabolism and participate in the intrinsic pathway of apoptosis. According to increasing evidence dysfunctions of mitochondria are associated with affective disorders, a hypothesis of impaired mitochondrial functions has been proposed in bipolar disorder pathogenesis. Mitochondrial DNA mutations and/or polymorphisms, impaired phospholipid metabolism and glycolytic shift, decrease in ATP production, increased oxidative stress and changes of intracellular calcium are concerned in mood disorders and effects of mood stabilizers. Recent studies have also provided data about the positive effects of chronic treatment by mood stabilizers on mitochondrial functions.</AbstractText><CopyrightInformation>Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cikankova</LastName><ForeName>Tereza</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Sigitova</LastName><ForeName>Ekaterina</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Zverova</LastName><ForeName>Martina</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Fisar</LastName><ForeName>Zdenek</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Raboch</LastName><ForeName>Jiri</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Hroudova</LastName><ForeName>Jana</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, First Faculty of Medicine, Charles University and General University Hospital in Prague, Ke Karlovu 11, 120 00 Prague 2, Czech Republic.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United Arab Emirates</Country><MedlineTA>CNS Neurol Disord Drug Targets</MedlineTA><NlmUniqueID>101269155</NlmUniqueID><ISSNLinking>1871-5273</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011619">Psychotropic Drugs</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008928" MajorTopicYN="N">Mitochondria</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D028361" MajorTopicYN="N">Mitochondrial Diseases</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011619" MajorTopicYN="N">Psychotropic Drugs</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bioenergetics</Keyword><Keyword MajorTopicYN="N">bipolar disorder</Keyword><Keyword MajorTopicYN="N">electron transport chain complexes</Keyword><Keyword MajorTopicYN="N">mitochondria</Keyword><Keyword MajorTopicYN="N">mitochondrial DNA</Keyword><Keyword MajorTopicYN="N">mood stabilizers</Keyword><Keyword MajorTopicYN="N">oxidative phosphorylation</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>08</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>09</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>09</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>12</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>5</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>12</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27978794</ArticleId><ArticleId IdType="doi">10.2174/1871527315666161213110518</ArticleId><ArticleId IdType="pii">CNSNDDT-EPUB-80290</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">8102624</PMID><DateCompleted><Year>1993</Year><Month>09</Month><Day>22</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0165-0327</ISSN><JournalIssue CitedMedium="Print"><Volume>28</Volume><Issue>2</Issue><PubDate><Year>1993</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Erythrocyte membrane structure in bipolar affective disorder: a non-replication.</ArticleTitle><Pagination><MedlinePgn>91-4</MedlinePgn></Pagination><Abstract><AbstractText>Fifteen bipolar patients were compared with sixteen controls in an attempt to replicate the findings of Pettegrew et al. in 1982 of decreased fluidity in the hydrocarbon core of the erythrocyte membrane. No significant differences were seen between groups. The present control group shows very similar membrane characteristics to the original control series; however, the bipolar patient group is not similar. Possible explanations are discussed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nurnberger</LastName><ForeName>J</ForeName><Initials>J</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>Indiana University School of Medicine, Institute of Psychiatric Research, Indianapolis 46202-4887.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Bowman</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Sullivan</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Brittain</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Lawrence</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>York</LastName><ForeName>C</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>2BMD2GNA4V</RegistryNumber><NameOfSubstance UI="D016651">Lithium Carbonate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004907" MajorTopicYN="N">Erythrocyte Deformability</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005454" MajorTopicYN="N">Fluorescence Polarization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016651" MajorTopicYN="N">Lithium Carbonate</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1993</Year><Month>6</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>3</Month><Day>28</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1993</Year><Month>6</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">8102624</ArticleId><ArticleId IdType="pii">0165-0327(93)90037-K</ArticleId><ArticleId IdType="doi">10.1016/0165-0327(93)90037-k</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12578431</PMID><DateCompleted><Year>2003</Year><Month>03</Month><Day>04</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0003-990X</ISSN><JournalIssue CitedMedium="Print"><Volume>60</Volume><Issue>2</Issue><PubDate><Year>2003</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Archives of general psychiatry</Title><ISOAbbreviation>Arch Gen Psychiatry</ISOAbbreviation></Journal><ArticleTitle>A randomized controlled study of cognitive therapy for relapse prevention for bipolar affective disorder: outcome of the first year.</ArticleTitle><Pagination><MedlinePgn>145-52</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Despite the use of mood stabilizers, a significant proportion of patients with bipolar affective disorder experience frequent relapses. A pilot study of cognitive therapy (CT) specifically designed to prevent relapses for bipolar affective disorder showed encouraging results when used in conjunction with mood stabilizers. This article reports the outcome of a randomized controlled study of CT to help prevent relapses and promote social functioning.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We randomized 103 patients with bipolar 1 disorder according to the DSM-IV, who experienced frequent relapses despite the prescription of commonly used mood stabilizers, into a CT group or control group. Both the control and CT groups received mood stabilizers and regular psychiatric follow-up. In addition, the CT group received an average of 14 sessions of CT during the first 6 months and 2 booster sessions in the second 6 months.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">During the 12-month period, the CT group had significantly fewer bipolar episodes, days in a bipolar episode, and number of admissions for this type of episode. The CT group also had significantly higher social functioning. During these 12 months, the CT group showed less mood symptoms on the monthly mood questionnaires. Furthermore, there was significantly less fluctuation in manic symptoms in the CT group. The CT group also coped better with manic prodromes at 12 months.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Our findings support the conclusion that CT specifically designed for relapse prevention in bipolar affective disorder is a useful tool in conjunction with mood stabilizers.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lam</LastName><ForeName>Dominic H</ForeName><Initials>DH</Initials><AffiliationInfo><Affiliation>Department of Psychology, Institute of Psychiatry, London, England. spjtdhl@iop.kcl.ac.uk</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Watkins</LastName><ForeName>Edward R</ForeName><Initials>ER</Initials></Author><Author ValidYN="Y"><LastName>Hayward</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Bright</LastName><ForeName>Jenifer</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Wright</LastName><ForeName>Kim</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Kerr</LastName><ForeName>Natalie</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Parr-Davis</LastName><ForeName>Gina</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Sham</LastName><ForeName>Pak</ForeName><Initials>P</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Gen Psychiatry</MedlineTA><NlmUniqueID>0372435</NlmUniqueID><ISSNLinking>0003-990X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011619">Psychotropic Drugs</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000223" MajorTopicYN="N">Adaptation, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015928" MajorTopicYN="Y">Cognitive Behavioral Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017063" MajorTopicYN="N">Outcome Assessment, Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010349" MajorTopicYN="N">Patient Compliance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010555" MajorTopicYN="N">Personality Inventory</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011619" MajorTopicYN="N">Psychotropic Drugs</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055502" MajorTopicYN="N">Secondary Prevention</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012917" MajorTopicYN="N">Social Adjustment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>2</Month><Day>13</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>3</Month><Day>5</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>2</Month><Day>13</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12578431</ArticleId><ArticleId IdType="pii">yoa20510</ArticleId><ArticleId IdType="doi">10.1001/archpsyc.60.2.145</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">6367496</PMID><DateCompleted><Year>1984</Year><Month>03</Month><Day>29</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0002-953X</ISSN><JournalIssue CitedMedium="Print"><Volume>141</Volume><Issue>3</Issue><PubDate><Year>1984</Year><Month>Mar</Month></PubDate></JournalIssue><Title>The American journal of psychiatry</Title><ISOAbbreviation>Am J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Open trial of S-adenosylmethionine for treatment of depression.</ArticleTitle><Pagination><MedlinePgn>448-50</MedlinePgn></Pagination><Abstract><AbstractText>Nine depressed inpatients completed trials with S-adenosylmethionine. Seven showed improvement or remission of their symptoms. As in European studies, no side effects were seen except the apparent induction of mania in two patients with bipolar disorder.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lipinski</LastName><ForeName>J F</ForeName><Initials>JF</Initials></Author><Author ValidYN="Y"><LastName>Cohen</LastName><ForeName>B M</ForeName><Initials>BM</Initials></Author><Author ValidYN="Y"><LastName>Frankenburg</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Tohen</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Waternaux</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Altesman</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>B</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Harris</LastName><ForeName>P</ForeName><Initials>P</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MH-36224</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MH-38313</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Psychiatry</MedlineTA><NlmUniqueID>0370512</NlmUniqueID><ISSNLinking>0002-953X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>7LP2MPO46S</RegistryNumber><NameOfSubstance UI="D012436">S-Adenosylmethionine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012436" MajorTopicYN="N">S-Adenosylmethionine</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1984</Year><Month>3</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1984</Year><Month>3</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1984</Year><Month>3</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">6367496</ArticleId><ArticleId IdType="doi">10.1176/ajp.141.3.448</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">27425597</PMID><DateCompleted><Year>2017</Year><Month>09</Month><Day>25</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1399-5618</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>5</Issue><PubDate><Year>2016</Year><Month>08</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>Individuals hospitalized with acute mania have increased exposure to antimicrobial medications.</ArticleTitle><Pagination><MedlinePgn>404-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/bdi.12416</ELocationID><Abstract><AbstractText Label="OBJECTIVES">We have preciously documented that many individuals with acute mania have immune activation. However, the sources of immune activation have not been identified. We investigated whether individuals hospitalized with acute mania have evidence of bacterial infections as determined by the prescription of systemic antimicrobial agents.</AbstractText><AbstractText Label="METHODS">We assessed the recent prescription of systemic antimicrobial medications and the site of presumed bacterial infection in 234 individuals hospitalized for acute mania in either an inpatient unit or a day hospital. We also assessed individuals hospitalized for other psychiatric disorders (n=368) and controls (n=555). We employed logistic regression models to compare the rates of antibiotic prescription in individuals with the different diagnoses, employing demographic variables as covariates.</AbstractText><AbstractText Label="RESULTS">We found that individuals hospitalized with acute mania had a substantially increased rate of recent antimicrobial prescription, defined as exposure within three days of ascertainment (adjusted odds ratio=5.5, 95% confidence interval: 2.2-14.1, P&lt;.0002). Overall, a total of 18 of the 234 (7.7%) individuals hospitalized for acute mania were prescribed antibiotics as opposed to seven of 555 (1.3%) controls. The prescription of antibiotics was associated with being on an inpatient unit as opposed to being in the day hospital, and having increased mania symptom severity but not with other clinical ratings, demographic variables, or psychiatric medications. Hospitalization for other psychiatric disorders was not associated with the recent prescription of antimicrobial medications. The urinary tract was the most common site of infection in women, while the respiratory tract and mucosal surfaces were the most common sites in men.</AbstractText><AbstractText Label="CONCLUSIONS">Individuals hospitalized with acute mania have a markedly increased rate of bacterial infections, as evidenced by the recent prescription of antimicrobial agents. The prevention and effective treatment of bacterial infections may be important interventions for the management of individuals with mania.</AbstractText><CopyrightInformation>© 2016 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yolken</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Stanley Neurovirology Laboratory, Johns Hopkins School of Medicine, Baltimore, MD,, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adamos</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Stanley Research Program, Sheppard Pratt Health System, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Katsafanas</LastName><ForeName>Emily</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Stanley Research Program, Sheppard Pratt Health System, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khushalani</LastName><ForeName>Sunil</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Stanley Research Program, Sheppard Pratt Health System, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Origoni</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Stanley Research Program, Sheppard Pratt Health System, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Savage</LastName><ForeName>Christina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Stanley Research Program, Sheppard Pratt Health System, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schweinfurth</LastName><ForeName>Lucy</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Stanley Research Program, Sheppard Pratt Health System, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stallings</LastName><ForeName>Cassie</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Stanley Research Program, Sheppard Pratt Health System, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sweeney</LastName><ForeName>Kevin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Stanley Research Program, Sheppard Pratt Health System, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dickerson</LastName><ForeName>Faith</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Stanley Research Program, Sheppard Pratt Health System, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P50 MH094268</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>07</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000890">Anti-Infective Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D055553">Prescription Drugs</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000890" MajorTopicYN="N">Anti-Infective Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001424" MajorTopicYN="Y">Bacterial Infections</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="Y">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016015" MajorTopicYN="N">Logistic Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055553" MajorTopicYN="N">Prescription Drugs</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013223" MajorTopicYN="N">Statistics as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">antibiotic</Keyword><Keyword MajorTopicYN="Y">infection</Keyword><Keyword MajorTopicYN="Y">inflammation</Keyword><Keyword MajorTopicYN="Y">mania</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>04</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>06</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>06</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>7</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>7</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>9</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27425597</ArticleId><ArticleId IdType="doi">10.1111/bdi.12416</ArticleId><ArticleId IdType="pmc">PMC5508736</ArticleId><ArticleId IdType="mid">NIHMS876231</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Br J Soc Clin Psychol. 1967 Dec;6(4):278-96</Citation><ArticleIdList><ArticleId IdType="pubmed">6080235</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2014 Nov;40(6):1518-25</Citation><ArticleIdList><ArticleId IdType="pubmed">24366719</ArticleId></ArticleIdList></Reference><Reference><Citation>J Antimicrob Chemother. 2011 Sep;66(9):2159-67</Citation><ArticleIdList><ArticleId IdType="pubmed">21719472</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2015 Feb;161(2-3):215-21</Citation><ArticleIdList><ArticleId IdType="pubmed">25487697</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA Psychiatry. 2013 Aug;70(8):812-20</Citation><ArticleIdList><ArticleId IdType="pubmed">23760347</ArticleId></ArticleIdList></Reference><Reference><Citation>World J Gastroenterol. 2016 Jan 7;22(1):361-8</Citation><ArticleIdList><ArticleId IdType="pubmed">26755882</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2015 Jul 06;10(7):e0132001</Citation><ArticleIdList><ArticleId IdType="pubmed">26147665</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Pract. 2015 Nov;21(6):402-11</Citation><ArticleIdList><ArticleId IdType="pubmed">26554322</ArticleId></ArticleIdList></Reference><Reference><Citation>Genome Med. 2016 Apr 06;8(1):36</Citation><ArticleIdList><ArticleId IdType="pubmed">27048547</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1978 Nov;133:429-35</Citation><ArticleIdList><ArticleId IdType="pubmed">728692</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Exp Neuropsychol. 1998 Jun;20(3):310-9</Citation><ArticleIdList><ArticleId IdType="pubmed">9845158</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2005 Oct;187:366-71</Citation><ArticleIdList><ArticleId IdType="pubmed">16199797</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Biobehav Rev. 2016 May;64:134-47</Citation><ArticleIdList><ArticleId IdType="pubmed">26905767</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2012 Aug;139(1-3):161-8</Citation><ArticleIdList><ArticleId IdType="pubmed">22704639</ArticleId></ArticleIdList></Reference><Reference><Citation>Transl Psychiatry. 2013 Oct 22;3:e314</Citation><ArticleIdList><ArticleId IdType="pubmed">24150223</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Psychiatry. 2015 Mar;2(3):258-70</Citation><ArticleIdList><ArticleId IdType="pubmed">26359903</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Neuropsychopharmacol. 2014 Oct 31;18(1):null</Citation><ArticleIdList><ArticleId IdType="pubmed">25539506</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2014 Aug;164:148-54</Citation><ArticleIdList><ArticleId IdType="pubmed">24856568</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacotherapy. 2014 Jul;34(7):677-85</Citation><ArticleIdList><ArticleId IdType="pubmed">24753176</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2015 May 15;60 Suppl 2:S77-84</Citation><ArticleIdList><ArticleId IdType="pubmed">25922405</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Clin North Am. 2016 Mar;39(1):125-37</Citation><ArticleIdList><ArticleId IdType="pubmed">26876323</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS One. 2013 Sep 03;8(9):e73520</Citation><ArticleIdList><ArticleId IdType="pubmed">24019926</ArticleId></ArticleIdList></Reference><Reference><Citation>Pediatrics. 2014 Dec;134(6):1059-66</Citation><ArticleIdList><ArticleId IdType="pubmed">25404720</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2015 Nov;70:18-27</Citation><ArticleIdList><ArticleId IdType="pubmed">26424419</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2015 Jun;17(4):409-14</Citation><ArticleIdList><ArticleId IdType="pubmed">25425421</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10746901</PMID><DateCompleted><Year>2000</Year><Month>04</Month><Day>27</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0010-440X</ISSN><JournalIssue CitedMedium="Print"><Volume>41</Volume><Issue>2 Suppl 1</Issue><PubDate><MedlineDate>2000 Mar-Apr</MedlineDate></PubDate></JournalIssue><Title>Comprehensive psychiatry</Title><ISOAbbreviation>Compr Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Does effective lithium prophylaxis result in a symptom-free state of manic-depressive illness? Some thoughts on the fine-tuning of mood stabilization.</ArticleTitle><Pagination><MedlinePgn>26-31</MedlinePgn></Pagination><Abstract><AbstractText>Recovered depressive or manic-depressive patients on long-term lithium medication may show oscillations in their state of well-being, neuropsychological impairment, and subclinical mood disturbances. It remains an open question as to whether such changes should be labeled as "subthreshold" symptoms of depression or mania, as a particular syndromal entity not directly related to the "mood disorder," or as subtle side effects of lithium. Within a psychological theory of the action of lithium, mental effects of lithium must be postulated and should not be simply considered as side effects. Depending on medical common sense and economic restrictions, the optimization and fine-tuning of lithium prophylaxis may be advisable in selected cases, including counseling, family therapy, cognitive therapy, well-being therapy, or interpersonal psychotherapy. Also, a change of medication may be considered in patients with subjective or objective cognitive impairment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Müller-Oerlinghausen</LastName><ForeName>B</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Freie Universität Berlin, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Compr Psychiatry</MedlineTA><NlmUniqueID>0372612</NlmUniqueID><ISSNLinking>0010-440X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>2BMD2GNA4V</RegistryNumber><NameOfSubstance UI="D016651">Lithium Carbonate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016651" MajorTopicYN="N">Lithium Carbonate</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="Y">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011613" MajorTopicYN="N">Psychotherapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>61</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>4</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>4</Month><Day>29</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>4</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10746901</ArticleId><ArticleId IdType="pii">S0010-440X(00)80005-X</ArticleId><ArticleId IdType="doi">10.1016/s0010-440x(00)80005-x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">26529281</PMID><DateCompleted><Year>2016</Year><Month>03</Month><Day>21</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1399-5618</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>6</Issue><PubDate><Year>2015</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>Differences in body mass index according to fat mass- and obesity-associated (FTO) genotype in Mexican patients with bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>662-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/bdi.12328</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">The prevalence of obesity has dramatically increased in many countries and it is particularly high in patients with bipolar disorder (BD). A region in the first intron of the fat mass- and obesity-associated (FTO) gene, encompassing markers rs9939973, rs8050136, and rs9939609, has been consistently associated with obesity and body mass index (BMI) in different populations. We sought to determine whether FTO is associated with BMI and/or obesity in patients with BD.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The sample included 129 Mexican Mestizo patients with bipolar I or bipolar II disorder. After obtaining informed consent, participants were evaluated with the Structured Clinical Interview for DSM-IV Axis I Disorders and weight, height, and body measurements were recorded. DNA was extracted from a 5-mL blood sample and real-time polymerase chain reaction was performed. The results were analyzed with Haploview v4.2 and SPSS v21.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Differences in mean BMI were explained by rs8050136 and rs9939609 genotypes, especially by comparing non-carriers and carriers of two copies of the risk allele (Tukey's p ≤ 0.019), with a mean difference in BMI as high as 7.81 kg/m(2) . Differences in BMI were also explained by the interaction of the genotype (rs8050136 and/or rs9939609), the use of second-generation antipsychotics, and the use of mood stabilizers (p ≤ 0.41). Obesity was also associated with these two markers when patients with and without obesity were compared.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In patients with BD, differences in BMI may be affected by the presence of FTO risk alleles, especially in homozygous individuals for these variants. Besides evaluating the possible metabolic effects of certain antipsychotics or mood stabilizers, it is important to evaluate the role of other factors such as FTO risk alleles.</AbstractText><CopyrightInformation>© 2015 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Díaz-Anzaldúa</LastName><ForeName>Adriana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Departamento de Genética, Subdirección de Investigaciones Clínicas, Instituto Nacional de Pisquiatría Ramón de la Fuente Muñiz (INPRF), Mexico D.F, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ocampo-Mendoza</LastName><ForeName>Yolanda</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Departamento de Genética, Subdirección de Investigaciones Clínicas, Instituto Nacional de Pisquiatría Ramón de la Fuente Muñiz (INPRF), Mexico D.F, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hernández-Lagunas</LastName><ForeName>José Octavio</ForeName><Initials>JO</Initials><AffiliationInfo><Affiliation>Departamento de Genética, Subdirección de Investigaciones Clínicas, Instituto Nacional de Pisquiatría Ramón de la Fuente Muñiz (INPRF), Mexico D.F, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Díaz-Madrid</LastName><ForeName>Federico Alejandro</ForeName><Initials>FA</Initials><AffiliationInfo><Affiliation>Departamento de Genética, Subdirección de Investigaciones Clínicas, Instituto Nacional de Pisquiatría Ramón de la Fuente Muñiz (INPRF), Mexico D.F, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Romo-Nava</LastName><ForeName>Francisco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Departamento de Psiquiatría y Salud Mental, Facultad de Medicina, Universidad Nacional Autónoma de México, Mexico D.F, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Juárez-García</LastName><ForeName>Francisco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Dirección de Investigaciones Epidemiológicas y Psicosociales, INPRF, Mexico D.F, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ortega-Ortiz</LastName><ForeName>Hiram</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Dirección de Servicios Clínicos, INPRF, Mexico D.F, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Díaz-Anzaldúa</LastName><ForeName>Alejandro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Dirección de Servicios Clínicos, INPRF, Mexico D.F, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gutiérrez-Mora</LastName><ForeName>Doris</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Dirección de Servicios Clínicos, INPRF, Mexico D.F, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Becerra-Palars</LastName><ForeName>Claudia</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Dirección de Servicios Clínicos, INPRF, Mexico D.F, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berlanga-Cisneros</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Subdirección de Investigaciones Clínicas, INPRF, Mexico D.F, Mexico.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011506">Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.14.11.33</RegistryNumber><NameOfSubstance UI="D000071516">Alpha-Ketoglutarate-Dependent Dioxygenase FTO</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.14.11.33</RegistryNumber><NameOfSubstance UI="C526492">FTO protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="N">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071516" MajorTopicYN="N">Alpha-Ketoglutarate-Dependent Dioxygenase FTO</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="Y">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015992" MajorTopicYN="Y">Body Mass Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008800" MajorTopicYN="N">Mexico</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009765" MajorTopicYN="Y">Obesity</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011506" MajorTopicYN="N">Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">FTO gene</Keyword><Keyword MajorTopicYN="N">antipsychotic agents</Keyword><Keyword MajorTopicYN="N">bipolar disorder</Keyword><Keyword MajorTopicYN="N">body mass index</Keyword><Keyword MajorTopicYN="N">gene for human fat mass- and obesity-associated protein</Keyword><Keyword MajorTopicYN="N">lithium carbonate</Keyword><Keyword MajorTopicYN="N">obesity</Keyword><Keyword MajorTopicYN="N">rs8050136</Keyword><Keyword MajorTopicYN="N">rs9939609</Keyword><Keyword MajorTopicYN="N">valproic acid</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>08</Month><Day>04</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>07</Month><Day>07</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>11</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>11</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>3</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26529281</ArticleId><ArticleId IdType="doi">10.1111/bdi.12328</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11758097</PMID><DateCompleted><Year>2002</Year><Month>01</Month><Day>29</Day></DateCompleted><DateRevised><Year>2019</Year><Month>10</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0028-2804</ISSN><JournalIssue CitedMedium="Print"><Volume>72</Volume><Issue>11</Issue><PubDate><Year>2001</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Der Nervenarzt</Title><ISOAbbreviation>Nervenarzt</ISOAbbreviation></Journal><ArticleTitle>[Paranoia erotica (de Clerambault syndrome) in affective disorder].</ArticleTitle><Pagination><MedlinePgn>879-83</MedlinePgn></Pagination><Abstract><AbstractText>Erotomania is a rare delusional disorder usually associated with other psychic disorders, especially paranoid schizophrenia. The primary form without comorbidity is very rare. A case report is presented with characteristic features of the pure form of erotomania in a female patient that was nevertheless an affective disorder. A historical review is presented and the division of Clérambault's syndrome into primary and secondary categories critically discussed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Debbelt</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Zentrum für Psychiatrie, Ruhr-Universität Bochum, Alexandrinenstrasse 1, 44791 Bochum.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Assion</LastName><ForeName>H J</ForeName><Initials>HJ</Initials></Author></AuthorList><Language>ger</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Paranoia erotica (de-Clerambault-Syndrom) bei affektiver Störung.</VernacularTitle></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Nervenarzt</MedlineTA><NlmUniqueID>0400773</NlmUniqueID><ISSNLinking>0028-2804</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003702" MajorTopicYN="N">Delusions</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004882" MajorTopicYN="Y">Erotica</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019965" MajorTopicYN="N">Neurocognitive Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010259" MajorTopicYN="N">Paranoid Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>1</Month><Day>5</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>1</Month><Day>30</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>1</Month><Day>5</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11758097</ArticleId><ArticleId IdType="doi">10.1007/s001150170024</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23621705</PMID><DateCompleted><Year>2015</Year><Month>04</Month><Day>10</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1399-5618</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>4</Issue><PubDate><Year>2013</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>White matter differences in euthymic bipolar I disorder: a combined magnetic resonance imaging and diffusion tensor imaging voxel-based study.</ArticleTitle><Pagination><MedlinePgn>365-76</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/bdi.12073</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">A broad range of subtle and markedly heterogenous neuroanatomical abnormalities of grey matter and white matter have been reported in bipolar disorder. Euthymic bipolar disorder patients represent a clinically homogenous group in which to identify trait-based biomarkers of bipolar disorder. In this study, we sought to clarify the nature and extent of neuroanatomical differences in a large, clinically homogeneous group of euthymic bipolar disorder patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Structural magnetic resonance imaging (sMRI) was obtained for 60 patients with prospectively confirmed euthymic bipolar I disorder and 60 individually age- and gender-matched healthy volunteers. High angular resolution diffusion tensor imaging (DTI) scans were obtained for a subset of this sample comprising 35 patients and 43 controls. Voxel-based analysis of both sMRI and DTI data sets was performed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Bipolar disorder patients displayed global reductions in white matter volume and fractional anisotropy reductions in the corpus callosum, posterior cingulum, and prefrontal white matter compared with controls. There were corresponding increases in radial diffusivity in the callosal splenium in patients compared with controls. No significant group differences were detected in grey matter. In patients, lithium was associated with a bilateral increase in grey matter volume in the temporal lobes, but not with any DTI parameter.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Euthymic bipolar I disorder is characterized by both diffuse global white matter deficits and potential regional disorganization in interhemispheric and longitudinal tracts, while grey matter appears to be preserved.</AbstractText><CopyrightInformation>© 2013 John Wiley &amp; Sons A/S. Published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Emsell</LastName><ForeName>Louise</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Clinical Neuroimaging Laboratory, National University of Ireland Galway, Galway, Ireland; Translational MRI, Department of Imaging and Pathology, KU Leuven and Radiology, University Hospitals Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Langan</LastName><ForeName>Camilla</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Van Hecke</LastName><ForeName>Wim</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Barker</LastName><ForeName>Gareth J</ForeName><Initials>GJ</Initials></Author><Author ValidYN="Y"><LastName>Leemans</LastName><ForeName>Alexander</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Sunaert</LastName><ForeName>Stefan</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>McCarthy</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Nolan</LastName><ForeName>Rachel</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Cannon</LastName><ForeName>Dara M</ForeName><Initials>DM</Initials></Author><Author ValidYN="Y"><LastName>McDonald</LastName><ForeName>Colm</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>04</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018020">Lithium Compounds</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000339" MajorTopicYN="N">Affect</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="Y">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D038524" MajorTopicYN="N">Diffusion Magnetic Resonance Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056324" MajorTopicYN="N">Diffusion Tensor Imaging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D066128" MajorTopicYN="N">Gray Matter</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018020" MajorTopicYN="N">Lithium Compounds</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009929" MajorTopicYN="N">Organ Size</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017063" MajorTopicYN="N">Outcome Assessment, Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D066127" MajorTopicYN="N">White Matter</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">bipolar disorder</Keyword><Keyword MajorTopicYN="N">diffusion tensor imaging</Keyword><Keyword MajorTopicYN="N">euthymic</Keyword><Keyword MajorTopicYN="N">morphometry</Keyword><Keyword MajorTopicYN="N">voxel-based analysis</Keyword><Keyword MajorTopicYN="N">white matter</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2012</Year><Month>07</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>01</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>4</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>4</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>4</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23621705</ArticleId><ArticleId IdType="doi">10.1111/bdi.12073</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">3753163</PMID><DateCompleted><Year>1986</Year><Month>10</Month><Day>02</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0003-990X</ISSN><JournalIssue CitedMedium="Print"><Volume>43</Volume><Issue>9</Issue><PubDate><Year>1986</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Archives of general psychiatry</Title><ISOAbbreviation>Arch Gen Psychiatry</ISOAbbreviation></Journal><ArticleTitle>A comparative study of manic vs schizophrenic speech disorganization.</ArticleTitle><Pagination><MedlinePgn>831-8</MedlinePgn></Pagination><Abstract><AbstractText>Recent studies have indicated that thought disorder occurs among manics at least to the same degree as among schizophrenics. The present study assumes that thought disorder can be considered as an abnormality of language whereby listeners are unable to organize speech into a single, coherent "whole." A model of language processing is presented that predicts that the incoherence of manic speech is due to shifts from one coherent discourse structure to another, while the ability of schizophrenic speakers to construct any discourse structure is deficient. A discourse analysis was applied to normal, manic, and schizophrenic speech samples. The two hypotheses were supported. The implications of these findings in light of other investigations of mania and schizophrenia are discussed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hoffman</LastName><ForeName>R E</ForeName><Initials>RE</Initials></Author><Author ValidYN="Y"><LastName>Stopek</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Andreasen</LastName><ForeName>N C</ForeName><Initials>NC</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Gen Psychiatry</MedlineTA><NlmUniqueID>0372435</NlmUniqueID><ISSNLinking>0003-990X</ISSNLinking></MedlineJournalInfo><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008960" MajorTopicYN="N">Models, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012564" MajorTopicYN="Y">Schizophrenic Language</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013060" MajorTopicYN="Y">Speech</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1986</Year><Month>9</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1986</Year><Month>9</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1986</Year><Month>9</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">3753163</ArticleId><ArticleId IdType="doi">10.1001/archpsyc.1986.01800090017003</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">7387908</PMID><DateCompleted><Year>1980</Year><Month>09</Month><Day>23</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0007-1129</ISSN><JournalIssue CitedMedium="Print"><Volume>53</Volume><Issue>2</Issue><PubDate><Year>1980</Year><Month>Jun</Month></PubDate></JournalIssue><Title>The British journal of medical psychology</Title><ISOAbbreviation>Br J Med Psychol</ISOAbbreviation></Journal><ArticleTitle>The narcissistic core as a focus in the group therapy of the borderline patient.</ArticleTitle><Pagination><MedlinePgn>137-43</MedlinePgn></Pagination><Abstract><AbstractText>An approach to the group psychotherapy of the hospitalized borderline patient is described. Drawing on recent formulations of the narcissistic constellation in these patients a focal interpretative approach is used emphasizing the defensive nature of the chronic rage, devaluation and self-interest of these patients. This allows the beginnings of group cohesiveness to be established based on shared hurt and damaged self-image, and facilitates the utilization of the various treatment modalities which are necessary in the long-term treatment of this group. These issues are illustrated with examples drawn from group sessions.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Macaskill</LastName><ForeName>N D</ForeName><Initials>ND</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Br J Med Psychol</MedlineTA><NlmUniqueID>0370640</NlmUniqueID><ISSNLinking>0007-1129</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009289" MajorTopicYN="Y">Narcissism</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011615" MajorTopicYN="N">Psychotherapy, Group</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011889" MajorTopicYN="N">Rage</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="N">Schizophrenic Psychology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012569" MajorTopicYN="N">Schizotypal Personality Disorder</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1980</Year><Month>6</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1980</Year><Month>6</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1980</Year><Month>6</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">7387908</ArticleId><ArticleId IdType="doi">10.1111/j.2044-8341.1980.tb01428.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17503134</PMID><DateCompleted><Year>2007</Year><Month>10</Month><Day>03</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0340-5354</ISSN><JournalIssue CitedMedium="Print"><Volume>254 Suppl 2</Volume><PubDate><Year>2007</Year><Month>May</Month></PubDate></JournalIssue><Title>Journal of neurology</Title><ISOAbbreviation>J Neurol</ISOAbbreviation></Journal><ArticleTitle>Neuropsychiatric syndromes associated with multiple sclerosis.</ArticleTitle><Pagination><MedlinePgn>II73-6</MedlinePgn></Pagination><Abstract><AbstractText>Multiple sclerosis is associated with diverse behavioral changes. Rates of major depression approach 50% over the course of patients' lives, rates of bipolar disorder and psychosis are twice as common when compared to rates in the general population and pseudobulbar affect will afflict one in ten patients. However, these disorders often respond well to pharmacologic treatment and in the case of major depression, some forms of psychotherapy too. This article summarizes these mental state changes, their pathogenesis and treatment. Correct diagnosis and treatment can substantially improve the quality of life for MS patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Feinstein</LastName><ForeName>Anthony</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Dept. of Psychiatry, University of Toronto, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, Ontario, Canada M4N 3M5. antfeinstein@aol.com</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>J Neurol</MedlineTA><NlmUniqueID>0423161</NlmUniqueID><ISSNLinking>0340-5354</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>J Neurol. 2008 Feb;255(2):309-10</RefSource></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009103" MajorTopicYN="N">Multiple Sclerosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading></MeshHeadingList><NumberOfReferences>27</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>5</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>4</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>5</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17503134</ArticleId><ArticleId IdType="doi">10.1007/s00415-007-2017-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Am J Psychiatry. 1991 Nov;148(11):1603</Citation><ArticleIdList><ArticleId IdType="pubmed">1928482</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1997 Oct;49(4):1105-10</Citation><ArticleIdList><ArticleId IdType="pubmed">9339697</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2002 Sep 10;59(5):674-8</Citation><ArticleIdList><ArticleId IdType="pubmed">12221156</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2004 Feb;161(2):226-31</Citation><ArticleIdList><ArticleId IdType="pubmed">14754769</ArticleId></ArticleIdList></Reference><Reference><Citation>Mult Scler. 2000 Oct;6(5):343-8</Citation><ArticleIdList><ArticleId IdType="pubmed">11064445</ArticleId></ArticleIdList></Reference><Reference><Citation>Mult Scler. 2003 Aug;9(4):393-6</Citation><ArticleIdList><ArticleId IdType="pubmed">12926845</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2004 Feb 24;62(4):586-90</Citation><ArticleIdList><ArticleId IdType="pubmed">14981175</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 1985 Jun 6;312(23):1480-2</Citation><ArticleIdList><ArticleId IdType="pubmed">3887172</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychosomatics. 1993 Mar-Apr;34(2):124-30</Citation><ArticleIdList><ArticleId IdType="pubmed">8456154</ArticleId></ArticleIdList></Reference><Reference><Citation>Mult Scler. 1999 Apr;5(2):69-73</Citation><ArticleIdList><ArticleId IdType="pubmed">10335513</ArticleId></ArticleIdList></Reference><Reference><Citation>Mult Scler. 2001 Dec;7(6):411-6</Citation><ArticleIdList><ArticleId IdType="pubmed">11795464</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2005 Oct 11;65(7):1123-5</Citation><ArticleIdList><ArticleId IdType="pubmed">16217073</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuroreport. 2000 Apr 27;11(6):1153-8</Citation><ArticleIdList><ArticleId IdType="pubmed">10817583</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Neurol. 1992 Dec;49(12):1296-303</Citation><ArticleIdList><ArticleId IdType="pubmed">1449409</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 2003 Dec 9;61(11):1524-7</Citation><ArticleIdList><ArticleId IdType="pubmed">14663036</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurology. 1991 Aug;41(8):1193-6</Citation><ArticleIdList><ArticleId IdType="pubmed">1866003</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Neurol. 1990 Jan;47(1):98-104</Citation><ArticleIdList><ArticleId IdType="pubmed">2403790</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Neurol. 2006 May;59(5):780-7</Citation><ArticleIdList><ArticleId IdType="pubmed">16634036</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1992 Nov;161:680-5</Citation><ArticleIdList><ArticleId IdType="pubmed">1422619</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Inj. 1992 May-Jun;6(3):267-70</Citation><ArticleIdList><ArticleId IdType="pubmed">1581749</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Neurol. 1997 Sep;54(9):1116-21</Citation><ArticleIdList><ArticleId IdType="pubmed">9311355</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1987 Jan-Feb;12(1):63-5</Citation><ArticleIdList><ArticleId IdType="pubmed">2952696</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1990 Nov;147(11):1493-7</Citation><ArticleIdList><ArticleId IdType="pubmed">2221162</ArticleId></ArticleIdList></Reference><Reference><Citation>J Consult Clin Psychol. 2001 Dec;69(6):942-9</Citation><ArticleIdList><ArticleId IdType="pubmed">11777121</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18683294</PMID><DateCompleted><Year>2008</Year><Month>11</Month><Day>04</Day></DateCompleted><DateRevised><Year>2017</Year><Month>02</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1440-1665</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>4</Issue><PubDate><Year>2008</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Australasian psychiatry : bulletin of Royal Australian and New Zealand College of Psychiatrists</Title><ISOAbbreviation>Australas Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Paediatric bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>293-4</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Haliburn</LastName><ForeName>Joan</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016420">Comment</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Australas Psychiatry</MedlineTA><NlmUniqueID>9613603</NlmUniqueID><ISSNLinking>1039-8562</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Australas Psychiatry. 2008 Apr;16(2):80-4; discussion 85-6</RefSource><PMID Version="1">18335361</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016265" MajorTopicYN="N">Conflict of Interest</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D039721" MajorTopicYN="N">Diagnostic and Statistical Manual of Mental Disorders</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004345" MajorTopicYN="N">Drug Industry</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019317" MajorTopicYN="N">Evidence-Based Medicine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>8</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>11</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>8</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18683294</ArticleId><ArticleId IdType="doi">10.1177/000486740801600402</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">3495248</PMID><DateCompleted><Year>1987</Year><Month>05</Month><Day>29</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0003-990X</ISSN><JournalIssue CitedMedium="Print"><Volume>44</Volume><Issue>5</Issue><PubDate><Year>1987</Year><Month>May</Month></PubDate></JournalIssue><Title>Archives of general psychiatry</Title><ISOAbbreviation>Arch Gen Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Big genes, little genes, affective disorder, and anxiety. A commentary.</ArticleTitle><Pagination><MedlinePgn>486-91</MedlinePgn></Pagination><Abstract><AbstractText>This article offers a brief explanation of the methods used for studying the genetic epidemiology of psychiatric disorder and comments on three articles in this issue of the Archives. Although the methods have had success in detecting genes of major effect for enzymes involved in neurotransmitter synthesis and degradation, they have not produced compelling evidence for a major locus in affective disorder. At the same time, simpler modes of transmission do not fully explain familial data on bipolar disorder or early-onset unipolar disorder. The problem of familial comorbidity of anxiety and depression is discussed, and an illustration is given of how assumptions about psychiatric classification and familial models can obscure the issue of comorbidity.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Carey</LastName><ForeName>G</ForeName><Initials>G</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="N"><Grant><GrantID>HD-07289</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HD-10333</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HD-18426</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arch Gen Psychiatry</MedlineTA><NlmUniqueID>0372435</NlmUniqueID><ISSNLinking>0003-990X</ISSNLinking></MedlineJournalInfo><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001008" MajorTopicYN="N">Anxiety Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004200" MajorTopicYN="N">Diseases in Twins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005796" MajorTopicYN="N">Genes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008957" MajorTopicYN="N">Models, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012107" MajorTopicYN="N">Research Design</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013223" MajorTopicYN="N">Statistics as Topic</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1987</Year><Month>5</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1987</Year><Month>5</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1987</Year><Month>5</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">3495248</ArticleId><ArticleId IdType="doi">10.1001/archpsyc.1987.01800170110014</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12523872</PMID><DateCompleted><Year>2003</Year><Month>02</Month><Day>05</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0160-6689</ISSN><JournalIssue CitedMedium="Print"><Volume>63</Volume><Issue>12</Issue><PubDate><Year>2002</Year><Month>Dec</Month></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Obsessive-compulsive-bipolar comorbidity: a systematic exploration of clinical features and treatment outcome.</ArticleTitle><Pagination><MedlinePgn>1129-34</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Notwithstanding the emerging literature on comorbidity between obsessive-compulsive disorder (OCD) and bipolar disorder, relatively few systematic data exist on the clinical characteristics of this interface and its treatment. The aim of the present study is to address this challenge as it appears in a setting of routine clinical practice.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">The sample comprised 68 patients with comorbid DSM-IV diagnoses of OCD and major depressive episode admitted and treated at the day-hospital in the Department of Psychiatry at the University of Pisa (Pisa, Italy) during a 3-year period (January 1995-December 1998). Thirty-eight patients (55.8%) showed lifetime comorbid bipolar disorder (12 [31.6%] bipolar I and 26 [68.4%] bipolar II). Diagnoses and clinical features were collected by means of structured (Structured Clinical Interview for DSM-IV) and semistructured interviews (OCD-Interview). Assessments of drug treatments, clinical outcome, and adverse effects were made prospectively as part of routine clinical care throughout the course of their day-hospitalization.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In contrast with non-bipolar OCD patients, OCD-bipolar patients showed a more episodic course with a greater number of concurrent major depressive episodes. They reported a significantly higher rate of sexual obsessions and significantly lower rate of ordering rituals. Furthermore, they reported more frequent current comorbidity with panic disorder-agoraphobia and abuse of different substances (alcohol, sedatives, nicotine, and coffee). Drug treatment with clomipramine and, to a lesser extent, with selective serotonin reuptake inhibitors was associated with hypomanic switches in OCD-bipolar patients, especially in those not concomitantly treated with mood stabilizers. A combination of multiple mood stabilizers was necessary in 16 OCD-bipolar patients (42.1%) and a combination of mood stabilizers with atypical antipsychotics was required in 4 cases (10.5%). OCD-bipolar patients tended to show a less positive outcome for mood symptomatology and general functioning. Three patients required hospitalization for severe mixed episode.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">In a tertiary care center, comorbidity between OCD and bipolar disorder is a significant clinical problem affecting a large number of patients and has a substantial impact on the clinical characteristics and treatment outcome of both disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Perugi</LastName><ForeName>Giulio</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Pisa, Pisa, Italy. gperugi@psico.med.unipi.it</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toni</LastName><ForeName>Cristina</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Frare</LastName><ForeName>Franco</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Travierso</LastName><ForeName>Maria Chiara</ForeName><Initials>MC</Initials></Author><Author ValidYN="Y"><LastName>Hantouche</LastName><ForeName>Elie</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Akiskal</LastName><ForeName>Hagop S</ForeName><Initials>HS</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000929">Antidepressive Agents, Tricyclic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>NUV44L116D</RegistryNumber><NameOfSubstance UI="D002997">Clomipramine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000929" MajorTopicYN="N">Antidepressive Agents, Tricyclic</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002997" MajorTopicYN="N">Clomipramine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009771" MajorTopicYN="N">Obsessive-Compulsive Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>1</Month><Day>14</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2003</Year><Month>2</Month><Day>6</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>1</Month><Day>14</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12523872</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">28025861</PMID><DateCompleted><Year>2018</Year><Month>02</Month><Day>19</Day></DateCompleted><DateRevised><Year>2018</Year><Month>02</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1440-1819</ISSN><JournalIssue CitedMedium="Internet"><Volume>71</Volume><Issue>6</Issue><PubDate><Year>2017</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Psychiatry and clinical neurosciences</Title><ISOAbbreviation>Psychiatry Clin Neurosci</ISOAbbreviation></Journal><ArticleTitle>Neurocognitive profile of euthymic Japanese patients with bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>373-382</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/pcn.12500</ELocationID><Abstract><AbstractText Label="AIM" NlmCategory="OBJECTIVE">Neurocognitive impairment is one of the core symptoms of bipolar disorder (BD). The MATRICS Cognitive Consensus Battery (MCCB) is a potential consensus assessment tool to evaluate cognitive function in patients with BD. Here, we report on cognitive deficits evaluated using the MCCB Japanese version (MCCB-J) in euthymic Japanese patients with BD, and compare them with scores in previous studies.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We compared neurocognitive function in 25 patients with euthymic BD and 53 healthy controls (HC). Additionally, we searched all available databases for studies that have evaluated cognitive function in BD using the MCCB, and conducted a meta-analysis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Canonical discriminant analysis revealed significant differences in MCCB-J domain scores between BD and HC. Patients with BD performed significantly worse on visual learning, social cognition, speed of processing, and MCCB composite scores. Our meta-analysis revealed that patients with BD performed worse than HC, as reflected by MCCB composite scores and scores on all seven cognitive domains. However, there are differences in the cognitive deficits identified in previous studies compared with our participants, particularly social cognition.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">As reported in previous studies, neurocognitive deficits were observed in Japanese euthymic BD patients assessed using the MCCB-J. Further study is needed to clarify whether differences in social cognition between this study and previous studies are a result of coping mechanisms for social settings in Japanese populations.</AbstractText><CopyrightInformation>© 2016 The Authors. Psychiatry and Clinical Neurosciences © 2016 Japanese Society of Psychiatry and Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ishisaka</LastName><ForeName>Nozomi</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Neuropsychiatry, Kyushu University, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shimano</LastName><ForeName>Satomi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neuropsychiatry, Kyushu University, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miura</LastName><ForeName>Tomofumi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neuropsychiatry, Kyushu University, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Motomura</LastName><ForeName>Keisuke</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neuropsychiatry, Kyushu University, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Horii</LastName><ForeName>Machiko</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neuropsychiatry, Kyushu University, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Imanaga</LastName><ForeName>Hisako</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neuropsychiatry, Kyushu University, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kishimoto</LastName><ForeName>Junji</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Research and Development of Next Generation Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaneda</LastName><ForeName>Yasuhiro</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Iwaki Clinic, Anan, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sora</LastName><ForeName>Ichiro</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Kobe University Graduate School of Medicine, Kobe, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kanba</LastName><ForeName>Shigenobu</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neuropsychiatry, Kyushu University, Fukuoka, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>02</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Australia</Country><MedlineTA>Psychiatry Clin Neurosci</MedlineTA><NlmUniqueID>9513551</NlmUniqueID><ISSNLinking>1323-1316</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D044466" MajorTopicYN="N">Asian Continental Ancestry Group</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060825" MajorTopicYN="N">Cognitive Dysfunction</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Japanese population</Keyword><Keyword MajorTopicYN="N">MATRICS Consensus Cognitive Battery</Keyword><Keyword MajorTopicYN="N">bipolar disorder</Keyword><Keyword MajorTopicYN="N">euthymic</Keyword><Keyword MajorTopicYN="N">neurocognitive impairment</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>06</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>11</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>12</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>12</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>2</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>12</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28025861</ArticleId><ArticleId IdType="doi">10.1111/pcn.12500</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18681763</PMID><DateCompleted><Year>2008</Year><Month>09</Month><Day>03</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1555-2101</ISSN><JournalIssue CitedMedium="Internet"><Volume>69</Volume><Issue>5</Issue><PubDate><Year>2008</Year><Month>May</Month></PubDate></JournalIssue><Title>The Journal of clinical psychiatry</Title><ISOAbbreviation>J Clin Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Aripiprazole joins the family of second-generation mood stabilizers.</ArticleTitle><Pagination><MedlinePgn>862-3</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rybakowski</LastName><ForeName>Janusz K</ForeName><Initials>JK</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Psychiatry</MedlineTA><NlmUniqueID>7801243</NlmUniqueID><ISSNLinking>0160-6689</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010879">Piperazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015363">Quinolones</NameOfSubstance></Chemical><Chemical><RegistryNumber>82VFR53I78</RegistryNumber><NameOfSubstance UI="D000068180">Aripiprazole</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000068180" MajorTopicYN="N">Aripiprazole</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010879" MajorTopicYN="N">Piperazines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015363" MajorTopicYN="N">Quinolones</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>8</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>9</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>8</Month><Day>7</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18681763</ArticleId><ArticleId IdType="doi">10.4088/jcp.v69n0522b</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10746620</PMID><DateCompleted><Year>2000</Year><Month>08</Month><Day>18</Day></DateCompleted><DateRevised><Year>2019</Year><Month>05</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0028-3878</ISSN><JournalIssue CitedMedium="Print"><Volume>54</Volume><Issue>6</Issue><PubDate><Year>2000</Year><Month>Mar</Month><Day>28</Day></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Hypomania from the left frontal AVM resection.</ArticleTitle><Pagination><MedlinePgn>1389-90</MedlinePgn></Pagination><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Benjamin</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Massachusetts Medical School, Worcester 01655, USA. sheldon.benjamin@umassmed.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kirsch</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Visscher</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Ozbayrak</LastName><ForeName>K R</ForeName><Initials>KR</Initials></Author><Author ValidYN="Y"><LastName>Weaver</LastName><ForeName>J P</ForeName><Initials>JP</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001165" MajorTopicYN="N">Arteriovenous Malformations</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005625" MajorTopicYN="N">Frontal Lobe</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>4</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2000</Year><Month>8</Month><Day>29</Day><Hour>11</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>4</Month><Day>4</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10746620</ArticleId><ArticleId IdType="doi">10.1212/wnl.54.6.1389</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20864620</PMID><DateCompleted><Year>2012</Year><Month>08</Month><Day>30</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1745-1701</ISSN><JournalIssue CitedMedium="Internet"><Volume>38</Volume><Issue>3</Issue><PubDate><Year>2012</Year><Month>May</Month></PubDate></JournalIssue><Title>Schizophrenia bulletin</Title><ISOAbbreviation>Schizophr Bull</ISOAbbreviation></Journal><ArticleTitle>Kraepelin was right: a latent class analysis of symptom dimensions in patients and controls.</ArticleTitle><Pagination><MedlinePgn>495-505</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/schbul/sbq103</ELocationID><Abstract><AbstractText>Phenotypic heterogeneity within patients and controls may explain why the genetic variants contributing to schizophrenia risk explain only a fraction of the heritability. The aim of this study is to investigate quantitative and qualitative differences in psychosis symptoms in a sample including psychosis patients, their relatives, and community controls. We combined factor analysis and latent class analysis to analyze variation in Comprehensive Assessment of Symptoms and History lifetime-rated symptoms in 4286 subjects. The Wechsler Adult Intelligence Scale-Intelligence Quotient (N = 2663) and the Camberwell Assessment of Need rating scale (N = 625) were assessed in a subsample. Variation in 5 continuous dimensions (disorganization, positive, negative, mania, and depression) was accounted for by the presence of 7 homogeneous classes (Kraepelinian schizophrenia, affective psychosis, manic-depression, deficit nonpsychosis, depression, healthy, and no symptoms). Eighty-five percent of the schizophrenia patients was assigned to the Kraepelinian schizophrenia class (characterized by high scores on the 5 dimensions, low IQ, and poor outcome) while 15% was assigned to the affective psychosis class (relatively low disorganization and negative scores, normal IQ, and good outcome). In bipolar patients (91% bipolar I), 41% was assigned to the Kraepelinian schizophrenia class, 44% to the affective psychosis class, and 10% to the manic-depression class. Latent class membership was associated with intelligence in psychosis patients and in their relatives but not in community controls. In conclusion, symptom heterogeneity is more pronounced in bipolar disorder compared with schizophrenia. Reducing phenotypic heterogeneity within psychosis patients and controls may facilitate etiological research.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Derks</LastName><ForeName>Eske M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Rudolf Magnus Institute of Neuroscience, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands. e.m.derks@umcutrecht.nl</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Allardyce</LastName><ForeName>Judith</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Boks</LastName><ForeName>Marco P</ForeName><Initials>MP</Initials></Author><Author ValidYN="Y"><LastName>Vermunt</LastName><ForeName>Jeroen K</ForeName><Initials>JK</Initials></Author><Author ValidYN="Y"><LastName>Hijman</LastName><ForeName>Ron</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Ophoff</LastName><ForeName>Roel A</ForeName><Initials>RA</Initials></Author><Author ValidYN="Y"><CollectiveName>GROUP</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>09</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Schizophr Bull</MedlineTA><NlmUniqueID>0236760</NlmUniqueID><ISSNLinking>0586-7614</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001530" MajorTopicYN="N" Type="Geographic">Belgium</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="Y">classification</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009426" MajorTopicYN="N" Type="Geographic">Netherlands</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="Y">classification</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014888" MajorTopicYN="N">Wechsler Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><InvestigatorList><Investigator ValidYN="Y"><LastName>Kahn</LastName><ForeName>René S</ForeName><Initials>RS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Linszen</LastName><ForeName>Don H</ForeName><Initials>DH</Initials></Investigator><Investigator ValidYN="Y"><LastName>van Os</LastName><ForeName>Jim</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wiersma</LastName><ForeName>Durk</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bruggeman</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cahn</LastName><ForeName>Wiepke</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>de Haan</LastName><ForeName>Lieuwe</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Krabbendam</LastName><ForeName>Lydia</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Myin-Germeys</LastName><ForeName>Inez</ForeName><Initials>I</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>9</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>9</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>8</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20864620</ArticleId><ArticleId IdType="pii">sbq103</ArticleId><ArticleId IdType="doi">10.1093/schbul/sbq103</ArticleId><ArticleId IdType="pmc">PMC3329975</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Arch Gen Psychiatry. 1992 Aug;49(8):615-23</Citation><ArticleIdList><ArticleId IdType="pubmed">1637251</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1998 Jun;55(6):502-4</Citation><ArticleIdList><ArticleId IdType="pubmed">9633667</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 2006 Oct;189:346-53</Citation><ArticleIdList><ArticleId IdType="pubmed">17012658</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2009 Jun;66(6):591-600</Citation><ArticleIdList><ArticleId IdType="pubmed">19487624</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2009 Aug 6;460(7256):748-52</Citation><ArticleIdList><ArticleId IdType="pubmed">19571811</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1970 Jan;126(7):983-7</Citation><ArticleIdList><ArticleId IdType="pubmed">5409569</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1998 Jun;55(6):508-9</Citation><ArticleIdList><ArticleId IdType="pubmed">9633668</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 1998 Jul;28(4):935-47</Citation><ArticleIdList><ArticleId IdType="pubmed">9723148</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Psychiatry. 2005 Jan;10(1):6-13</Citation><ArticleIdList><ArticleId IdType="pubmed">15618952</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2001 Jan;31(1):159-71</Citation><ArticleIdList><ArticleId IdType="pubmed">11200955</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 1998 May 25;31(2-3):113-20</Citation><ArticleIdList><ArticleId IdType="pubmed">9689715</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2009 Dec;115(2-3):346-50</Citation><ArticleIdList><ArticleId IdType="pubmed">19840897</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2005 Apr;35(4):499-510</Citation><ArticleIdList><ArticleId IdType="pubmed">15856720</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2009 Oct;66(10):1058-67</Citation><ArticleIdList><ArticleId IdType="pubmed">19805696</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Psychiatry. 1995 Nov;167(5):589-95</Citation><ArticleIdList><ArticleId IdType="pubmed">8564313</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2009 Feb;39(2):179-95</Citation><ArticleIdList><ArticleId IdType="pubmed">18606047</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2007 Jul;93(1-3):178-85</Citation><ArticleIdList><ArticleId IdType="pubmed">17383856</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2003 Dec;60(12):1187-92</Citation><ArticleIdList><ArticleId IdType="pubmed">14662550</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Psychiatry Rep. 2008 Apr;10(2):164-70</Citation><ArticleIdList><ArticleId IdType="pubmed">18474210</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2007 Dec;64(12):1348-55</Citation><ArticleIdList><ArticleId IdType="pubmed">18056542</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1998 Jun;55(6):492-9</Citation><ArticleIdList><ArticleId IdType="pubmed">9633666</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2009 Mar 15;65(6):527-34</Citation><ArticleIdList><ArticleId IdType="pubmed">19013556</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2008 Jul 15;64(2):121-7</Citation><ArticleIdList><ArticleId IdType="pubmed">18255048</ArticleId></ArticleIdList></Reference><Reference><Citation>Behav Genet. 1994 May;24(3):207-15</Citation><ArticleIdList><ArticleId IdType="pubmed">7945151</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2008 Nov 6;456(7218):18-21</Citation><ArticleIdList><ArticleId IdType="pubmed">18987709</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2003 Apr;160(4):636-45</Citation><ArticleIdList><ArticleId IdType="pubmed">12668349</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Bull. 2003;29(3):413-25</Citation><ArticleIdList><ArticleId IdType="pubmed">14609237</ArticleId></ArticleIdList></Reference><Reference><Citation>Aust N Z J Psychiatry. 2000 Oct;34(5):792-800</Citation><ArticleIdList><ArticleId IdType="pubmed">11037365</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2004 Dec 1;71(2-3):285-95</Citation><ArticleIdList><ArticleId IdType="pubmed">15474899</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2008 Apr;165(4):497-506</Citation><ArticleIdList><ArticleId IdType="pubmed">18198266</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">1752178</PMID><DateCompleted><Year>1992</Year><Month>01</Month><Day>27</Day></DateCompleted><DateRevised><Year>2006</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0412-4057</ISSN><JournalIssue CitedMedium="Print"><Volume>24</Volume><Issue>5</Issue><PubDate><Year>1991</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Zhonghua shen jing jing shen ke za zhi = Chinese journal of neurology and psychiatry</Title><ISOAbbreviation>Zhonghua Shen Jing Jing Shen Ke Za Zhi</ISOAbbreviation></Journal><ArticleTitle>[Quantitative EEG analysis and the value for differential diagnosis on depression: I. Spectral power and coherence analysis].</ArticleTitle><Pagination><MedlinePgn>275-7, 317</MedlinePgn></Pagination><Abstract><AbstractText>Spectral power and coherence analysis were taken on 47 depressive patients and 43 normal controls. Depressive patients showed abnormal brain activity mostly in frontal-central regions. The endogenous and manic-depressive groups mainly presented higher power of slow activity and predominant in right hemisphere, while the non-endogenous and other groups presented higher power mainly in the fast bands. Coherence analysis showed that the coherence of EEG between homogenous points of two hemispheres was decreased in depressed patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>X</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Institute of Mental Health, Beijing Medical University.</Affiliation></AffiliationInfo></Author></AuthorList><Language>chi</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Zhonghua Shen Jing Jing Shen Ke Za Zhi</MedlineTA><NlmUniqueID>16210510R</NlmUniqueID><ISSNLinking>0412-4057</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004569" MajorTopicYN="Y">Electroencephalography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1991</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1991</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1991</Year><Month>10</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">1752178</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">2399297</PMID><DateCompleted><Year>1990</Year><Month>10</Month><Day>12</Day></DateCompleted><DateRevised><Year>2018</Year><Month>02</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0254-4962</ISSN><JournalIssue CitedMedium="Print"><Volume>23</Volume><Issue>1</Issue><PubDate><Year>1990</Year></PubDate></JournalIssue><Title>Psychopathology</Title><ISOAbbreviation>Psychopathology</ISOAbbreviation></Journal><ArticleTitle>The issue of the core syndrome of endogenous depression.</ArticleTitle><Pagination><MedlinePgn>1-8</MedlinePgn></Pagination><Abstract><AbstractText>The psychopathological findings in 339 patients treated for depressive disorder were investigated. The classification was made according to ICD 9 and DSM III. The classification and diagnosis of depressive disorders are based on the symptoms, etiology and the course of the disease. Therefore we aim at a three-dimensional scheme of classification that takes into account all these variables. We do not want to follow the basic problems of classification and all dimensions of depressive disorders. We just want to analyze our psychopathological findings in depressive patients, who have been classified according to ICD 9 and DSM III, and we want to turn our attention to the core syndrome of endogenous depression.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bron</LastName><ForeName>B</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, University of Göttingen, FRG.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lehmann</LastName><ForeName>K</ForeName><Initials>K</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Psychopathology</MedlineTA><NlmUniqueID>8401537</NlmUniqueID><ISSNLinking>0254-4962</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000275" MajorTopicYN="N">Adjustment Disorders</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="Y">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011599" MajorTopicYN="N">Psychopathology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013577" MajorTopicYN="N">Syndrome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1990</Year><Month>1</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1990</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1990</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">2399297</ArticleId><ArticleId IdType="doi">10.1159/000284630</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10093780</PMID><DateCompleted><Year>1999</Year><Month>04</Month><Day>27</Day></DateCompleted><DateRevised><Year>2006</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0720-4299</ISSN><JournalIssue CitedMedium="Print"><Volume>67</Volume><Issue>2</Issue><PubDate><Year>1999</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Fortschritte der Neurologie-Psychiatrie</Title><ISOAbbreviation>Fortschr Neurol Psychiatr</ISOAbbreviation></Journal><ArticleTitle>[Predictors of response to phase prophylactics (mood stabilizers) in bipolar affective disorders].</ArticleTitle><Pagination><MedlinePgn>75-80</MedlinePgn></Pagination><Abstract><AbstractText>Since the introduction of lithium ions in the acute treatment and in the prophylaxis of bipolar disorders the antiepileptic drugs valproate and carbamazepine have been in use for several years as mood stabilizers. In a number of open and controlled clinical studies predictors of response for the single drugs were investigated. These studies indicated that valproate was a predictor of good response in mixed (dysphoric) mania and bipolar rapid cycling. Moreover, valproate has a better response than lithium in secondary mania (organic origin) and atypical mania (episode sequence: depression-mania-euthymia rather than mania-depression-euthymia). The preferential efficacy in the spectrum of bipolar disorders of the new antiepileptic drugs lamotrigine and gabapentin must be analysed in more detail in future studies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Walden</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Universitätsklinik für Psychiatrie und Psychosomatik, Abt. für Psychiatrie und Psychotherapie der Universität Freiburg.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Normann</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Langosch</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Grunze</LastName><ForeName>H</ForeName><Initials>H</Initials></Author></AuthorList><Language>ger</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Wirksamkeitsprädiktoren für Phasenprophylaktika (Stimmungsstabilisierer) bei bipolaren affektiven Störungen.</VernacularTitle></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Fortschr Neurol Psychiatr</MedlineTA><NlmUniqueID>8103137</NlmUniqueID><ISSNLinking>0720-4299</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000339" MajorTopicYN="N">Affect</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>62</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1999</Year><Month>3</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1999</Year><Month>3</Month><Day>27</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1999</Year><Month>3</Month><Day>27</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10093780</ArticleId><ArticleId IdType="doi">10.1055/s-2007-993984</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23915232</PMID><DateCompleted><Year>2014</Year><Month>05</Month><Day>07</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1537-4424</ISSN><JournalIssue CitedMedium="Internet"><Volume>42</Volume><Issue>5</Issue><PubDate><Year>2013</Year></PubDate></JournalIssue><Title>Journal of clinical child and adolescent psychology : the official journal for the Society of Clinical Child and Adolescent Psychology, American Psychological Association, Division 53</Title><ISOAbbreviation>J Clin Child Adolesc Psychol</ISOAbbreviation></Journal><ArticleTitle>Future directions for research on youth with bipolar spectrum disorders.</ArticleTitle><Pagination><MedlinePgn>734-47</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/15374416.2013.817312</ELocationID><Abstract><AbstractText>The past 25 years has witnessed significant advances in our knowledge of Bipolar Spectrum Disorders (BPSD) in youth. Cross-sectional and longitudinal studies are clarifying the unique features of its pediatric presentation, including continuities and discontinuities across the spectrum of severity. Advances have been made, both in the pharmacological and psychological management of BPSD in youth. Current investigations may ultimately shed light on new treatment strategies. Future research is anticipated to be influenced by NIMH's Research Domain Criteria (RDoC). With this article, we summarize what is currently known about the basic phenomenology of pediatric BPSD, its clinical course, assessment and treatment, beginning with a summary of the major studies that have shed light on the topic. Next, we present a tally and content review of current research as an indicator of trends for the future. Then, we describe what we believe are important future directions for research. Finally, we conclude with implications for contemporary clinicians and researchers. </AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fristad</LastName><ForeName>Mary A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>a Department of Psychiatry , The Ohio State University.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Algorta</LastName><ForeName>Guillermo Perez</ForeName><Initials>GP</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 MH073953</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R34 MH090148</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH073816</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R34MH085875</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH073801</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 MH073967</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R34 MH085875</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>08</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Clin Child Adolesc Psychol</MedlineTA><NlmUniqueID>101133858</NlmUniqueID><ISSNLinking>1537-4416</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D035843" MajorTopicYN="N">Biomedical Research</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="Y">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>8</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>8</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>5</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23915232</ArticleId><ArticleId IdType="doi">10.1080/15374416.2013.817312</ArticleId><ArticleId IdType="pmc">PMC4137316</ArticleId><ArticleId IdType="mid">NIHMS516123</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bipolar Disord. 2007 Aug;9(5):490-5</Citation><ArticleIdList><ArticleId IdType="pubmed">17680919</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2008 Dec 25;359(26):2753-66</Citation><ArticleIdList><ArticleId IdType="pubmed">18974308</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2007 May;64(5):543-52</Citation><ArticleIdList><ArticleId IdType="pubmed">17485606</ArticleId></ArticleIdList></Reference><Reference><Citation>J Child Psychol Psychiatry. 1996 Jan;37(1):3-12</Citation><ArticleIdList><ArticleId IdType="pubmed">8655656</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 1995 Apr;34(4):464-71</Citation><ArticleIdList><ArticleId IdType="pubmed">7751260</ArticleId></ArticleIdList></Reference><Reference><Citation>J Abnorm Child Psychol. 2003 Feb;31(1):29-39</Citation><ArticleIdList><ArticleId IdType="pubmed">12597697</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2002 Jun;59(6):530-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12044195</ArticleId></ArticleIdList></Reference><Reference><Citation>World Psychiatry. 2012 Feb;11(1):40-6</Citation><ArticleIdList><ArticleId IdType="pubmed">22295008</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 1995 Apr;34(4):454-63</Citation><ArticleIdList><ArticleId IdType="pubmed">7751259</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2011 Sep;72(9):1250-6</Citation><ArticleIdList><ArticleId IdType="pubmed">21672501</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2012 Jun;51(6):605-21</Citation><ArticleIdList><ArticleId IdType="pubmed">22632620</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2013 Feb;170(2):173-9</Citation><ArticleIdList><ArticleId IdType="pubmed">23377638</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2007 Jan;46(1):107-125</Citation><ArticleIdList><ArticleId IdType="pubmed">17195735</ArticleId></ArticleIdList></Reference><Reference><Citation>J Altern Complement Med. 2012 Jul;18(7):678-85</Citation><ArticleIdList><ArticleId IdType="pubmed">22747095</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2011 Feb;168(2):129-42</Citation><ArticleIdList><ArticleId IdType="pubmed">21123313</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Child Adolesc Psychol. 2014;43(3):339-55</Citation><ArticleIdList><ArticleId IdType="pubmed">23927375</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2007 Aug;164(8):1238-41</Citation><ArticleIdList><ArticleId IdType="pubmed">17671287</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychoneuroendocrinology. 2011 Feb;36(2):258-65</Citation><ArticleIdList><ArticleId IdType="pubmed">20732746</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2000 Dec;39(12):1543-8</Citation><ArticleIdList><ArticleId IdType="pubmed">11128332</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2004 Jul;43(7):847-58</Citation><ArticleIdList><ArticleId IdType="pubmed">15213586</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2009 Sep;66(9):1013-21</Citation><ArticleIdList><ArticleId IdType="pubmed">19736358</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1998 Nov;51(2):81-91</Citation><ArticleIdList><ArticleId IdType="pubmed">10743841</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2010 Mar;12(2):116-41</Citation><ArticleIdList><ArticleId IdType="pubmed">20402706</ArticleId></ArticleIdList></Reference><Reference><Citation>J Child Adolesc Psychopharmacol. 2003 Fall;13(3):253-66</Citation><ArticleIdList><ArticleId IdType="pubmed">14642013</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2010 May;12(3):327-34</Citation><ArticleIdList><ArticleId IdType="pubmed">20565440</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2005 Oct 1;58(7):576-82</Citation><ArticleIdList><ArticleId IdType="pubmed">16084859</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2004 May;43(5):528-37</Citation><ArticleIdList><ArticleId IdType="pubmed">15100559</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nerv Ment Dis. 2007 Sep;195(9):745-51</Citation><ArticleIdList><ArticleId IdType="pubmed">17984774</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Sci. 2010 Jul;21(7):1021-7</Citation><ArticleIdList><ArticleId IdType="pubmed">20519486</ArticleId></ArticleIdList></Reference><Reference><Citation>Child Adolesc Psychiatr Clin N Am. 2011 Jan;20(1):67-79</Citation><ArticleIdList><ArticleId IdType="pubmed">21092913</ArticleId></ArticleIdList></Reference><Reference><Citation>J Abnorm Child Psychol. 2010 Jul;38(5):695-706</Citation><ArticleIdList><ArticleId IdType="pubmed">20180010</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2010 Aug 30;179(1):47-52</Citation><ArticleIdList><ArticleId IdType="pubmed">20478632</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2012 Jun;14(4):313-25</Citation><ArticleIdList><ArticleId IdType="pubmed">22631617</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2007 Oct;64(10):1132-43</Citation><ArticleIdList><ArticleId IdType="pubmed">17909125</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2008 May;69(5):831-9</Citation><ArticleIdList><ArticleId IdType="pubmed">18452343</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2012 Oct;73(10):1342-50</Citation><ArticleIdList><ArticleId IdType="pubmed">23140653</ArticleId></ArticleIdList></Reference><Reference><Citation>Depress Anxiety. 2012 Apr;29(4):253-6</Citation><ArticleIdList><ArticleId IdType="pubmed">22511361</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2012 Mar;14(2):185-97</Citation><ArticleIdList><ArticleId IdType="pubmed">22420594</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2006 May;45(5):550-560</Citation><ArticleIdList><ArticleId IdType="pubmed">16601399</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychopharmacol Bull. 1985;21(4):991-4</Citation><ArticleIdList><ArticleId IdType="pubmed">4089115</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2009 Apr;114(1-3):174-83</Citation><ArticleIdList><ArticleId IdType="pubmed">18715651</ArticleId></ArticleIdList></Reference><Reference><Citation>J Child Psychol Psychiatry. 2012 Nov;53(11):1149-56</Citation><ArticleIdList><ArticleId IdType="pubmed">22650379</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Serv. 2013 May 1;64(5):483-6</Citation><ArticleIdList><ArticleId IdType="pubmed">23632576</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2004 Feb;6(1):67-74</Citation><ArticleIdList><ArticleId IdType="pubmed">14996143</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2007 Jul;46(7):820-30</Citation><ArticleIdList><ArticleId IdType="pubmed">17581446</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychol. 2012 May;68(5):502-13</Citation><ArticleIdList><ArticleId IdType="pubmed">22504610</ArticleId></ArticleIdList></Reference><Reference><Citation>J Consult Clin Psychol. 2009 Jun;77(3):463-473</Citation><ArticleIdList><ArticleId IdType="pubmed">19485588</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2012 Nov;69(11):1113-22</Citation><ArticleIdList><ArticleId IdType="pubmed">22752079</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand Suppl. 2013;(442):11-8</Citation><ArticleIdList><ArticleId IdType="pubmed">23581788</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2009 Dec;48(12):1143-54</Citation><ArticleIdList><ArticleId IdType="pubmed">19858761</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2013 Feb;170(2):136-9</Citation><ArticleIdList><ArticleId IdType="pubmed">23377631</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2012 Jun;14(4):356-74</Citation><ArticleIdList><ArticleId IdType="pubmed">22631620</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2010 Oct;167(10):1194-201</Citation><ArticleIdList><ArticleId IdType="pubmed">20713498</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2005 Dec;7(6):483-96</Citation><ArticleIdList><ArticleId IdType="pubmed">16403174</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2003 Mar;160(3):430-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12611821</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2013 Jan;170(1):59-70</Citation><ArticleIdList><ArticleId IdType="pubmed">23111466</ArticleId></ArticleIdList></Reference><Reference><Citation>Depress Anxiety. 2010 May;27(5):457-64</Citation><ArticleIdList><ArticleId IdType="pubmed">20186968</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2006 Oct;95(1-3):149-58</Citation><ArticleIdList><ArticleId IdType="pubmed">16797720</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2009 Jun;48(6):643-651</Citation><ArticleIdList><ArticleId IdType="pubmed">19454920</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nerv Ment Dis. 2010 Oct;198(10):715-21</Citation><ArticleIdList><ArticleId IdType="pubmed">20921861</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Child Fam Psychol Rev. 2009 Sep;12(3):271-93</Citation><ArticleIdList><ArticleId IdType="pubmed">19466543</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1999 Dec;56(12):1073-86</Citation><ArticleIdList><ArticleId IdType="pubmed">10591283</ArticleId></ArticleIdList></Reference><Reference><Citation>Dialogues Clin Neurosci. 2012 Mar;14(1):29-37</Citation><ArticleIdList><ArticleId IdType="pubmed">22577302</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2009 Sep;11(6):637-49</Citation><ArticleIdList><ArticleId IdType="pubmed">19689506</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2010 Jul 30;178(2):440-2</Citation><ArticleIdList><ArticleId IdType="pubmed">20488558</ArticleId></ArticleIdList></Reference><Reference><Citation>Perspect Psychol Sci. 2011 Jan;6(1):21-37</Citation><ArticleIdList><ArticleId IdType="pubmed">26162113</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Assess. 2001 Jun;13(2):267-76</Citation><ArticleIdList><ArticleId IdType="pubmed">11433802</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2004 Aug 18;292(7):807-20</Citation><ArticleIdList><ArticleId IdType="pubmed">15315995</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2005 Oct 1;58(7):583-8</Citation><ArticleIdList><ArticleId IdType="pubmed">16197929</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2013 May;52(5):466-81</Citation><ArticleIdList><ArticleId IdType="pubmed">23622848</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Psychol Rev. 2010 Mar;30(2):145-54</Citation><ArticleIdList><ArticleId IdType="pubmed">19945203</ArticleId></ArticleIdList></Reference><Reference><Citation>Pediatr Clin North Am. 2011 Feb;58(1):173-87, xii</Citation><ArticleIdList><ArticleId IdType="pubmed">21281855</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2008 Sep;65(9):1053-61</Citation><ArticleIdList><ArticleId IdType="pubmed">18762591</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2006 May;67(5):827-30</Citation><ArticleIdList><ArticleId IdType="pubmed">16841633</ArticleId></ArticleIdList></Reference><Reference><Citation>J Child Adolesc Psychopharmacol. 2009 Aug;19(4):453-60</Citation><ArticleIdList><ArticleId IdType="pubmed">19702498</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Neuropsychopharmacol. 2005 Aug;15(4):425-34</Citation><ArticleIdList><ArticleId IdType="pubmed">15935623</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Clin Psychiatry. 1995 Sep;7(3):127-32</Citation><ArticleIdList><ArticleId IdType="pubmed">8646272</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2005 Dec;7(6):623-34</Citation><ArticleIdList><ArticleId IdType="pubmed">16403188</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2011 Mar;68(3):241-51</Citation><ArticleIdList><ArticleId IdType="pubmed">21383262</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2006 Feb;63(2):175-83</Citation><ArticleIdList><ArticleId IdType="pubmed">16461861</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Clin Psychol. 2013;9:151-76</Citation><ArticleIdList><ArticleId IdType="pubmed">23157450</ArticleId></ArticleIdList></Reference><Reference><Citation>Child Adolesc Psychiatr Clin N Am. 2009 Apr;18(2):339-52, viii</Citation><ArticleIdList><ArticleId IdType="pubmed">19264267</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2006 Oct;8(5 Pt 1):508-15</Citation><ArticleIdList><ArticleId IdType="pubmed">17042890</ArticleId></ArticleIdList></Reference><Reference><Citation>Pediatrics. 2004 Apr;113(4):754-61</Citation><ArticleIdList><ArticleId IdType="pubmed">15060224</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1987 Apr;44(4):314-9</Citation><ArticleIdList><ArticleId IdType="pubmed">3566454</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2011 Oct;45(10):1283-94</Citation><ArticleIdList><ArticleId IdType="pubmed">21561628</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2004 May 1;55(9):875-81</Citation><ArticleIdList><ArticleId IdType="pubmed">15110730</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 1996 Jul 24-31;276(4):293-9</Citation><ArticleIdList><ArticleId IdType="pubmed">8656541</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Psychiatry Rep. 2010 Dec;12(6):479-89</Citation><ArticleIdList><ArticleId IdType="pubmed">20857347</ArticleId></ArticleIdList></Reference><Reference><Citation>J Child Psychol Psychiatry. 2007 Sep;48(9):863-71</Citation><ArticleIdList><ArticleId IdType="pubmed">17714371</ArticleId></ArticleIdList></Reference><Reference><Citation>Pediatrics. 2009 Mar;123(3):e446-52</Citation><ArticleIdList><ArticleId IdType="pubmed">19254981</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2011 Oct;45(10):1273-82</Citation><ArticleIdList><ArticleId IdType="pubmed">21683960</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2009 Dec;66(12):1341-52</Citation><ArticleIdList><ArticleId IdType="pubmed">19996039</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 1970 Jan;126(7):983-7</Citation><ArticleIdList><ArticleId IdType="pubmed">5409569</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2003 Feb;107(2):124-31</Citation><ArticleIdList><ArticleId IdType="pubmed">12534438</ArticleId></ArticleIdList></Reference><Reference><Citation>J Abnorm Psychol. 2009 Aug;118(3):431-47</Citation><ArticleIdList><ArticleId IdType="pubmed">19685942</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2010 Dec;71(12):1664-72</Citation><ArticleIdList><ArticleId IdType="pubmed">21034685</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2005 Dec;7(6):507-17</Citation><ArticleIdList><ArticleId IdType="pubmed">16403176</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1985 Jul;42(7):696-702</Citation><ArticleIdList><ArticleId IdType="pubmed">4015311</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2001 Aug;40(8):871-8</Citation><ArticleIdList><ArticleId IdType="pubmed">11501685</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Psychiatry. 2012 May 09;12:38</Citation><ArticleIdList><ArticleId IdType="pubmed">22571731</ArticleId></ArticleIdList></Reference><Reference><Citation>J Child Adolesc Psychopharmacol. 2013 Oct;23(8):558-67</Citation><ArticleIdList><ArticleId IdType="pubmed">24138009</ArticleId></ArticleIdList></Reference><Reference><Citation>Pediatrics. 2004 Apr;113(4):762-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15060225</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2011 Nov;50(11):1173-1185.e2</Citation><ArticleIdList><ArticleId IdType="pubmed">22024005</ArticleId></ArticleIdList></Reference><Reference><Citation>J Child Adolesc Psychopharmacol. 2002 Spring;12(1):3-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12014593</ArticleId></ArticleIdList></Reference><Reference><Citation>J Child Adolesc Psychopharmacol. 2013 Mar;23(2):72-9</Citation><ArticleIdList><ArticleId IdType="pubmed">23480324</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2003 Jan 17;299(5605):350-1</Citation><ArticleIdList><ArticleId IdType="pubmed">12532001</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2011 Jun 18;377(9783):2093-102</Citation><ArticleIdList><ArticleId IdType="pubmed">21652063</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2007 Mar;46(3):341-355</Citation><ArticleIdList><ArticleId IdType="pubmed">17314720</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 2011 Aug;50(8):749-62.e39</Citation><ArticleIdList><ArticleId IdType="pubmed">21784295</ArticleId></ArticleIdList></Reference><Reference><Citation>J Abnorm Psychol. 2010 Nov;119(4):631-9</Citation><ArticleIdList><ArticleId IdType="pubmed">20939653</ArticleId></ArticleIdList></Reference><Reference><Citation>J Child Adolesc Psychopharmacol. 2002 Spring;12(1):11-25</Citation><ArticleIdList><ArticleId IdType="pubmed">12014591</ArticleId></ArticleIdList></Reference><Reference><Citation>World Psychiatry. 2002 Oct;1(3):146-8</Citation><ArticleIdList><ArticleId IdType="pubmed">16946835</ArticleId></ArticleIdList></Reference><Reference><Citation>Child Adolesc Psychiatr Clin N Am. 2012 Oct;21(4):911-39</Citation><ArticleIdList><ArticleId IdType="pubmed">23040907</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2012 Sep;69(9):943-51</Citation><ArticleIdList><ArticleId IdType="pubmed">22566563</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1999 Dec;56(12):1088-96</Citation><ArticleIdList><ArticleId IdType="pubmed">10591284</ArticleId></ArticleIdList></Reference><Reference><Citation>J Can Acad Child Adolesc Psychiatry. 2009 Aug;18(3):239-46</Citation><ArticleIdList><ArticleId IdType="pubmed">19718425</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2012 Aug;14(5):497-506</Citation><ArticleIdList><ArticleId IdType="pubmed">22788253</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Acad Child Adolesc Psychiatry. 1992 Mar;31(2):252-7</Citation><ArticleIdList><ArticleId IdType="pubmed">1564026</ArticleId></ArticleIdList></Reference><Reference><Citation>Biometrics. 1946 Jun;2(3):47-53</Citation><ArticleIdList><ArticleId IdType="pubmed">21001024</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2002 Aug;4(4):254-62</Citation><ArticleIdList><ArticleId IdType="pubmed">12190715</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Child Adolesc Psychol. 2005 Sep;34(3):449-76</Citation><ArticleIdList><ArticleId IdType="pubmed">16026214</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Child Adolesc Psychol. 2014;43(3):459-72</Citation><ArticleIdList><ArticleId IdType="pubmed">23795823</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">7790672</PMID><DateCompleted><Year>1995</Year><Month>07</Month><Day>27</Day></DateCompleted><DateRevised><Year>2019</Year><Month>09</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0165-0327</ISSN><JournalIssue CitedMedium="Print"><Volume>33</Volume><Issue>3</Issue><PubDate><Year>1995</Year><Month>Mar</Month><Day>14</Day></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Decreased temporal lobe phosphomonoesters in bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>195-9</MedlinePgn></Pagination><Abstract><AbstractText>In vivo [31P]magnetic resonance spectroscopic imaging ([31P]MRSI) was performed on 12 unmedicated, euthymic bipolar patients and 14 control subjects to determine if there were alterations in high-energy P metabolism in the temporal lobes of bipolar patients. Compared with the control group, the patients with bipolar disorder demonstrated significantly lower phosphomonoesters (PME) in both the left and right temporal lobes. No other group differences in P metabolites or lateralized asymmetries were noted. This preliminary study provides support for altered temporal lobe phospholipid metabolism in bipolar disorder.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Deicken</LastName><ForeName>R F</ForeName><Initials>RF</Initials><AffiliationInfo><Affiliation>Magnetic Resonance Unit, VA Medical Center, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weiner</LastName><ForeName>M W</ForeName><Initials>MW</Initials></Author><Author ValidYN="Y"><LastName>Fein</LastName><ForeName>G</ForeName><Initials>G</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>S07-RR05755</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010755">Organophosphates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010710">Phosphates</NameOfSubstance></Chemical><Chemical><RegistryNumber>020IUV4N33</RegistryNumber><NameOfSubstance UI="D010725">Phosphocreatine</NameOfSubstance></Chemical><Chemical><RegistryNumber>8L70Q75FXE</RegistryNumber><NameOfSubstance UI="D000255">Adenosine Triphosphate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000255" MajorTopicYN="N">Adenosine Triphosphate</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004292" MajorTopicYN="N">Dominance, Cerebral</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009682" MajorTopicYN="Y">Magnetic Resonance Spectroscopy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010755" MajorTopicYN="N">Organophosphates</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010552" MajorTopicYN="N">Personality Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010710" MajorTopicYN="N">Phosphates</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010725" MajorTopicYN="N">Phosphocreatine</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012016" MajorTopicYN="N">Reference Values</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013702" MajorTopicYN="N">Temporal Lobe</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1995</Year><Month>3</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1995</Year><Month>3</Month><Day>14</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1995</Year><Month>3</Month><Day>14</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">7790672</ArticleId><ArticleId IdType="pii">016503279400089R</ArticleId><ArticleId IdType="doi">10.1016/0165-0327(94)00089-r</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">21621272</PMID><DateCompleted><Year>2011</Year><Month>11</Month><Day>04</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2517</ISSN><JournalIssue CitedMedium="Internet"><Volume>133</Volume><Issue>3</Issue><PubDate><Year>2011</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Journal of affective disorders</Title><ISOAbbreviation>J Affect Disord</ISOAbbreviation></Journal><ArticleTitle>Early Maladaptive Schemas in the risk for bipolar spectrum disorders.</ArticleTitle><Pagination><MedlinePgn>428-36</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jad.2011.04.040</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The hypomanic personality style is a risk factor for bipolar spectrum disorders and shares many cognitive and affective features with the bipolar spectrum. Schema theory may serve as a unifying theory that would explain many of these features. This study is an exploratory investigation of Early Maladaptive Schemas (EMSs) in association with the hypomanic personality and bipolar spectrum risk.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A sample of 966 participants completed the Young Schema Questionnaire, the Hypomanic Personality Scale and the Patient Health Questionnaire. Associations were investigated using univariate and multivariate analyses. Participants deemed at risk of developing a bipolar disorder (N=107) were compared to low-risk controls (N=681).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The Entitlement/Grandiosity and Insufficient Self-Control/Self-Discipline positively predicted the risk of developing a bipolar disorder, while Emotional Inhibition negatively predicted risk. High-risk participants demonstrated higher mean scores on all EMSs except Emotional Inhibition. These three EMSs, combined with Vulnerability to Harm or Illness, significantly predicted group membership.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">A bipolar spectrum EMS profile was identified, consisting of Entitlement/Grandiosity, Insufficient Self-Control/Self-Discipline and the absence of Emotional Inhibition. These EMSs are highly consistent with characteristics of the bipolar spectrum. This study supports the application of schema theory to the hypomanic personality and bipolar spectrum. Future research should explore the possible interaction between EMSs, life events and affective symptoms and the applicability of schema therapy to the bipolar spectrum.</AbstractText><CopyrightInformation>Crown Copyright © 2011. Published by Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hawke</LastName><ForeName>Lisa D</ForeName><Initials>LD</Initials><AffiliationInfo><Affiliation>Université Laval, Quebec City, Canada. lisa.hawke.1@ulaval.ca</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Provencher</LastName><ForeName>Martin D</ForeName><Initials>MD</Initials></Author><Author ValidYN="Y"><LastName>Arntz</LastName><ForeName>Arnoud</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>05</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Affect Disord</MedlineTA><NlmUniqueID>7906073</NlmUniqueID><ISSNLinking>0165-0327</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004644" MajorTopicYN="N">Emotions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010551" MajorTopicYN="Y">Personality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010555" MajorTopicYN="N">Personality Inventory</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012649" MajorTopicYN="N">Self Concept</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>02</Month><Day>02</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>04</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>5</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>5</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>11</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21621272</ArticleId><ArticleId IdType="pii">S0165-0327(11)00207-2</ArticleId><ArticleId IdType="doi">10.1016/j.jad.2011.04.040</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19485960</PMID><DateCompleted><Year>2010</Year><Month>08</Month><Day>02</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1600-0447</ISSN><JournalIssue CitedMedium="Internet"><Volume>120</Volume><Issue>6</Issue><PubDate><Year>2009</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Acta psychiatrica Scandinavica</Title><ISOAbbreviation>Acta Psychiatr Scand</ISOAbbreviation></Journal><ArticleTitle>Preliminary results of a fine-grain analysis of mood swings and treatment modalities of bipolar I and II patients using the daily prospective life-chart-methodology.</ArticleTitle><Pagination><MedlinePgn>474-80</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1600-0447.2009.01412.x</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The study aimed to increase the knowledge about the detailed course differences between different forms of bipolar disorder.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Using the prospective life-chart-clinician version, we compared the fine-grain analysis of mood swings and treatment modalities of 18 bipolar II with 31 bipolar I patients.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">During an observational period of a mean of 26 months we observed an increase of euthymic days, and a decrease of (sub)depressive and (hypo)manic days. Days in a (sub)depressed state were more frequent than days of (hypo)mania as well as days of subdepression or hypomania in comparison to days of full-blown depression or mania. Bipolar II patients showed an increase in hypomanic days receiving more frequently antidepressants. Bipolar I patients, with a decrease of manic days, were significantly taking more often mood stabilizers.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Treatment in a specialized bipolar clinic improves the overall outcome, but bipolar II disorder seems to be still treated sub-optimally with a possible iatrogenic increase of hypomanic days.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Born</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Ludwig-Maximilian- University, Munich, Germany. christoph.born@med.uni-muenchen.de</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seitz</LastName><ForeName>N-N</ForeName><Initials>NN</Initials></Author><Author ValidYN="Y"><LastName>Grunze</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Vieta</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Dittmann</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Seemüller</LastName><ForeName>F</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Amann</LastName><ForeName>B</ForeName><Initials>B</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>05</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Acta Psychiatr Scand</MedlineTA><NlmUniqueID>0370364</NlmUniqueID><ISSNLinking>0001-690X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000927">Anticonvulsants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014150">Antipsychotic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000927" MajorTopicYN="N">Anticonvulsants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014150" MajorTopicYN="N">Antipsychotic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="Y">Bipolar Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>6</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>6</Month><Day>3</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>8</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19485960</ArticleId><ArticleId IdType="pii">ACP1412</ArticleId><ArticleId IdType="doi">10.1111/j.1600-0447.2009.01412.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23030601</PMID><DateCompleted><Year>2013</Year><Month>04</Month><Day>18</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1399-5618</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>7</Issue><PubDate><Year>2012</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Bipolar disorders</Title><ISOAbbreviation>Bipolar Disord</ISOAbbreviation></Journal><ArticleTitle>Cerebrospinal fluid kynurenic acid is associated with manic and psychotic features in patients with bipolar I disorder.</ArticleTitle><Pagination><MedlinePgn>719-26</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/bdi.12009</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Kynurenic acid (KYNA), an end metabolite of tryptophan degradation, antagonizes glutamatergic and cholinergic receptors in the brain. Recently, we reported elevated levels of cerebrospinal fluid (CSF) KYNA in male patients with bipolar disorder. Here, we investigate the relationship between symptomatology and the concentration of CSF KYNA in patients with bipolar I disorder.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">CSF KYNA levels from euthymic male {n = 21; mean age: 41 years [standard deviation (SD) = 14]} and female [n = 34; mean age: 37 years (SD = 14)] patients diagnosed with bipolar I disorder were analyzed using high-performance liquid chromatography (HPLC).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Euthymic bipolar I disorder patients with a lifetime occurrence of psychotic features had higher CSF levels of KYNA {2.0 nm [standard error of the mean (SEM) = 0.2]; n = 43} compared to patients without any history of psychotic features [1.3 nm (SEM = 0.2); n = 12] (p = 0.01). Logistic regression, with age as covariate, similarly showed an association between a history of psychotic features and CSF KYNA levels [n = 55; odds ratio (OR) = 4.9, p = 0.03]. Further, having had a recent manic episode (within the previous year) was also associated with CSF KYNA adjusted for age (n = 34; OR = 4.4, p = 0.03), and the association remained significant when adjusting for a lifetime history of psychotic features (OR = 4.1, p = 0.05).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Although the causality needs to be determined, the ability of KYNA to influence dopamine transmission and behavior, along with previous reports showing increased brain levels of the compound in patients with schizophrenia and bipolar disorder, may indicate a possible pathophysiological role of KYNA in the development of manic or psychotic symptoms.</AbstractText><CopyrightInformation>© 2012 John Wiley and Sons A/S.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Olsson</LastName><ForeName>Sara K</ForeName><Initials>SK</Initials><AffiliationInfo><Affiliation>Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sellgren</LastName><ForeName>Carl</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Engberg</LastName><ForeName>Göran</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Landén</LastName><ForeName>Mikael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Erhardt</LastName><ForeName>Sophie</ForeName><Initials>S</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>10</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Bipolar Disord</MedlineTA><NlmUniqueID>100883596</NlmUniqueID><ISSNLinking>1398-5647</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>H030S2S85J</RegistryNumber><NameOfSubstance UI="D007736">Kynurenic Acid</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002851" MajorTopicYN="N">Chromatography, High Pressure Liquid</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007736" MajorTopicYN="N">Kynurenic Acid</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016015" MajorTopicYN="N">Logistic Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018709" MajorTopicYN="N">Statistics, Nonparametric</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>10</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>10</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>4</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23030601</ArticleId><ArticleId IdType="doi">10.1111/bdi.12009</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22906117</PMID><DateCompleted><Year>2013</Year><Month>08</Month><Day>30</Day></DateCompleted><DateRevised><Year>2013</Year><Month>04</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1600-0447</ISSN><JournalIssue CitedMedium="Internet"><Volume>127</Volume><Issue>5</Issue><PubDate><Year>2013</Year><Month>May</Month></PubDate></JournalIssue><Title>Acta psychiatrica Scandinavica</Title><ISOAbbreviation>Acta Psychiatr Scand</ISOAbbreviation></Journal><ArticleTitle>Bipolar disorder in a national survey using the World Mental Health Version of the Composite International Diagnostic Interview: the impact of differing diagnostic algorithms.</ArticleTitle><Pagination><MedlinePgn>381-93</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/acps.12005</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The World Mental Health Version of the Composite International Diagnostic Interview (WMH-CIDI) DSM-IV bipolar disorder diagnostic algorithms were recalibrated in about 2006 following evidence of over-diagnosis of bipolar I disorder. There have been no reports of the impact of this recalibration on epidemiological findings.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Data were taken from the 2007 Australian National Survey of Mental Health and Wellbeing. Findings for cases identified by the recalibrated bipolar disorder definition were contrasted against those identified by the un-recalibrated definition.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The 12-month prevalence of recalibrated bipolar disorder and un-recalibrated bipolar disorder were 0.9% and 1.7% respectively. The un-recalibrated bipolar disorder group was younger and more likely to have never married than the recalibrated bipolar disorder group. They were also more likely to have a comorbid alcohol use disorder, substance use disorder and asthma or arthritis. While they were more likely to have at least severe interference in at least one of the Sheehan Scale domains of functioning, they were less likely to have made a suicide attempt. Similarly, they were less likely to have consulted a psychiatrist.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">It is not possible to be certain about the nature of these differences. Some may be artifactual (reflecting greater statistical power to detect differences with the larger un-recalibrated bipolar disorder defined sample), while others may be indicative of the inclusion of a clinically distinct subpopulation with the un-recalibrated bipolar disorder definition, thereby producing a more heterogeneous sample. These findings indicate the need for clarity in the diagnostic algorithm used in epidemiological reports on bipolar disorder using the World Mental Health Version of the Composite International Diagnostic Interview.</AbstractText><CopyrightInformation>© 2012 John Wiley &amp; Sons A/S.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mitchell</LastName><ForeName>P B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>School of Psychiatry, University of New South Wales, Sydney, Australia. phil.mitchell@unsw.edu.au</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Johnston</LastName><ForeName>A K</ForeName><Initials>AK</Initials></Author><Author ValidYN="Y"><LastName>Frankland</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Slade</LastName><ForeName>T</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Green</LastName><ForeName>M J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Roberts</LastName><ForeName>G</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Wright</LastName><ForeName>A</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Corry</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Hadzi-Pavlovic</LastName><ForeName>D</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2012</Year><Month>08</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Acta Psychiatr Scand</MedlineTA><NlmUniqueID>0370364</NlmUniqueID><ISSNLinking>0001-690X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000203" MajorTopicYN="N">Activities of Daily Living</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000437" MajorTopicYN="N">Alcoholism</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000465" MajorTopicYN="N">Algorithms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001168" MajorTopicYN="N">Arthritis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001249" MajorTopicYN="N">Asthma</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001315" MajorTopicYN="N" Type="Geographic">Australia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007406" MajorTopicYN="Y">Interview, Psychological</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017533" MajorTopicYN="N">Marital Status</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019966" MajorTopicYN="N">Substance-Related Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>8</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>8</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>8</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22906117</ArticleId><ArticleId IdType="doi">10.1111/acps.12005</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">29189086</PMID><DateCompleted><Year>2018</Year><Month>07</Month><Day>10</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1502-4725</ISSN><JournalIssue CitedMedium="Internet"><Volume>72</Volume><Issue>3</Issue><PubDate><Year>2018</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Nordic journal of psychiatry</Title><ISOAbbreviation>Nord J Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Case series of diagnostic shift from bipolar disorder to schizoaffective disorder.</ArticleTitle><Pagination><MedlinePgn>232-235</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/08039488.2017.1411524</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To describe three cases of diagnostic shift from bipolar I disorder (BD) to schizoaffective disorder (SAD).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">BD patients were clinically assessed and followed up in a mood disorder program. A questionnaire was applied to assess clinical and socio-demographic characteristics, and a Structured Clinical Interview (SCID-I) was conducted.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We identified three patients with diagnosis conversion to SAD from 2005 to 2016. The mean time between BD diagnosis and the diagnostic shift to SAD was 9 years.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Psychotic symptoms may become persistent, chronic and unrelated to the presence of mood episodes many years after the beginning of BD. Psychiatrists should be aware of this and reassess the diagnosis during the longitudinal course of BD, especially in those patients who present psychotic symptoms.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Argolo</LastName><ForeName>Lucas</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>a Medicine and Health Postgraduate Program , Federal University of Bahia , Salvador , BA , Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>b Mood and Anxiety Disorders Program (CETHA) , Federal University of Bahia , Salvador , BA , Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>c Department of Life Sciences , State University of Bahia , Salvador , BA , Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Batista</LastName><ForeName>Fabrício</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>b Mood and Anxiety Disorders Program (CETHA) , Federal University of Bahia , Salvador , BA , Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bezerra-Filho</LastName><ForeName>Severino</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>a Medicine and Health Postgraduate Program , Federal University of Bahia , Salvador , BA , Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>b Mood and Anxiety Disorders Program (CETHA) , Federal University of Bahia , Salvador , BA , Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kapczinski</LastName><ForeName>Flávio</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>d Department of Psychiatry and Behavioral Neurosciences , McMaster University , Hamilton , ON , Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miranda-Scippa</LastName><ForeName>Ângela</ForeName><Initials>Â</Initials><AffiliationInfo><Affiliation>a Medicine and Health Postgraduate Program , Federal University of Bahia , Salvador , BA , Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>b Mood and Anxiety Disorders Program (CETHA) , Federal University of Bahia , Salvador , BA , Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>e Department of Neurosciences and Mental Health , Medical School, Federal University of Bahia , Salvador , BA , Brazil.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>11</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nord J Psychiatry</MedlineTA><NlmUniqueID>100927567</NlmUniqueID><ISSNLinking>0803-9488</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bipolar</Keyword><Keyword MajorTopicYN="N">conversion</Keyword><Keyword MajorTopicYN="N">diagnostic shift</Keyword><Keyword MajorTopicYN="N">schizoaffective</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>12</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>7</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>12</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29189086</ArticleId><ArticleId IdType="doi">10.1080/08039488.2017.1411524</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24310088</PMID><DateCompleted><Year>2016</Year><Month>04</Month><Day>14</Day></DateCompleted><DateRevised><Year>2013</Year><Month>12</Month><Day>06</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1300-2163</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>4</Issue><PubDate><Year>2013</Year><Season>Winter</Season></PubDate></JournalIssue><Title>Turk psikiyatri dergisi = Turkish journal of psychiatry</Title><ISOAbbreviation>Turk Psikiyatri Derg</ISOAbbreviation></Journal><ArticleTitle>[Neuropsychological profiles of adolescents with bipolar disorder and adolescents with a high risk of bipolar disorder].</ArticleTitle><Pagination><MedlinePgn>221-30</MedlinePgn></Pagination><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">In recent years evidence of an association between bipolar disorder (BD), and specific neuropsychological impairment and familial transmission of BD has been mounting. The aim of this study was to identify the clinical and neuropsychological features of BD in adolescents, to assess the clinical and neuropsychological parameters in adolescents with a high risk of familial transmission of BD, and to identify probable early markers of the disorder.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">The study included 25 patients aged 12-18 years that were diagnosed as BD (case group), 25 adolescents without a mood disorder that had a parent and/or sibling diagnosed as BD, (risk group), and 25 typically developing adolescents (control group). To determine neuropsychological profiles the participants were administered the Wisconsin Card Sorting Test (WCST), Stroop Color Word Test (SCWT), and Continuous Performance Test (CPT), and to evaluate clinical and behavioral profiles the Children's Depression Inventory (CDI), Parent-Young Mania Rating Scale (P-YMRS), Youth Self-Report (YSR), and Conners' Parent Rating Scale (CPRS-48) were administered.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The case group performed significantly lower on the WCST, SCWT, and CPT in terms of executive and attention functions, whereas there wasn't a difference between the risk group and control group. In addition, significantly more of the adolescents in the case and risk groups had clinical and behavioral problems than those in the control group.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The findings show that behavioral and clinical problems were more common in the risk group than in the control group, and that the frequency of attention and executive function impairment was similar in both of those groups. The findings suggest that BD itself may be associated with attention and executive function impairments, whereas a familial risk of BD may be associated with some behavioral problems. Follow-up and neuroimaging studies conducted with a larger number of participants, and neuropsychological test profiles may provide more detailed information about the neuropsychological profiles of individuals with a genetic risk for BD and may provide descriptive data about where and how the biological and psychometric deterioration initiate.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Karakurt</LastName><ForeName>Melih Nuri</ForeName><Initials>MN</Initials></Author><Author ValidYN="Y"><LastName>Karabekiroğllu</LastName><ForeName>M Z Koray</ForeName><Initials>MZ</Initials></Author><Author ValidYN="Y"><LastName>Yüce</LastName><ForeName>Murat</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Baykal</LastName><ForeName>Saliha</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Şenses</LastName><ForeName>Ahmet</ForeName><Initials>A</Initials></Author></AuthorList><Language>tur</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Bipolar bozukluk tanısı olan ve bipolar bozukluk için yüksek riskli ergenlerin nöropsikolojik özellikleri.</VernacularTitle></Article><MedlineJournalInfo><Country>Turkey</Country><MedlineTA>Turk Psikiyatri Derg</MedlineTA><NlmUniqueID>9425936</NlmUniqueID><ISSNLinking>1300-2163</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000294" MajorTopicYN="N">Adolescent Behavior</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016497" MajorTopicYN="N">Adolescent Health Services</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="Y">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>12</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>12</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>4</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24310088</ArticleId><ArticleId IdType="pii">906</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24862657</PMID><DateCompleted><Year>2015</Year><Month>02</Month><Day>19</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-1379</ISSN><JournalIssue CitedMedium="Internet"><Volume>56</Volume><PubDate><Year>2014</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Journal of psychiatric research</Title><ISOAbbreviation>J Psychiatr Res</ISOAbbreviation></Journal><ArticleTitle>Inflammatory mediators of cognitive impairment in bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>18-27</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jpsychires.2014.04.017</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0022-3956(14)00123-X</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Recent studies have pointed to neuroinflammation, oxidative stress and neurotrophic factors as key mediators in the pathophysiology of mood disorders. Little is however known about the cascade of biological episodes underlying the cognitive deficits observed during the acute and euthymic phases of bipolar disorder (BD). The aim of this review is to assess the potential association between cognitive impairment and biomarkers of inflammation, oxidative stress and neurotrophic activity in BD.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Scopus (all databases), Pubmed and Ovid Medline were systematically searched with no language or year restrictions, up to November 2013, for human studies that collected both inflammatory markers and cognitive data in BD. Selected search terms were bipolar disorder, depression, mania, psychosis, inflammatory, cognitive and neurotrophic.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Ten human studies satisfied the criteria for consideration. The findings showed that high levels of peripheral inflammatory-cytokine, oxidative stress and reduced brain derived neurotrophic factor (BDNF) levels were associated with poor cognitive performance. The BDNF val66met polymorphism is a potential vulnerability factor for cognitive impairment in BD.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Current data provide preliminary evidence of a link between the cognitive decline observed in BD and mechanisms of neuroinflammation and neuroprotection. The identification of BD specific inflammatory markers and polymorphisms in inflammatory response genes may be of assistance for therapeutic intervention.</AbstractText><CopyrightInformation>Copyright © 2014 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bauer</LastName><ForeName>Isabelle E</ForeName><Initials>IE</Initials><AffiliationInfo><Affiliation>University of Texas Health Science Center at Houston, Department of Psychiatry and Behavioral Sciences, 77054 Houston, TX, United States. Electronic address: Isabelle.E.Bauer@uth.tmc.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pascoe</LastName><ForeName>Michaela C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Department of Clinical Neuroscience and Rehabilitation, Sahlgrenska Academy at University of Gothenburg, Box 440, 40530 Gothenburg, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wollenhaupt-Aguiar</LastName><ForeName>Bianca</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Laboratório de Psiquiatria Molecular, Instituto Nacional de Ciência e Tecnologia - Translacional em Medicina (INCT), Hospital de Clínicas de Porto Alegre, Programa de Pós-Graduação em Ciências Biológicas: Bioquímica, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kapczinski</LastName><ForeName>Flavio</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>University of Texas Health Science Center at Houston, Department of Psychiatry and Behavioral Sciences, 77054 Houston, TX, United States; Laboratório de Psiquiatria Molecular, Instituto Nacional de Ciência e Tecnologia - Translacional em Medicina (INCT), Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soares</LastName><ForeName>Jair C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>University of Texas Health Science Center at Houston, Department of Psychiatry and Behavioral Sciences, 77054 Houston, TX, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 MH085667</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR000371</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>1R01MH085667</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>05</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Psychiatr Res</MedlineTA><NlmUniqueID>0376331</NlmUniqueID><ISSNLinking>0022-3956</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015213" MajorTopicYN="N">Neuroimmunomodulation</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bipolar disorder</Keyword><Keyword MajorTopicYN="N">Cognitive functioning</Keyword><Keyword MajorTopicYN="N">Neuroinflammation</Keyword><Keyword MajorTopicYN="N">Neurotrophin</Keyword><Keyword MajorTopicYN="N">Oxidative stress</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>11</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2014</Year><Month>04</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>04</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>5</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>5</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>2</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24862657</ArticleId><ArticleId IdType="pii">S0022-3956(14)00123-X</ArticleId><ArticleId IdType="doi">10.1016/j.jpsychires.2014.04.017</ArticleId><ArticleId IdType="pmc">PMC4167370</ArticleId><ArticleId IdType="mid">NIHMS601042</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Neuropsychopharmacology. 2004 Aug;29(8):1538-45</Citation><ArticleIdList><ArticleId IdType="pubmed">15127079</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Lett. 2011 Sep 15;502(2):103-6</Citation><ArticleIdList><ArticleId IdType="pubmed">21820487</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Mol Cell Biol. 2000 Nov;1(2):120-9</Citation><ArticleIdList><ArticleId IdType="pubmed">11253364</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2003 Dec;5(6):468-72</Citation><ArticleIdList><ArticleId IdType="pubmed">14636373</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2002 Dec;72(3):209-26</Citation><ArticleIdList><ArticleId IdType="pubmed">12450638</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2011 Aug;45(8):995-1004</Citation><ArticleIdList><ArticleId IdType="pubmed">21550050</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Behav Immun. 2003 Feb;17 Suppl 1:S119-24</Citation><ArticleIdList><ArticleId IdType="pubmed">12615197</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Metab. 2013 Aug 6;18(2):145-6</Citation><ArticleIdList><ArticleId IdType="pubmed">23931748</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychol Med. 2009 Mar;39(3):413-23</Citation><ArticleIdList><ArticleId IdType="pubmed">18533059</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuropsychobiology. 2001;43(4):242-7</Citation><ArticleIdList><ArticleId IdType="pubmed">11340363</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2013 Mar;47(3):391-400</Citation><ArticleIdList><ArticleId IdType="pubmed">23260171</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2010 Sep;122(3):235-45</Citation><ArticleIdList><ArticleId IdType="pubmed">20105148</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Med. 2009 Jul 21;6(7):e1000097</Citation><ArticleIdList><ArticleId IdType="pubmed">19621072</ArticleId></ArticleIdList></Reference><Reference><Citation>Med J Aust. 2010 Aug 16;193(S4):S36-40</Citation><ArticleIdList><ArticleId IdType="pubmed">20712560</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2012 Aug;14(5):478-87</Citation><ArticleIdList><ArticleId IdType="pubmed">22834460</ArticleId></ArticleIdList></Reference><Reference><Citation>Aust N Z J Psychiatry. 2007 Apr;41(4):321-6</Citation><ArticleIdList><ArticleId IdType="pubmed">17464718</ArticleId></ArticleIdList></Reference><Reference><Citation>J Geriatr Psychiatry Neurol. 2012 Dec;25(4):201-7</Citation><ArticleIdList><ArticleId IdType="pubmed">23172762</ArticleId></ArticleIdList></Reference><Reference><Citation>Hum Psychopharmacol. 2013 Mar;28(2):160-7</Citation><ArticleIdList><ArticleId IdType="pubmed">23532748</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurochem Res. 2006 May;31(5):699-703</Citation><ArticleIdList><ArticleId IdType="pubmed">16770742</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2012 Jun;14(4):313-25</Citation><ArticleIdList><ArticleId IdType="pubmed">22631617</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2007 Oct 15;62(8):910-6</Citation><ArticleIdList><ArticleId IdType="pubmed">17543288</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Biobehav Rev. 2008;32(4):675-92</Citation><ArticleIdList><ArticleId IdType="pubmed">18199480</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2011 Oct 1;70(7):663-71</Citation><ArticleIdList><ArticleId IdType="pubmed">21641581</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neuropsychopharmacol Biol Psychiatry. 2014 Jan 3;48:295-303</Citation><ArticleIdList><ArticleId IdType="pubmed">23313563</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neuropsychopharmacol Biol Psychiatry. 2011 Jul 1;35(5):1349-54</Citation><ArticleIdList><ArticleId IdType="pubmed">21549798</ArticleId></ArticleIdList></Reference><Reference><Citation>Nutr Neurosci. 2013 Jan;16(1):13-20</Citation><ArticleIdList><ArticleId IdType="pubmed">23321679</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Neuropsychopharmacol. 2010 Jun;13(5):617-22</Citation><ArticleIdList><ArticleId IdType="pubmed">20392298</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Clin Neurosci. 2009 Apr;63(2):202-8</Citation><ArticleIdList><ArticleId IdType="pubmed">19175760</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Endocrinol Metab. 2006 Apr;17(3):117-21</Citation><ArticleIdList><ArticleId IdType="pubmed">16530421</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 2012 Dec 1;72(11):943-9</Citation><ArticleIdList><ArticleId IdType="pubmed">22770649</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Res. 2006 Jun 30;1097(1):224-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16730669</ArticleId></ArticleIdList></Reference><Reference><Citation>Metab Brain Dis. 2009 Mar;24(1):55-68</Citation><ArticleIdList><ArticleId IdType="pubmed">19067144</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Lett. 2006 May 8;398(3):215-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16480819</ArticleId></ArticleIdList></Reference><Reference><Citation>Prog Neuropsychopharmacol Biol Psychiatry. 2013 Oct 1;46:181-8</Citation><ArticleIdList><ArticleId IdType="pubmed">23876786</ArticleId></ArticleIdList></Reference><Reference><Citation>J Psychiatr Res. 2011 Feb;45(2):156-61</Citation><ArticleIdList><ArticleId IdType="pubmed">20541770</ArticleId></ArticleIdList></Reference><Reference><Citation>Immunity. 1998 Mar;8(3):363-72</Citation><ArticleIdList><ArticleId IdType="pubmed">9529153</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Psychiatry Rep. 2012 Dec;14(6):667-75</Citation><ArticleIdList><ArticleId IdType="pubmed">23090632</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Neuropsychopharmacol. 2009 May;12(4):447-58</Citation><ArticleIdList><ArticleId IdType="pubmed">18771602</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nutr Biochem. 2009 Sep;20(9):735-41</Citation><ArticleIdList><ArticleId IdType="pubmed">18829287</ArticleId></ArticleIdList></Reference><Reference><Citation>Glia. 2013 Jan;61(1):62-70</Citation><ArticleIdList><ArticleId IdType="pubmed">22740320</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Res. 2006 Jun 15;142(2-3):139-50</Citation><ArticleIdList><ArticleId IdType="pubmed">16631256</ArticleId></ArticleIdList></Reference><Reference><Citation>Cogn Behav Neurol. 2013 Mar;26(1):1-5</Citation><ArticleIdList><ArticleId IdType="pubmed">23538566</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2012 Dec 20;143(1-3):131-7</Citation><ArticleIdList><ArticleId IdType="pubmed">22889524</ArticleId></ArticleIdList></Reference><Reference><Citation>CNS Drugs. 2013 Jun;27(6):457-68</Citation><ArticleIdList><ArticleId IdType="pubmed">23696308</ArticleId></ArticleIdList></Reference><Reference><Citation>Brain Behav Immun. 2007 Jan;21(1):9-19</Citation><ArticleIdList><ArticleId IdType="pubmed">17070667</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurosci Biobehav Rev. 2011 Jan;35(3):804-17</Citation><ArticleIdList><ArticleId IdType="pubmed">20934453</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Genet. 2005 Mar;42(3):193-204</Citation><ArticleIdList><ArticleId IdType="pubmed">15744031</ArticleId></ArticleIdList></Reference><Reference><Citation>J Lipid Res. 1997 Oct;38(10):2012-22</Citation><ArticleIdList><ArticleId IdType="pubmed">9374124</ArticleId></ArticleIdList></Reference><Reference><Citation>Exp Neurol. 1998 Sep;153(1):35-48</Citation><ArticleIdList><ArticleId IdType="pubmed">9743565</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Clin Neurosci. 2006 Feb;60(1):70-6</Citation><ArticleIdList><ArticleId IdType="pubmed">16472361</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2007 Feb-Mar;9(1-2):114-25</Citation><ArticleIdList><ArticleId IdType="pubmed">17391355</ArticleId></ArticleIdList></Reference><Reference><Citation>Braz J Psychiatry. 2013 Mar;35(1):70-4</Citation><ArticleIdList><ArticleId IdType="pubmed">23567604</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Neuropsychopharmacol. 2007 Apr;17(5):313-20</Citation><ArticleIdList><ArticleId IdType="pubmed">17140772</ArticleId></ArticleIdList></Reference><Reference><Citation>Braz J Psychiatry. 2009 Jun;31(2):136-40</Citation><ArticleIdList><ArticleId IdType="pubmed">19578686</ArticleId></ArticleIdList></Reference><Reference><Citation>J Child Adolesc Psychopharmacol. 2011 Oct;21(5):479-84</Citation><ArticleIdList><ArticleId IdType="pubmed">22040193</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2006 Jul;93(1-3):105-15</Citation><ArticleIdList><ArticleId IdType="pubmed">16677713</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Neurosci. 2001;24:677-736</Citation><ArticleIdList><ArticleId IdType="pubmed">11520916</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatry Clin Neurosci. 2012 Dec;66(7):553-63</Citation><ArticleIdList><ArticleId IdType="pubmed">23252921</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Arch Psychiatry Clin Neurosci. 2007 Aug;257(5):250-60</Citation><ArticleIdList><ArticleId IdType="pubmed">17401728</ArticleId></ArticleIdList></Reference><Reference><Citation>Exp Cell Res. 2012 Jul 1;318(11):1221-8</Citation><ArticleIdList><ArticleId IdType="pubmed">22465479</ArticleId></ArticleIdList></Reference><Reference><Citation>Pediatrics. 2007 Dec;120(6):1326-33</Citation><ArticleIdList><ArticleId IdType="pubmed">18055683</ArticleId></ArticleIdList></Reference><Reference><Citation>Expert Rev Neurother. 2009 Jul;9(7):957-66</Citation><ArticleIdList><ArticleId IdType="pubmed">19589046</ArticleId></ArticleIdList></Reference><Reference><Citation>Braz J Psychiatry. 2011 Sep;33(3):268-74</Citation><ArticleIdList><ArticleId IdType="pubmed">21971780</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Psychiatr Scand. 2013 Sep;128(3):149-62</Citation><ArticleIdList><ArticleId IdType="pubmed">23617548</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Neuropsychopharmacol. 2008 Oct;18(10):717-22</Citation><ArticleIdList><ArticleId IdType="pubmed">18554875</ArticleId></ArticleIdList></Reference><Reference><Citation>Schizophr Res. 2007 Mar;91(1-3):1-5</Citation><ArticleIdList><ArticleId IdType="pubmed">17306505</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2009 Sep;11(6):663-71</Citation><ArticleIdList><ArticleId IdType="pubmed">19689509</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2013 Sep 5;150(2):456-9</Citation><ArticleIdList><ArticleId IdType="pubmed">23684514</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2012 Mar;137(1-3):151-5</Citation><ArticleIdList><ArticleId IdType="pubmed">22252095</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11893872</PMID><DateCompleted><Year>2002</Year><Month>05</Month><Day>07</Day></DateCompleted><DateRevised><Year>2017</Year><Month>11</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0302-282X</ISSN><JournalIssue CitedMedium="Print"><Volume>45 Suppl 1</Volume><PubDate><Year>2002</Year></PubDate></JournalIssue><Title>Neuropsychobiology</Title><ISOAbbreviation>Neuropsychobiology</ISOAbbreviation></Journal><ArticleTitle>Neurobiological findings before and during successful lithium therapy of a patient with 48-hour rapid-cycling bipolar disorder.</ArticleTitle><Pagination><MedlinePgn>13-9</MedlinePgn></Pagination><Abstract><AbstractText>48-hour rapid cycling is a very rare form of bipolar disorder, characterized by regular periodic changes of mood from one day to the other. We report on a patient who suffered from a 48-hour rapid cycling without a history of bipolar disorder before the abrupt onset of his rapid mood cycles. We present polysomnographic and neuroendocrine findings and the clinical course based on daily self-ratings of mood. Treatment with lithium carbonate effectively reduced the amplitude of the mood cycles. With plasma levels between 0.8 and 1.0 mmol, almost complete remission occurred. An overview on previous reports on the therapeutic effect of mood stabilizers in this rare form of bipolar disorder is presented.</AbstractText><CopyrightInformation>Copyright 2002 S. Karger AG, Basel</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Voderholzer</LastName><ForeName>Ulrich</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, Albert Ludwig University, Freiburg, Germany. Ulrich_Voderholzer@psyallg.ukl.uni-freiburg.de</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weske</LastName><ForeName>Gesa</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Ecker</LastName><ForeName>Sabine</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Riemann</LastName><ForeName>Dieter</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Gann</LastName><ForeName>Horst</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Berger</LastName><ForeName>Mathias</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Neuropsychobiology</MedlineTA><NlmUniqueID>7512895</NlmUniqueID><ISSNLinking>0302-282X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019275">Radiopharmaceuticals</NameOfSubstance></Chemical><Chemical><RegistryNumber>0Z5B2CJX4D</RegistryNumber><NameOfSubstance UI="D019788">Fluorodeoxyglucose F18</NameOfSubstance></Chemical><Chemical><RegistryNumber>9002-71-5</RegistryNumber><NameOfSubstance UI="D013972">Thyrotropin</NameOfSubstance></Chemical><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical><Chemical><RegistryNumber>WI4X0X7BPJ</RegistryNumber><NameOfSubstance UI="D006854">Hydrocortisone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000339" MajorTopicYN="N">Affect</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019788" MajorTopicYN="N">Fluorodeoxyglucose F18</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006854" MajorTopicYN="N">Hydrocortisone</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017286" MajorTopicYN="N">Polysomnography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019275" MajorTopicYN="N">Radiopharmaceuticals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012463" MajorTopicYN="N">Saliva</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012890" MajorTopicYN="N">Sleep</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013972" MajorTopicYN="N">Thyrotropin</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014055" MajorTopicYN="N">Tomography, Emission-Computed</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2002</Year><Month>3</Month><Day>15</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2002</Year><Month>5</Month><Day>8</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2002</Year><Month>3</Month><Day>15</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11893872</ArticleId><ArticleId IdType="pii">49256</ArticleId><ArticleId IdType="doi">10.1159/000049256</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15524097</PMID><DateCompleted><Year>2004</Year><Month>12</Month><Day>09</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0017-7768</ISSN><JournalIssue CitedMedium="Print"><Volume>143</Volume><Issue>6</Issue><PubDate><Year>2004</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Harefuah</Title><ISOAbbreviation>Harefuah</ISOAbbreviation></Journal><ArticleTitle>[On the relevance of protein kinase C to lithium therapy in bipolar disorder].</ArticleTitle><Pagination><MedlinePgn>414-6, 462</MedlinePgn></Pagination><Abstract><AbstractText>The discovery of lithium's efficacy as a mood-stabilizing agent revolutionized the treatment of patients with bipolar disorder and after 5 decades this drug continues to be the mainstay of treatment of this disorder. Valproate, which is dissimilar structurally to lithium, shares most of the effects of lithium at the level of protein kinase C (PKC). Both drugs reduce the activity of PKC, though via different mechanisms. In comparison to patients with major depressive disorder, schizophrenia, or healthy controls, PKC activity is significantly elevated in manic patients, suggesting that changes of PKC activity may be a central pathological trait of the illness. The precise physiological role of PKC activity in the regulation of mood is unclear. The enzyme modulates cellular responses via phosphorylation of numerous substrate proteins. Such substrates of PKC include cytoskeletal proteins, neurotransmitter and hormone receptors, G proteins, GAP-43, MARCKS etc. Further studies are required to clarify any causal role of CPK changes in bipolar-disorder.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sela</LastName><ForeName>B</ForeName><Initials>B</Initials></Author></AuthorList><Language>heb</Language><PublicationTypeList><PublicationType UI="D016420">Comment</PublicationType><PublicationType UI="D016421">Editorial</PublicationType><PublicationType UI="D004740">English Abstract</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Israel</Country><MedlineTA>Harefuah</MedlineTA><NlmUniqueID>0034351</NlmUniqueID><ISSNLinking>0017-7768</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018692">Antimanic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>9FN79X2M3F</RegistryNumber><NameOfSubstance UI="D008094">Lithium</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.11.13</RegistryNumber><NameOfSubstance UI="D011493">Protein Kinase C</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentOn"><RefSource>Harefuah. 2004 Jun;143(6):420-5, 462</RefSource><PMID Version="1">15524099</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D018692" MajorTopicYN="N">Antimanic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008094" MajorTopicYN="N">Lithium</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011493" MajorTopicYN="N">Protein Kinase C</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>11</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>12</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>11</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15524097</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17935734</PMID><DateCompleted><Year>2008</Year><Month>09</Month><Day>26</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0022-3956</ISSN><JournalIssue CitedMedium="Print"><Volume>42</Volume><Issue>9</Issue><PubDate><Year>2008</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Journal of psychiatric research</Title><ISOAbbreviation>J Psychiatr Res</ISOAbbreviation></Journal><ArticleTitle>Screening for bipolar disorder in a county jail at the time of criminal arrest.</ArticleTitle><Pagination><MedlinePgn>778-86</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">This study assessed the operating characteristics of the mood disorder questionnaire (MDQ) among offenders arrested and detained at a county jail.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">The MDQ, a brief self-report instrument designed to screen for all subtypes of bipolar disorder (BP I, II and NOS) was voluntarily administered to adult detainees at the Ottawa County Jail in Port Clinton, Ohio. A confirmatory diagnostic evaluation was also performed using the mini-international neuropsychiatric interview (MINI). The MDQ was scored using a standard algorithm requiring endorsement of 7/13 mood items as well as two items that assess whether manic or hypomanic symptoms co-occur and cause moderate to severe functional impairment. In addition to the standard algorithm for scoring the MDQ, modifications were also tested in an attempt to improve overall sensitivity.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among 526 jail detainees who completed the MDQ, 37 (7%) screened positive for bipolar disorder. Of 164 detainees who agreed to a research diagnostic evaluation, 32 (19.5%) screened positive on the MDQ, while 55 (33.5%) met criteria for bipolar disorder according to the MINI. When administered to the sample of 164 adult jail detainees, the sensitivity of the MDQ was 0.47 and the specificity was 0.94. The MDQ was significantly better at detecting BP I (0.59) than BP II/NOS (0.19; p=0.008). Modification of scoring the MDQ improved the sensitivity for detection of BP II from 0.23 to 0.54 with minimal decrease in specificity (0.84). The optimum sensitivity and specificity of the MDQ was achieved by decreasing the item threshold to 3/13 and eliminating the symptom co-occurrence and functional impairment items.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The MDQ was found to have limited utility as a screening tool for bipolar disorder in a correctional setting, particularly for the BP II subtype.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kemp</LastName><ForeName>David E</ForeName><Initials>DE</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Case Western Reserve University, Cleveland, OH 44106, USA. kemp.david@gmail.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hirschfeld</LastName><ForeName>Robert M A</ForeName><Initials>RM</Initials></Author><Author ValidYN="Y"><LastName>Ganocy</LastName><ForeName>Stephen J</ForeName><Initials>SJ</Initials></Author><Author ValidYN="Y"><LastName>Elhaj</LastName><ForeName>Omar</ForeName><Initials>O</Initials></Author><Author ValidYN="Y"><LastName>Slembarski</LastName><ForeName>Renee</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Bilali</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Conroy</LastName><ForeName>Carla</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Pontau</LastName><ForeName>James</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Findling</LastName><ForeName>Robert L</ForeName><Initials>RL</Initials></Author><Author ValidYN="Y"><LastName>Calabrese</LastName><ForeName>Joseph R</ForeName><Initials>JR</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P20 MH066054-01A1</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>C76 HF 00502-01</GrantID><Agency>PHS HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P20 MH066054</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P20 MH-66054</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>KL2 RR024990</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>11</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Psychiatr Res</MedlineTA><NlmUniqueID>0376331</NlmUniqueID><ISSNLinking>0022-3956</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003415" MajorTopicYN="N">Crime</DescriptorName><QualifierName UI="Q000331" MajorTopicYN="Y">legislation &amp; jurisprudence</QualifierName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007406" MajorTopicYN="N">Interview, Psychological</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009111" MajorTopicYN="Y">Local Government</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008403" MajorTopicYN="N">Mass Screening</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011330" MajorTopicYN="N">Prisons</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012372" MajorTopicYN="N">ROC Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>02</Month><Day>04</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>08</Month><Day>02</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>10</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>9</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>10</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17935734</ArticleId><ArticleId IdType="pii">S0022-3956(07)00130-6</ArticleId><ArticleId IdType="doi">10.1016/j.jpsychires.2007.08.001</ArticleId><ArticleId IdType="pmc">PMC2475656</ArticleId><ArticleId IdType="mid">NIHMS53214</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Affect Disord. 1994 Aug;31(4):281-94</Citation><ArticleIdList><ArticleId IdType="pubmed">7989643</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2000 Sep;59 Suppl 1:S5-S30</Citation><ArticleIdList><ArticleId IdType="pubmed">11121824</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 1998;59 Suppl 20:22-33;quiz 34-57</Citation><ArticleIdList><ArticleId IdType="pubmed">9881538</ArticleId></ArticleIdList></Reference><Reference><Citation>Can J Psychiatry. 2002 Mar;47(2):125-34</Citation><ArticleIdList><ArticleId IdType="pubmed">11926074</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1996 Jun;53(6):505-12</Citation><ArticleIdList><ArticleId IdType="pubmed">8639033</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Serv. 2005 Jul;56(7):816-22</Citation><ArticleIdList><ArticleId IdType="pubmed">16020813</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1997 Jan;42(1):29-38</Citation><ArticleIdList><ArticleId IdType="pubmed">9089056</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2003 Feb;64(2):161-74</Citation><ArticleIdList><ArticleId IdType="pubmed">12633125</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2004 Nov;65(11):1499-504</Citation><ArticleIdList><ArticleId IdType="pubmed">15554762</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2003 Apr;64(4):425-32</Citation><ArticleIdList><ArticleId IdType="pubmed">12716245</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2003 Jan;73(1-2):123-31</Citation><ArticleIdList><ArticleId IdType="pubmed">12507745</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1999 Jul;56(7):617-26</Citation><ArticleIdList><ArticleId IdType="pubmed">10401507</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2004 Aug;81(2):167-71</Citation><ArticleIdList><ArticleId IdType="pubmed">15306144</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2005 Sep;88(1):103-8</Citation><ArticleIdList><ArticleId IdType="pubmed">16054228</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Pract Epidemiol Ment Health. 2005 Jul 21;1:8</Citation><ArticleIdList><ArticleId IdType="pubmed">16042762</ArticleId></ArticleIdList></Reference><Reference><Citation>Biol Psychiatry. 1996 May 15;39(10):896-9</Citation><ArticleIdList><ArticleId IdType="pubmed">8860192</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacoeconomics. 2003;21(9):601-22</Citation><ArticleIdList><ArticleId IdType="pubmed">12807364</ArticleId></ArticleIdList></Reference><Reference><Citation>J Am Board Fam Pract. 2005 Jul-Aug;18(4):233-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15994469</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2003 Jan;160(1):178-80</Citation><ArticleIdList><ArticleId IdType="pubmed">12505821</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2005 Jun;62(6):617-27</Citation><ArticleIdList><ArticleId IdType="pubmed">15939839</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2005 Feb 23;293(8):956-63</Citation><ArticleIdList><ArticleId IdType="pubmed">15728166</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Public Health. 1990 Jun;80(6):663-9</Citation><ArticleIdList><ArticleId IdType="pubmed">2343947</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2000 Nov;157(11):1873-5</Citation><ArticleIdList><ArticleId IdType="pubmed">11058490</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2005 Feb;84(2-3):273-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15708426</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2006 Jun;92(2-3):141-8</Citation><ArticleIdList><ArticleId IdType="pubmed">16529822</ArticleId></ArticleIdList></Reference><Reference><Citation>Can J Psychiatry. 2003 Dec;48(11):770-1</Citation><ArticleIdList><ArticleId IdType="pubmed">14733459</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2004 Feb;65(2):198-203</Citation><ArticleIdList><ArticleId IdType="pubmed">15003073</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2006 May;67(5):827-30</Citation><ArticleIdList><ArticleId IdType="pubmed">16841633</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 1998 Sep;50(2-3):143-51</Citation><ArticleIdList><ArticleId IdType="pubmed">9858074</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2005 Oct;88(2):217-33</Citation><ArticleIdList><ArticleId IdType="pubmed">16125784</ArticleId></ArticleIdList></Reference><Reference><Citation>BMC Psychiatry. 2003 Jul 10;3:8</Citation><ArticleIdList><ArticleId IdType="pubmed">12854971</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2004 May;65(5):605-10; discussion 721</Citation><ArticleIdList><ArticleId IdType="pubmed">15163245</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19166147</PMID><DateCompleted><Year>2009</Year><Month>03</Month><Day>04</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0041-4131</ISSN><JournalIssue CitedMedium="Print"><Volume>85</Volume><Issue>11</Issue><PubDate><Year>2007</Year><Month>Nov</Month></PubDate></JournalIssue><Title>La Tunisie medicale</Title><ISOAbbreviation>Tunis Med</ISOAbbreviation></Journal><ArticleTitle>[Influence of consanguinity on clinical characteristics and affective disorders frequency in relatives of bipolar I patients].</ArticleTitle><Pagination><MedlinePgn>951-4</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The genetic transmission of bipolar disorder remained undetermined up to now, partly due to clinical and genetically heterogeneity. In Tunisia, genetic study will profit from the existence of high rates of consanguinity.</AbstractText><AbstractText Label="AIM" NlmCategory="OBJECTIVE">To determine the rate of consanguinity in bipolar I disorders sample and to compare the clinical characteristics and the frequency of affective disorders in first and second degree relatives of probands with and without consanguinity.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">One hundred thirty subjects met DSM-IV criteria for a bipolar I disorder were recruited. Available Information was obtained from a structured clinical interview, collateral history and medical records. The family investigation allowed completion of genealogies over three generations. The comparison was based on the clinical characteristics (age of onset, numbers of affective episodes, nature and severity of the last affective episode) and the frequency of affective disorders in first and second degree relatives of probands with and without consanguinity.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">the rate of consanguinity was estimated to 28,5% It was higher in patients with family history of affective disorders : 34,2% versus 20,4% (p=0,08). Bipolar I patients with consanguinity were characterised by a high frequency of affective episodes and a more severe of the last affective episode, but theses differences were not significantly. However, the frequency of affective disorders was significantly increased in first degree relatives of probands with consanguinity: 10,5% versus 6,1% (p=0,01), and in first and second degree relatives of probands with consanguinity : 4,5% versus 29% (p=0,02).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The influence of consanguinity on the clinical characteristics and the frequency of affective disorders in first and second degree relatives of bipolar patients is en favour the recessive polygenetic transmission of bipolar disorders.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mechri</LastName><ForeName>Anwar</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Laboratoire de recherche Vulnérabilité aux psychoses, Service de Psychiatrie, hôpital universitaire de Monastir, Monastir, Tunisie.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rouissi</LastName><ForeName>Khadija</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Mehdi</LastName><ForeName>Boutheina</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Khiari</LastName><ForeName>Geneviève</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Abdelhak</LastName><ForeName>Sonia</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Gaha</LastName><ForeName>Lotfi</ForeName><Initials>L</Initials></Author></AuthorList><Language>fre</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Influence de la consanguinité sur les caractéristiques cliniques et le risque morbide dans le trouble bipolaire type I.</VernacularTitle></Article><MedlineJournalInfo><Country>Tunisia</Country><MedlineTA>Tunis Med</MedlineTA><NlmUniqueID>0413766</NlmUniqueID><ISSNLinking>0041-4131</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000341" MajorTopicYN="N">Affective Disorders, Psychotic</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017668" MajorTopicYN="N">Age of Onset</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003241" MajorTopicYN="Y">Consanguinity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010375" MajorTopicYN="N">Pedigree</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014416" MajorTopicYN="N" Type="Geographic">Tunisia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>1</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>11</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>3</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19166147</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">30165326</PMID><DateCompleted><Year>2019</Year><Month>03</Month><Day>05</Day></DateCompleted><DateRevised><Year>2019</Year><Month>03</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-7123</ISSN><JournalIssue CitedMedium="Internet"><Volume>268</Volume><PubDate><Year>2018</Year><Month>10</Month></PubDate></JournalIssue><Title>Psychiatry research</Title><ISOAbbreviation>Psychiatry Res</ISOAbbreviation></Journal><ArticleTitle>Motor function in an animal model with ouabain-induced bipolar disorder and comorbid anxiety behavior.</ArticleTitle><Pagination><MedlinePgn>508-513</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0165-1781(17)31952-2</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.psychres.2018.07.031</ELocationID><Abstract><AbstractText>In a clinical setting, anxiety disorder is highly correlated with bipolar I disorder in humans. However, the comorbidity of anxiety behavior and bipolar disorder still remains unclear in an animal model. This study utilized an ouabain-induced animal mode to examine anxiety and mania in an open field test. In the present study, 5 µl of artificial cerebrospinal fluid (aCSF) or ouabain (10<sup>-5</sup>, 10<sup>-4</sup>, and 10<sup>-3</sup> M) were administered into the left ventricle. The animals' motor functions and anxiety behaviors were measured for 15 min. The results showed that 10<sup>-3</sup> M ouabain significantly increased the animal's total distance traveled, average speed, and maximum speed compared to the control group. The time spent inside (i.e., how much time rats spent in the center of the square) and the inside-outside times of the central square (i.e., how many times rats ran across the center square) of the higher-concentration groups (10<sup>-4</sup> M and 10<sup>-3</sup> M) were significantly decreased. Therefore, a high concentration of ouabain may induce hyperactivity. The 10<sup>-4</sup> M and 10<sup>-3</sup> M ouabain groups exhibited more anxiety behaviors. The study is the first model to examine comorbid anxiety behaviors and bipolar disorder in an animal model. The study provides some insights for comorbid anxiety and bipolar disorder in clinics.</AbstractText><CopyrightInformation>Copyright © 2018 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Ying-Chou</ForeName><Initials>YC</Initials><AffiliationInfo><Affiliation>Department of Clinical Psychology, Fu Jen Catholic University, New Taipei City 24205, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Ying Hao</ForeName><Initials>YH</Initials><AffiliationInfo><Affiliation>Department of Psychology, Fo Guang University, Yilan County 26247, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tsai</LastName><ForeName>Meng-Li</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Department of Biomechatronic Engineering, National Ilan University, Ilan, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Andrew Chih Wei</ForeName><Initials>ACW</Initials><AffiliationInfo><Affiliation>Department of Psychology, Fo Guang University, Yilan County 26247, Taiwan. Electronic address: chweihuang@mail.fgu.edu.tw.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>07</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Psychiatry Res</MedlineTA><NlmUniqueID>7911385</NlmUniqueID><ISSNLinking>0165-1781</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>5ACL011P69</RegistryNumber><NameOfSubstance UI="D010042">Ouabain</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D017109" MajorTopicYN="N">Akathisia, Drug-Induced</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001007" MajorTopicYN="N">Anxiety</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001522" MajorTopicYN="N">Behavior, Animal</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010042" MajorTopicYN="N">Ouabain</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011597" MajorTopicYN="N">Psychomotor Performance</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017208" MajorTopicYN="N">Rats, Wistar</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Anxiety behavior</Keyword><Keyword MajorTopicYN="Y">Bipolar disorder</Keyword><Keyword MajorTopicYN="Y">Locomotor activity</Keyword><Keyword MajorTopicYN="Y">Open field test</Keyword><Keyword MajorTopicYN="Y">Ouabain</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>10</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>04</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>07</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>8</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>3</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>8</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30165326</ArticleId><ArticleId IdType="pii">S0165-1781(17)31952-2</ArticleId><ArticleId IdType="doi">10.1016/j.psychres.2018.07.031</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20525372</PMID><DateCompleted><Year>2010</Year><Month>08</Month><Day>06</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-244X</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><PubDate><Year>2010</Year><Month>Jun</Month><Day>04</Day></PubDate></JournalIssue><Title>BMC psychiatry</Title><ISOAbbreviation>BMC Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Depression diagnoses following the identification of bipolar disorder: costly incongruent diagnoses.</ArticleTitle><Pagination><MedlinePgn>39</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/1471-244X-10-39</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Previous research has documented that the symptoms of bipolar disorder are often mistaken for unipolar depression prior to a patient's first bipolar diagnosis. The assumption has been that once a patient receives a bipolar diagnosis they will no longer be given a misdiagnosis of depression. The objectives of this study were 1) to assess the rate of subsequent unipolar depression diagnosis in individuals with a history of bipolar disorder and 2) to assess the increased cost associated with this potential misdiagnosis.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This study utilized a retrospective cohort design using administrative claims data from 2002 and 2003. Patient inclusion criteria for the study were 1) at least 2 bipolar diagnoses in 2002, 2) continuous enrollment during 2002 and 2003, 3) a pharmacy benefit, and 4) age 18 to 64. Patients with at least 2 unipolar depression diagnoses in 2003 were categorized as having an incongruent diagnosis of unipolar depression. We used propensity scoring to control for selection bias. Utilization was evaluated using negative binomial models. We evaluated cost differences between patient cohorts using generalized linear models.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of the 7981 patients who met all inclusion criteria for the analysis, 17.5% (1400) had an incongruent depression diagnosis (IDD). After controlling for background differences, individuals who received an IDD had higher rates of inpatient and outpatient psychiatric utilization and cost, on average, an additional $1641 per year compared to individuals without an IDD.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">A strikingly high proportion of bipolar patients are given the differential diagnosis of unipolar depression after being identified as having bipolar disorder. Individuals with an IDD had increased acute psychiatric care services, suggesting higher levels of relapses, and were at risk for inappropriate treatment, as antidepressant therapy without a concomitant mood-stabilizing medication is contraindicated in bipolar disorder. Further prospective research is needed to validate the findings from this retrospective administrative claims-based analysis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Stensland</LastName><ForeName>Michael D</ForeName><Initials>MD</Initials><AffiliationInfo><Affiliation>i3 Innovus, Eden Prairie, Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schultz</LastName><ForeName>Jennifer F</ForeName><Initials>JF</Initials></Author><Author ValidYN="Y"><LastName>Frytak</LastName><ForeName>Jennifer R</ForeName><Initials>JR</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>06</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Psychiatry</MedlineTA><NlmUniqueID>100968559</NlmUniqueID><ISSNLinking>1471-244X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003866" MajorTopicYN="N">Depressive Disorder</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003951" MajorTopicYN="N">Diagnostic Errors</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016527" MajorTopicYN="N">Drug Costs</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017048" MajorTopicYN="N">Health Care Costs</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019538" MajorTopicYN="N">Health Care Surveys</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055118" MajorTopicYN="N">Medication Adherence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017063" MajorTopicYN="N">Outcome Assessment, Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012008" MajorTopicYN="N">Recurrence</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2008</Year><Month>08</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>06</Month><Day>04</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>6</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>6</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>8</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20525372</ArticleId><ArticleId IdType="pii">1471-244X-10-39</ArticleId><ArticleId IdType="doi">10.1186/1471-244X-10-39</ArticleId><ArticleId IdType="pmc">PMC2894758</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mayo Clin Proc. 2005 Aug;80(8):991-4</Citation><ArticleIdList><ArticleId IdType="pubmed">16092576</ArticleId></ArticleIdList></Reference><Reference><Citation>Am Heart J. 2004 Jul;148(1):99-104</Citation><ArticleIdList><ArticleId IdType="pubmed">15215798</ArticleId></ArticleIdList></Reference><Reference><Citation>Stat Med. 1998 Oct 15;17(19):2265-81</Citation><ArticleIdList><ArticleId IdType="pubmed">9802183</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2000 Nov;157(11):1873-5</Citation><ArticleIdList><ArticleId IdType="pubmed">11058490</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2005 Feb;84(2-3):117-25</Citation><ArticleIdList><ArticleId IdType="pubmed">15708408</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2003 Feb;64(2):161-74</Citation><ArticleIdList><ArticleId IdType="pubmed">12633125</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Epidemiol. 2002 Sep;55(9):929-37</Citation><ArticleIdList><ArticleId IdType="pubmed">12393082</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1994 Jan;51(1):8-19</Citation><ArticleIdList><ArticleId IdType="pubmed">8279933</ArticleId></ArticleIdList></Reference><Reference><Citation>Bipolar Disord. 2004 Oct;6(5):395-405</Citation><ArticleIdList><ArticleId IdType="pubmed">15383132</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur Neuropsychopharmacol. 2004 May;14 Suppl 2:S83-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15142612</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Manag Care. 2005 Sep;11(9):578-84</Citation><ArticleIdList><ArticleId IdType="pubmed">16159049</ArticleId></ArticleIdList></Reference><Reference><Citation>Psychiatr Serv. 1998 Aug;49(8):1072-8</Citation><ArticleIdList><ArticleId IdType="pubmed">9712215</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2008 Jun;69(6):935-40</Citation><ArticleIdList><ArticleId IdType="pubmed">18466044</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2002 Jun;59(6):530-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12044195</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Psychiatry. 2003 Jul;160(7):1286-90</Citation><ArticleIdList><ArticleId IdType="pubmed">12832243</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 1973 Sep;29(3):420-5</Citation><ArticleIdList><ArticleId IdType="pubmed">4579507</ArticleId></ArticleIdList></Reference><Reference><Citation>J Nerv Ment Dis. 1981 Jun;169(6):364-6</Citation><ArticleIdList><ArticleId IdType="pubmed">7229633</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Psychiatry. 2008 May;69(5):749-58</Citation><ArticleIdList><ArticleId IdType="pubmed">18363423</ArticleId></ArticleIdList></Reference><Reference><Citation>J Health Econ. 2001 Jul;20(4):461-94</Citation><ArticleIdList><ArticleId IdType="pubmed">11469231</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2005 Feb 23;293(8):956-63</Citation><ArticleIdList><ArticleId IdType="pubmed">15728166</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Gen Psychiatry. 2005 Jun;62(6):593-602</Citation><ArticleIdList><ArticleId IdType="pubmed">15939837</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2001 Dec;67(1-3):45-59</Citation><ArticleIdList><ArticleId IdType="pubmed">11869752</ArticleId></ArticleIdList></Reference><Reference><Citation>J Affect Disord. 2007 Aug;101(1-3):187-93</Citation><ArticleIdList><ArticleId IdType="pubmed">17254637</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 1996 Jul 24-31;276(4):293-9</Citation><ArticleIdList><ArticleId IdType="pubmed">8656541</ArticleId></ArticleIdList></Reference><Reference><Citation>Prim Care Companion J Clin Psychiatry. 2005;7(1):15-21</Citation><ArticleIdList><ArticleId IdType="pubmed">15841189</ArticleId></ArticleIdList></Reference><Reference><Citation>J Health Econ. 1999 Apr;18(2):153-71</Citation><ArticleIdList><ArticleId IdType="pubmed">10346351</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">31132573</PMID><DateCompleted><Year>2020</Year><Month>03</Month><Day>24</Day></DateCompleted><DateRevised><Year>2020</Year><Month>03</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-7123</ISSN><JournalIssue CitedMedium="Internet"><Volume>278</Volume><PubDate><Year>2019</Year><Month>08</Month></PubDate></JournalIssue><Title>Psychiatry research</Title><ISOAbbreviation>Psychiatry Res</ISOAbbreviation></Journal><ArticleTitle>Relative importance of symptoms, cognition, and other multilevel variables for psychiatric disease classifications by machine learning.</ArticleTitle><Pagination><MedlinePgn>27-34</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0165-1781(18)32189-9</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.psychres.2019.03.048</ELocationID><Abstract><AbstractText>This study used machine-learning algorithms to make unbiased estimates of the relative importance of various multilevel data for classifying cases with schizophrenia (n = 60), schizoaffective disorder (n = 19), bipolar disorder (n = 20), unipolar depression (n = 14), and healthy controls (n = 51) into psychiatric diagnostic categories. The Random Forest machine learning algorithm, which showed best efficacy (92.9% SD: 0.06), was used to generate variable importance ranking of positive, negative, and general psychopathology symptoms, cognitive indexes, global assessment of function (GAF), and parental ages at birth for sorting participants into diagnostic categories. Symptoms were ranked most influential for separating cases from healthy controls, followed by cognition and maternal age. To separate schizophrenia/schizoaffective disorder from bipolar/unipolar depression, GAF was most influential, followed by cognition and paternal age. For classifying schizophrenia from all other psychiatric disorders, low GAF and paternal age were similarly important, followed by cognition, psychopathology and maternal age. Controls misclassified as schizophrenia cases showed lower nonverbal abilities, mild negative and general psychopathology symptoms, and younger maternal or older paternal age. The importance of symptoms for classification of cases and lower GAF for diagnosing schizophrenia, notably more important and distinct from cognition and symptoms, concurs with current practices. The high importance of parental ages is noteworthy and merits further study.</AbstractText><CopyrightInformation>Copyright © 2019. Published by Elsevier B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Walsh-Messinger</LastName><ForeName>Julie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Psychology, University of Dayton, Dayton, OH, United States; Department of Psychiatry, Wright State University Boonshoft School of Medicine, Dayton, OH, United States. Electronic address: jmessinger1@udayton.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Haoran</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Applied Mathematics and Statistics, Stony Brook University, Stony Brook, NY, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Hyejoo</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Korea Institute of Science and Technology, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rothman</LastName><ForeName>Karen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Psychology, University of Miami, Coral Gables, FL, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahn</LastName><ForeName>Hongshik</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Applied Mathematics and Statistics, Stony Brook University, Stony Brook, NY, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malaspina</LastName><ForeName>Dolores</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Icahn Medical School at Mount Sinai, New York, NY, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 MH066428</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RC1 MH088843</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24 MH001699</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>03</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>Ireland</Country><MedlineTA>Psychiatry Res</MedlineTA><NlmUniqueID>7911385</NlmUniqueID><ISSNLinking>0165-1781</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="Y">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="Y">classification</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="Y">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069550" MajorTopicYN="N">Machine Learning</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="Y">classification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010290" MajorTopicYN="N">Parents</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011618" MajorTopicYN="N">Psychotic Disorders</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="Y">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="Y">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012565" MajorTopicYN="N">Schizophrenic Psychology</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Machine learning</Keyword><Keyword MajorTopicYN="Y">Major depressive disorder, Bipolar disorder</Keyword><Keyword MajorTopicYN="Y">Nosology</Keyword><Keyword MajorTopicYN="Y">Schizoaffective disorder</Keyword><Keyword MajorTopicYN="Y">Schizophrenia</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>11</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2019</Year><Month>03</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>03</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>5</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>3</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>5</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31132573</ArticleId><ArticleId IdType="pii">S0165-1781(18)32189-9</ArticleId><ArticleId IdType="doi">10.1016/j.psychres.2019.03.048</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>